Psychological Case History Record by Hemalatha, P
FORMULATION AND DEVELOPMENT OF 
SELF EMULSIFYING DRUG DELIVERY 
SYSTEM FOR FEW DRUGS 
 
 
 
A THESIS 
 
Submitted to 
 
The Tamil Nadu Dr.M.G.R. Medical University, 
Chennai 
 
In the partial fulfilment of the requirements for  
the award of the degree of  
 
DOCTOR OF PHILOSOPHY 
In 
FACULTY OF PHARMACY  
 
By 
 
D. AKILADEVI, M.Pharm. 
 
(Register no. 141340001) 
 
Under the guidance and supervision of 
 
Dr. M. NAPPINNAI, M.Pharm., Ph.D 
Professor, Department of Pharmaceutics, 
School of Pharmacy, Surya Group of Institutions, 
Vikravandi, Villupuram District 605 652. 
January 2017 
1 
CHAPTER 1 
INTRODUCTION 
1.1 DRUG DELIVERY ISSUES 
The major, popular route of administering drug from time immemorial is the 
oral route for both chronic and acute dosage regimen. Unfortunately more than 50 % 
of drug compounds have unfavorable physicochemical property of which high 
lipophilicity is major one. Almost 40% of the new drug candidates exhibit low 
solubility in water which leads to poor bioavailability, high intra and inter -subject 
variability, lack of dose proportionality. Thus for such compounds, among numerous 
factors limiting bioavailability is the absorption rate from gastrointestinal lumen. This 
is in turn is related to dissolution1. According to the BCS classification, two classes of 
drugs show poor aqueous solubility namely BCS II and BCS IV. BCS II drugs 
possess poor aqueous solubility but have good permeation properties. BCS class IV 
drugs are poorly water soluble and poorly permeable. A formulation of developing for 
a class IV drug is nearly impossible. 
Various approaches for enhancing bioavailability of poorly soluble drugs2  
Ø Formation of salt: The drugs in acidic or basic forms have increased 
solubility because of salt formation. But it’s highly significant when the drug 
exists in salt form.  
Ø Micronization: It  is  one  of  the  methods  of  reducing  the  particles  to  micron  
size but the approach proved insufficient for enhancement of dissolution rate 
of the drugs in solid dosage forms.   
Ø Nanocrystals: These are developed products for nanoparticle approach in the 
market with modern technology supplier. They are procured only under 
license but the secondary step required is to avoid agglomeration of 
nanocrystals. Nanocrystals by the dense gas technology are used as an 
alternative method for producing nanocrystals. But it was not marketed and 
the product was so failed. 
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Ø Solid solutions: Solid solutions are prepared using novel extrusion technology 
by the solvent free continuous process and can be easily operated. But this 
approach  may  lead  to  problems  which  affect  the  physical  stability  of  the  
product and crystallization of drug. Numerous methods are adopted with the 
limitation of reproducibility and stability. The ease of manufacturing and 
scale-up process is major obstacles in all above mentioned approaches which 
resulted to put an end to these methods.  
Problems associated with methods used for improvement of bioavailability  
The improvement of solubility of hydrophobic drugs remains one of the most 
challenging aspects of drug development. Although salt formation, solubilization and 
particle size reduction have commonly been used to increase dissolution rate, there 
are practical limitations for these techniques. The salt formation is not feasible for 
neutral compounds and the synthesis of appropriate salt forms of drugs that are 
weakly acidic or weakly basic may often not be practical. The solubilization of drugs 
in organic solvents or in aqueous media by the use of surfactants and cosolvents leads 
to liquid formulations that are usually undesirable from the  
viewpoints of patient acceptability and commercialization. Although particle 
size reduction is commonly used to increase dissolution rate, there is a practical limit 
to how much size reduction can be achieved by such commonly used methods as 
controlled crystallization, grinding, etc. The use of very fine powders in a dosage 
form may also be problematic because of improper handling and wetting3. To prevail 
over these limitations, various formulation methods  are available like addition of 
cyclodextrins and permeation enhancers and preparation of  nanoparticles and solid 
dispersions 4.  
1.2  LIPID BASED DRUG DELIVERY  
One of the popular and recent approaches to improve the oral bioavailability 
of poorly water soluble compounds are lipid based formulations in which the drug 
compounds are incorporated into inert lipid vehicles such as oils and surfactant 
dispersions, self-emulsifying drug formulations and emulsions5, 6. 
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1)  Self-dispersing solid (solution with surfactants): The stearic hindrance to 
aggregation may build into product and the physical stability of the product is 
questionable as the drug or polymer may crystallize. 
2)  Lipid solution (LFCS Type I): These are effective for lipophilic drugs and 
drug is presented in solution avoiding the dissolution step.  
3)  Self-emulsifying drug delivery system (LCFS Type II or Type III lipid 
systems):  It  is  an  effective  method  to  incorporate  the  drug  into  self-
emulsifying liquid whereby emulsification forms an o/w emulsion 
spontaneously on mixing with water. For such formulations dispersion leads to 
rapid absorption and absorption is independent on digestion.  
4)  Solid or semi-solid SEDDS: They are prepared as a free flowing powder or 
compressed into a tablet form. The surfactant used may be poorly tolerated in 
chronic use and physical stability of the product is questionable as drug or 
polymer may crystallize. 
5)  Surfactant-cosolvent systems (LCFS  Type  IV  lipid  systems):  These  
formulations have the relatively high solvent capacity for typical APIs. The 
surfactant used may be poorly tolerated in chronic use. There is the significant 
threat of drug precipitation on dilution.  
Requisites to formulate lipid-based drug delivery systems7 
1. The lipids should be capable of solubilizing the therapeutic amount of the drug 
in its final dosage form. 
2. The solubility of the drug in lipid vehicles should be maintained under all 
predicted storage conditions throughout the shelf-life of the drug product.  
3. It should not affect the stability of the drug and its formulation ingredients. 
4. The inactive approved ingredients added in lipid formulations should be under 
GRAS (Generally regarded as safe) or any pharmacopoeial category. 
5. Lipids should increases or maintains drug solubilization. 
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6. The absorption of drug from the lipids by intestinal mucosal cells should be 
optimized. 
Tentative drug candidates selected for oral lipid based formulations 
The BCS is a scientific framework for classifying a drug candidate based on 
aqueous solubility and intestinal permeability. It is a prognostic tool for predicting the 
oral absorption. According to the description of the BCS proposed by Amidon1 in 
1995, both BCS II and IV drugs are promising suitable candidates identified for oral 
lipid formulations. 
The promising drug candidates suitable for oral lipid formulations can be 
identified based on drug solubility and permeability according to Amidon et al1 BCS 
which is related with bioavailability. The lipid based formulations which are depicted 
in Table 1 can potentially improve bioavailability for selected compounds in every 
BCS category. The BCS Category II compounds possessing poor water solubility and 
high membrane permeability exhibit substantial enhancements in bioavailability when 
formulated in solubilizing lipid excipient. Although these compounds are 
hydrophobic, they possess solubility (50-100mg/ml) in a dietary triglyceride in which 
drugs can be dispersed and enhances bioavailability by overcoming absorptive 
barriers of poor aqueous solubility and slow dissolution in the gastrointestinal tract. 
The enhanced absorption of hydrophobic molecules through lipid formulations 
involves a mechanism of transfer into the bile salt-mixed micellar phase in which the 
absorption occurs readily across the intestinal epithelium. The lipids can improve 
bioavailability through mitigation of intestinal efflux by the p-glycoprotein 
transporter, which enhances the reduction in first pass metabolism caused by 
membrane bound cytochrome enzymes and thereby results in changing the 
permeability of the intestinal membrane. Lipid soluble drugs enter directly into the 
intestinal lymph in which the drugs enter into the systemic blood circulation, thereby 
circumventing the potential first pass metabolism. Self-emulsifying drug delivery 
systems (SEDDS) are a bioavailability enhancer for oral delivery of poorly soluble 
drugs. 
Pouton and Wakerly, the innovators of novel lipid based formulations such as 
SEDDS disclosed that the self-emulsification process is  specific to the nature of the 
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oil and surfactant pair8,  9. The process depends on the oil nature, surfactant 
concentration  and  the  oil/surfactant  ratio  and  the  temperature  at  which  the  self-
emulsification occurs. For selected compounds under BCS category of lipid based 
formulations can potentially enhance bioavailability which is illustrated in Table 1. 
The typical composition of various types of lipid formulations according to Lipid 
formulation classification system LFCS is indicated in Table 2. 
Table 1 : Potential bioavailability improvement of active ingredients categorized 
by the Biopharmaceutical classification system using oral lipid based 
formulations10 
Aqueous 
Solubility 
Membrane 
permeability 
Type1 
Potential 
formulation 
Type 
Potential benefits of the 
system 
High High I 
Microemulsion 
w/o 
Stabilization, chemical 
enzymatic protection 
against hydrolysis 
(+efflux). 
High Low III 
Microemulsion 
w/o 
Stabilization, chemical 
enzymatic protection 
against hydrolysis 
(+efflux). 
Low High II 
Self-micro 
emulsifying drug 
delivery system 
(SMEDDS) o/w 
Enhancement of 
dissolution, solubilization, 
and improved 
bioavailability 
Low Low IV 
Self-micro 
emulsifying drug 
delivery system 
(SMEDDS) o/w 
Enhancement of 
dissolution, solubilization 
and improved 
bioavailability (+efflux). 
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Table 2 Typical Composition of Lipid formulation classification system by 
Pouton10 
Types of excipients in 
formulation 
Percentage content of formulation  in weight basis 
Type I Type II Type IIIA Type IIIB Type IV 
Triglycerides or mixed 
mono and diglycerides 
100 40-80 40-80 <20 – 
Water insoluble 
Surfactants (HLB < 12) 
– – 20-60 – – – – 0-20 
Water soluble surfactants 
(HLB > 12) 
– – – – 20-40 20-50 30-80 
Cosolvents (Hydrophilic) 
(e.g. PEG, propylene, 
transcutol) 
– – – – 0-40 20-50 0-50 
 
1.3 SELF - EMULSIFYING DRUG DELIVERY SYSTEMS (SEDDS) 
SEDDS are considered one of the promising approaches for tackling 
formulation problems associated with drugs with poor aqueous solubility. SEDDS is 
an oral lipid dosage form composed of a mixture of oils, surfactant and solvent of 
hydrophilic capacity and co solvents/surfactants11. These formulations disperse freely 
when  they  come  to  contact  with  gastric  fluids  and  form  an  o/w  emulsion  or  micro  
emulsion utilizing mild agitation conditions provided by gastric motility. The 
lipophilic drug is delivered in liquid form, in small droplets of oil, leading to the 
elimination of the dissolution which is rate limited process in the absorption of poorly 
soluble drugs. The bioavailability of SEDDS is thereby improved and the drug 
content in plasma profile is reproducible in such systems. Fine oil droplets are 
expected to be emptied rapidly from the stomach and promote a better distribution of 
the drug throughout the gastrointestinal tract. This can minimize irritation caused by 
extended contact between drug substance and the gut wall. When compared to 
conventional oily solutions, SEDDS provide a large interfacial area which enhances 
drug absorption by increasing the rate of diffusion from oil to the aqueous media of 
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the gastrointestinal tract. The dispersibility of the administered lipids depends on the 
extent of drug absorption from lipid vehicles.  
The self - emulsifying delivery systems are broadly classified according to 
their particle size as:  
1. Self-emulsifying drug delivery system (SEDDS): They have droplets of 
emulsion size more than 600 nm.  
2. Self -micro emulsifying drug delivery system (SMEDDS): They have 
droplets of micron size lying between 100-150 nm. 
3.  Self-nano emulsifying drug delivery system (SNEDDS): They have droplets 
of nanosize lying between 10-100 nm. 
Advantages of the system12   
i. The  drug  absorption  will  be  more:  SEDDS  formulations  can  enhance  the  
bioavailability by increasing the solubility of the drug and minimizes the 
gastric  irritation.  In  SEDDS,  the  lipid  phase  interacts  readily  with  water,  
forming a fine particulate o/w emulsion. The emulsion droplets will deliver the 
drug to the gastrointestinal mucosa in the dissolved state readily accessible for 
absorption.  
ii. The drug can be protected from the gut environment: Many drugs are 
degraded in the physiological system because of acidic pH in the stomach, 
enzymatic degradation or hydrolytic degradation. Such drugs, when presented 
in the form of SEDDS, can be well protected against the degradation processes 
as a liquid crystalline phase in SEDDS might act as the barrier between the 
degrading environment and the drug13. 
iii. The sensitive drug compounds are protected: SEDDS and SMEDDS are self-
emulsified  dosage  form  by  agitation  in  GI  tract  with  the  size  of  droplet  less  
than 50 nm for SMEDDS and for SEDDS between 100 to 300 nm which are 
physically stable formulations that are easy to manufacture14.  
iv. The oral dose is reduced therefore, the oral bioavailability is enhanced. 
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v. The efficiency of drug loading is increased and the side effects can be 
minimized. 
vi. They require minimum energy for formation. 
vii. They are thermodynamically stable. 
viii. The manufacturing and scale-up of the system are easy. 
Disadvantage of the system15  
i. Deficient of reliable in vitro models for assessment of the formulations since 
traditional methods of dissolution cannot be used, because the SEDDS 
formulations potentially are dependent on digestion prior to the release of the 
drug. 
ii. Lack of suitable in vivo animal model  for testing lipid based formulations 
1.4 CONTENTS OF SEDDS 
List of Typical Oil, Fatty and Lipid Compounds used in formulation of SEDDS 
and SMEDDS 
Oils 
In the design of formulation of SEDDS, triglyceride oils of long and medium 
chain with different degrees of saturation are used. Further edible oils/natural oils are 
preferred in lipid excipient for the development of SEDDS. The oil components used 
in the SEDDS formulation solubilizing relevant amount of poorly water soluble drug, 
facilitate self-emulsification and increase the absorption of the drug from the gastro 
intestinal tract, depending on the molecular nature of the triglyceride (TG)15.  Some of 
the fatty acids, salts, and esters are aluminium monostearate, calcium stearate, ethyl 
oleate, isopropyl myristate, esters of isopropyl alcohol and palmitic acid, magnesium 
stearate, oleic acid, PEG 40 stearate, propionic acid, sodium stearate and zinc stearate.   
Examples of oils and oil esters  
Almond oil, castor oil, cod liver oil, corn oil, cotton seed oil, diacetylated 
monoglyceride, glycerides of behenic acid, glycerol ester of stearic acid, 
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hydrogenated castor oil, hydrogenated mineral oil, mineral oil, mono and 
diglycerides, oil soluble vitamins, olive oil, orange flower oil, peanut oil, peppermint 
oil, oil soluble vitamins persic oil, polyoxyl 40 hydrogenated castor oil, rose oil, 
safflower oil, sesame oil, soyabean oil, squalene, vitamin E, vitamin E succinate. 
Fatty Alcohols 
They comprise of benzyl alcohol, butyl alcohol, cetostearyl alcohol, lanolin 
alcohol octyldodecanol, oleyl alcohol and stearyl alcohol. 
Phospholipids: Lecithin and derivatives 
Waxes: Carnauba wax, emulsifying wax, hard fat, petrolatum, microcrystalline wax, 
yellow ointment, white wax and yellow wax. 
Triglycerides Vegetable Oils 
Generally, vegetable oils containing Long chain triglycerides (LCT) and 
medium chain triglyceride (MCT) with various degree of saturation are utilzed in the 
design of SEDDS. MCT's are largely replaced by novel semi-synthetic derivatives, 
which can be defined as amphiphilic compounds exhibiting surfactant properties. 
MCT's are also known as fractionated coconut oil which is highly stable and resistant 
to oxidation mainly to the saturation of medium chain fatty acids such as caproic (C6), 
capric (C10), and lauric acid (C12). MCT is rapidly absorbed from the small intestine, 
hydrolyzed after ingestion and is transported through portal circulation and MCT is 
therefore considered to facilitate the uptake of lipophilic drugs. 
Vegetable oils derivatives 
The vegetable oil derivatives popularly used are the vegetable oil 
(hydrogenated), glycerides (mixed), polyoxyl glycerides, ethoxylated glycerides and 
esters of fatty acids with various alcohols. The hydrogenations of the unsaturated 
bonds present in the oil result in a formation of hydrogenated vegetable oils. The 
chemical stability of the oil is increased by hydrogenation. Examples of such 
hydrogenated oils are cottonseed oil, palm oil, castor oil and soybean oil.    
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Mixed partial glycerides  
They are the mixture of mono, di, and tri-glycerides formed by partial 
hydrolysis of triglycerides present in the vegetable oil. The physical state, melt 
characteristics and the HLB of the partial glycerides depend on the nature of the fatty 
acid present and the degree of esterification. The saturated long chain fatty acids are 
used for sustained release purposes16 and  glycerides  with  a  medium  chain  or  
unsaturated fatty acids are used for improving bioavailability. Examples of glycerides 
with the medium chain fatty acids are glyceryl mono capryl caprate (Capmul MCM) 
and with a long chain, fatty acids are glyceryl monooleate (Peceol) and glyceryl mono 
linoleate (Maisine 35-1).    
Ethoxylated glycerides 
They are formed from ethoxylation (etherification) of ricinoleic acid (present 
in glyceride) of castor oil which makes the oil hydrophilic. Examples of such 
glycerides are ethoxylated castor oil (Cremophor EL) and ethoxylated hydrogenated 
castor oil (Cremophor RH40 and Cremophor RH 60). Cremophor’s are widely used as 
surfactants in the formulation of SEDDS because of its amphiphilic nature. Moreover, 
they can dissolve large quantities of drugs, have good self-emulsification property and 
their degradation products are similar to those obtained from intestinal digestion17.  
Polyglycolyzed glycerides (PGG) 
They differ in HLB value as they possess different diverging fatty acid and 
polyethylene glycol (PEG) chain. PEG with vegetable oils has been used to 
solubilizing poorly water soluble drugs for improving their bioavailability. 
Polyalcohol esters of fatty acids 
These are newer oil derivatives that possess surfactant properties because of 
its amphiphilic nature and are effective in replacing conventionally used oils. Their 
composition is based on nature of alcohol used. They can be polyglycerol (Plurol 
Oleique CC 497) and propylene glycol (Capryol), and polyoxyethylene glycol (Mirj). 
Recently the emulsification and solubilization properties of polyglycolyzed glyceride 
based oils, Labrafil M1944 CS (oleoyl macro glycerides), Labrafil M 2125 CS 
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(linoleoyl macrogol glycerides), and Labrasol (caprylo caproyl macro glycerides) in 
self - emulsifying formulations have been explored using Tween 80 and Tween 20 as 
surfactants18.  
Surfactants 
The nonionic surfactants with a high lipophilic and hydrophilic balance (HLB) 
are widely used in designing self - emulsifying drug delivery system. The widely used 
emulsifiers are ethoxylated polyglycolysed glycerides and polyoxyethylene 20 oleate 
(Tween 80). Nonionic surfactants are less toxic than ionic surfactants that result in 
changes in permeability of intestinal lumen which are reversible.  The formulation of a 
stable SEDDS involves the addition of surfactant ranging between 30-60%. For an 
effective absorption, the precipitation of the drug compound within the lumen should 
be  prevented  for  a  long  period  of  time  the  site  of  absorption.  When  a  mixture  of  a  
surfactant containing C8-C10 polyglycolyzed glycerides (Labrafac) are used in 
increase concentration the mean droplet size is smaller in SEDDS. 
Examples of Surfactants and co-surfactants 
Capmul MCM C8, Capryol 90, Carbitol, Cremophor EL, Cremophor RH 40, 
Crodamol EO, Crodamol GTCC, Emulsifier OP, Ethoxylated polyglycolysed 
glycerides, Gelucire® 44/14, Glycerine, Glycerol, Hexanol, Labrafac PG, Labrafil 
2609 WL, Lauroglycol FCC, Maisine 35-1 (glyceryl mono linoleate), Octanol, Oleic 
acid, PEG 200, PEG 400, Pentanol, Plurol Oleique, Plurol Oleique CC 497, 
Poloxamer 188, Poloxamer 407, Polysorbate 80, Propylene glycol, Solutol HS 15, 
Span 20, Span 80, Transcutol, Transcutol HP, etc.  
Cosolvents used in SEDDS 
The solvents like ethanol, propylene glycol and polyethylene glycol (PEG) 
phase19 are used as co solvents in SEDDS formulation which aid the dissolution of 
hydrophilic surfactants of the drug in lipid and used as co-surfactants in SMEDDS. 
The  limitation  of  these  solvents  is  evaporation  through shells  of  soft  or  hard  gelatin  
capsules in conventional SEDDS precipitate the drug. Hence alcohol-free 
formulations are formulated but their lipophilic drug dissolution ability may be 
restricted.  
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Additional excipients in SEDDS 
  To stabilize the oily phase of SEDDS, some excipients such as pH adjusters, 
flavoring agents and antioxidants like butylated hydroxyl toluene, ascorbyl palmitate, 
propyl gallate are added to the formulation. The precipitation of drug in the 
gastrointestinal tract can be prevented by adding a polymeric precipitation inhibitor 
which results in the supersaturated state of the drug after the micro emulsion is 
formed. Hydroxy propyl methyl cellulose is incorporated in the formulation act as a 
precipitation inhibitor for the development of supersaturated SEDDS.   
Phase behavior studies in SEDDS  
The construction of phase diagram is used to study the phase behavioral 
studies of oil, water and surfactant components used in the formulation of SEDDS in 
which the apex of the triangular phase diagram is represented by 100% of that specific 
component. The pseudo ternary phase diagram consists of two components of 
drug/oil, surfactant/co surfactant and water/drug representing the apex of the triangle. 
The delineation of the phase boundary is achieved by increasing the time consuming 
for the system in equilibrium. The process can be rapid by applying heat and 
sonicating the system with amphiphilic surfactants. A series of pseudo binary 
compositions was prepared and titrated with the third component; finally, the mixture 
was evaluated after each addition. The aid of phase diagram is to capture the 
relationship between the phase behavior of a mixture and its composition. By using 
the function of temperature and pressure the compositional variables are studied. The 
amphiphilic co-surfactants added to the system get separated between the water and 
oil interface and reduces the interfacial tension.    
Biopharmaceutical aspects20 of SEDDS 
The various mechanisms responsible for enhanced drug absorption in SEDDS 
are as follows: 
i. The lipid in the GIT causes the delay in gastric emptying. This process enables 
the better dissolution of the drug and improves drug absorption.  
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ii. Lipids in GI tract enhances the production of bile salts (BS), endogenous 
biliary lipid including phospholipids (PL) and cholesterol (CH) which is 
responsible for the development of BS/PL/CH intestinal mixed micelles leads 
to enhancement of solubilization capacity in GIT. Further enhancement of 
solubilization capacity may be due to intercalation of administered 
(exogenous) lipids into already developed BS structures either directly (if 
sufficiently polar) or secondary to digestion causes swelling of micellar 
structures21 
iii. The lipids may enhance the lymphatic transport and increase the 
bioavailability directly or indirectly through the reduction in first pass 
metabolism. The intestinal lymphatic transport is stimulated. 
iv. The physical and biochemical barrier function of the gastrointestinal tract is 
changed. 
v. The oils exhibit a peculiar effect on absorption to the human body: The 
SEDDS formulation form o/w emulsion on gentle agitation due to 
gastrointestinal motility. The self - emulsifying formulations can reduce the 
batch to batch variation of plasma level-time profile. The mechanism of 
absorption of poorly aqueous soluble drugs on oils includes variation of 
gastrointestinal motility with enhanced bile flow, mucosal permeability, 
mesenteric lymph flow and lymphatic absorption which in turn enhances 
gastrointestinal absorption depending on the molecular nature of the 
triglyceride. The peculiar effect of oil absorption depends on the lipophilic 
drug when incorporated into the mixed micelles which are formed on 
digestion of the oil are thereby incorporated into the fatty acid uptake 
mechanism and such drugs are taken up by the lymphatic system, while 
hydrophilic molecules are absorbed into the hepatic portal vein22.  
The schematic diagram for drug absorption pathway from lipid formulations is 
illustrated in Fig. 1. 
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Fig. 1 Pathways for drug absorption from lipid based formulations: a) Change in 
composition and character in the environment of colloids (Mixed micelles, 
micelles) by enhancing drug solubilization. b) Lipids interacting with enterocyte 
based transport and metabolic processes. c) By altering the pathway of transport 
of the drug, therefore, minimizing the effect of hepatic first pass metabolism. The 
sustainability and release of the drug (D) are influenced by altered lipid 
excipients.  
Micellar solubilization properties of SEDDS 
Table 3 describes the classification and characteristics of four lipid based 
formulations based on their varying composition. A crude o/w emulsion of droplet 
size of 1µm is formed in its aqueous dispersion if the solubilization system is stable. 
The type I SEDDS consists of surfactants with HLB value less than 12 of particle size 
ranging from 100-250 nm with the solvent capacity very closer to that of lipid 
solution. The type II SEDDS are prepared with amphiphiles of HLB  value more than 
12, for dissolving the hydrophobic drugs, sometimes co-surfactants are added to 
restore the ability of micellar solubilization within SEDDS.  
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Table 3 : Classification System for Lipid Formulations with Characteristics10 
Parameters 
Lipid 
Solution 
SEDDS 
type 1 
SEDDS 
type 2 
SMEDDS 
Oil (%) 100 40-80 40-80 <20 
Surfactants (%) 0 20-60 
(HLB<12) 
20-60 
(HLB>12) 
20-50 
(HLB>11) 
Cosolvents (%) 0 0 0-40 50-100 
Droplet size (nm) >1000 100-250 100-250 <100 
Ease of self -
emulsification 
Very 
Low 
Low to 
medium 
Medium to 
high 
High 
Solvent capacity Low Low to 
medium 
Medium to 
high 
High 
Loss of solvent capacity 
upon dilution  
None None to 
slight 
Slight to 
moderate 
Moderate to 
high 
Digestibility significance 
on absorption 
Crucial Not crucial, 
not likely to 
occur  
Not crucial 
but may be 
inhibited 
Not required 
not likely to 
occur. 
 
Mechanism of self-emulsification in SEDDS 
In conventional emulsions, the interface between oil and water are stabilized 
by the presence of an emulsifying agent, which forms a protective film around the 
dispersed phase of the globule and the excess of free energy depend on the globule 
size and interfacial tension between two phases. There will be a decrease in surface 
free energy and interfacial tension if the emulsion is not stabilized by surfactants. But 
in the case of SEDDS, spontaneous emulsification results and the surface free energy 
is  much  minimized.  The  self-emulsification  occurs  due  to  the  entry  of  water  in  the  
liquid crystalline phase and it is responsible for droplet formation. The resulting 
nanoemulsion formed against coalescence23 is  formed  due  to  the  stability  of  the  
crystalline liquid phase. 
 
16 
1.5 DEVELOPMENT OF SEDDS FORMULATIONS 
Solubility Studies  
The  solubility  of  the  drug  in  different  oils,  surfactants  and  co  surfactants  are  
determined by adding the excess amount (150 mg/2ml) of the drug sample to each 
glass vials containing oil, surfactant, and solubilizer selected for the formulation of 
SEDDS. The proper mixing of the drug with the vehicles can be performed by sealing 
the mixture of drug samples in glass vials and kept in a vortex mixer for 10 min. The 
equilibrium was attained by shaking the samples at 37 ± 1°C for 72 hours in an 
isothermal shaker. The drug samples are then centrifuged at 5000 rpm for 15 min and 
a solution is subsequently filtered through 0.22µm of a membrane filter. The 
supernatant layer of the drug samples are diluted with organic solvent (methanol) and 
the samples are quantified by a suitable analytical method. Methanol is commonly 
used because it is relatively inexpensive, lots of compounds can be dissolved and 
relatively free of regulation compared to ethanol, cost effectiveness and working 
efficiency.  
Pseudo ternary phase diagram 
The feasibility of the micro emulsion formed is the first step in formulation 
development of SEDDS. The delineation of the boundaries in the pseudo ternary 
phase diagram is accessed from the components shortlisted by the result of solubility 
studies by water titration method24. The different ratios of surfactant to co-surfactant 
are varied and mixed and (1:1, 2:1 and 3:1) on the weight basis. The different ratios of 
oil: Smix (surfactant to co-surfactant mixture) are mixed in the ratios varying from 
1:9 to 9:1 are prepared and the resultant mixture was added drop wise with water in 
which the end point is determined by sign of turbidity and the titration is continued 
until the clear emulsion is formed. The preparation of SEDDS is based on the micro 
emulsion region clarity which is selected based upon the fact that the solution remains 
clear on several dilutions.  
Preparation of L- SEDDS 
A series of SEDDS formulations are generally prepared using different Smix 
combinations  and  the  oil.  In  all  the  formulations,  the  level  of  active  moiety  is  kept  
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constant according to the required dose. The accurately weighed drug is placed in a 
glass vial and oil, surfactant and co surfactant are added according to their ratios. 
Then the components are mixed by gentle stirring and vortex mixing and are heated at 
40-50ºC on a magnetic stirrer if required until the drug is perfectly dissolved. The 
mixture is stored at room temperature until further use. The mixture was observed for 
any signs of turbidity or phase separation for a period of 48 hours. The novel 
preparation is employed by altering temperature and pressure in SEDDS 
formulations25.  
Preparation of S-SEDDS 
S-SEDDS was prepared by mixing liquid SEDDS containing drug with 
Aerosil 200 in 1:1 proportion. In brief liquid, SEDDS was added drop wise over 
Aerosil 200 contained in a broad porcelain dish. After each addition, the mixture was 
homogenized using a glass rod to ensure uniform distribution of formulation. The 
resultant damp mass was passed through sieve no. 120 and dried at ambient 
temperature and stored until further use26. 
Techniques for conversion of liquid SEDDS into solid SEDDS 
The  liquid  formulations  of  SEDDS  are  filled  in  soft  or  hard  capsules  of  
gelatin. Spray drying, adsorption to solid carriers by cross–linked sodium 
polymethylmethacrylate, encapsulation of liquid and semisolid SEDDS, extrusion 
spheronization and melt granulation are some of the techniques used for converting 
liquid SEDDS to solid SEDDS27.  
1.6 EVALUATION TESTS FOR SEDDS 
Evaluation tests for L-SEDDS formulations 
Self-emulsification and Dispersibility test  
The efficiency of self-emulsification of oral micro/nanoemulsion is assessed 
using a standard USP dissolution apparatus II 28, 29. One ml of each formulation is 
added to 500 ml of water at 37 ± 0.5°C. A standard stainless steel dissolution paddle 
rotating at 50 rpm is used to provide gentle agitation. The in vitro performance of the 
formulations is visually assessed from such dispersion using a suitable grading system 
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which has been reported to be based on the formation of a micro emulsion (o/w or 
w/o), micro emulsion gel, emulsion or emulgel is given below:  
Grade A: Rapidly forming (within 1 min) nanoemulsion, having a clear or bluish 
appearance. (Micro emulsion) 
Grade B: Rapidly forming, slightly less clear emulsion, having a bluish white 
appearance. (Micro emulsion gel)  
Grade C:  Fine milky emulsion that formed within 2 min. (Emulsion) 
Grade D: A dull, grayish white emulsion having a slightly oily appearance that is slow 
to emulsify (longer than 2 min). (Emulgel)  
Grade E: Formulation, exhibiting either poor or minimal emulsification with large oil 
globules present on the surface.  
Grade  A  and  Grade  B  formulation  will  remain  as  nanoemulsion  when  
dispersed in GIT, while formulation falling in Grade C could be recommended for 
SEDDS formulation. The primary means of self-emulsification is the visual 
evaluation. The effectiveness of self-emulsification of SEDDS can be optimized by its 
rate of emulsification, droplet size distribution and turbidity measurements.   
Turbidity measurement 
Turbidity measurement determines an efficiency of self-emulsification by 
determining the reproducible time after which the dispersion reaches the 
equilibrium30. The dissolution apparatus is connected to the turbidity meter. The 
apparatus is placed under continuous stirring (50 rpm) on a magnetic plate at ambient 
temperature and a fixed quantity of self-emulsifying system is added to defined 
quantity of suitable medium (0.1N hydrochloric acid).  After every 15 secs, the optical 
clarity  of  the  formulations  is  analyzed  to  determine  the  clarity  of  nano  or  micro  
emulsion formed and emulsification time using a turbidimeter. The rate of change of 
turbidity (rate of emulsification) cannot be monitored because the time required for 
complete emulsification is too short.  
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Droplet size measurement 
The droplet size and polydispersity index (PDI) of L-SEDDS, S-SEDDS by 
diluting it 100 times with double distilled water and were determined using a Malvern 
Zeta Sizer Nano ZS 90 (Malvern Instruments,  Malvern,  UK). The PDI indicates the 
width  of  a  particle  distribution  (e.g.  0.0  for  a  narrow,  0.5  for  a  very  broad  
distribution). Prior to the measurement, the samples were diluted with double distilled 
filtered water to a suitable scattering intensity. All measurements were performed in 
triplicate. The results are expressed as mean size ± SD. 
Zeta Potential measurement (ZP) 
The Zeta potential is a measure of the electric charge at the surface of the 
particles indicating the physical stability of colloidal systems31. ZP was measured 
using  a  Zeta  Sizer  Nano  ZS  90  (Malvern  Instruments,  Malvern,  UK).  Each  sample  
was suitably diluted with double distilled filtered water and placed in a disposable 
zeta cell. The ZP values were assessed by determining the particle electrophoretic 
mobility. The electrophoretic mobility was converted to the ZP via the Helmholtz 
Smoluchowski equation. All measurements were performed in triplicate. The results 
are expressed as mean ± SD.  
Conductance 
The type of micro emulsion (o/w or w/o) can be determined by the measure of 
conductance. It was measured by a conductivity meter. The electro conductivity of the 
resultant system was measured by an electroconductometer. For the conductivity 
measurements, the tested micro emulsions were prepared with a 0.01N aqueous 
solution of sodium chloride instead of distilled water. 
Viscosity Determination  
 SEDDS system is generally administered in soft gelatin or hard gelatin 
capsules. So it can be easily pourable into capsules and such system should not be too 
thick  to  create  a  problem.  The  rheological  properties  of  the  micro  emulsion  are  
evaluated by Brookfield viscometer. The w/o or o/w is confirmed by viscosity 
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determination. If a system has low viscosity then it is o/w type of the system and if a 
high viscosity then it is w/o type of the system.  
Refractive Index and Percent Transmittance   
The refractive index of the system was measured by an Abbe refractometer by 
placing one drop of solution on the slide and it compared with water (1.333). The 
percent transmittance of the system was measured by diluting 1 ml of SEDDS 
formulation to 100 times with double distilled water and analyzed at 650 nm using 
UV spectrophotometer keeping distilled water as a blank. If the refractive index of the 
system is similar to the refractive index of water (1.333) and formulation has percent 
transmittance > 99 percent, then formulation is in transparent nature.  
Cloud point measurement 
The cloud point is the temperature above which the formulation clarity turns 
into cloudiness.  The cloud point is  an essential  factor in the SMEDDS consisting of 
nonionic surfactants and it is responsible for the successful formation of a stable 
micro emulsion. When the temperature is higher than the cloud point, an irreversible 
phase separation will occur and the cloudiness of the preparation would have a bad 
effect on drug absorption, because of the dehydration of the polyethylene oxide 
moiety32. Hence, the cloud point for SMEDDS should be above 37°C, which will 
avoid phase separation occurring in the gastrointestinal tract.  
pH 
The SEDDS were diluted with double distilled water and its pH was measured 
using pH meter. 
Dissolution study 
In vitro dissolution studies of L-SMEDDS and S-SMEDDS were performed as 
per the procedure followed in the “Dissolution Methods for Drug Products” guide of 
Food and Drug Administration33. The dissolution tests were performed in triplicate. A 
graph of percent cumulative drug release against time was plotted. The dissolution 
profiles were evaluated on the basis of dissolution efficiency (DE) and percentage of 
drug dissolved (DP) at 5 min and 60 min, time needed to dissolve 50% of drug (t50%), 
21 
area  under  the  curve  (AUC)  and  mean  dissolution  time  (MDT).  The  DE  of  a  
pharmaceutical form is defined as the area under the dissolution curve up to a certain 
time, t expressed as a percentage of the area of the rectangle described by 100% 
dissolution in the same time.33, 34. It can be calculated by the following equation 
                     t 
                   ò y×dt×100%     
DE =     0              
y100×t 
where y is the percentage of dissolved product. 
The  Mean  dissolution  time  (MDT),  which  is  a  measure  of  the  rate  of  the  
dissolution process was calculated using equation 35. 
i=n 
∑ tmid×DM  
i=1 
MDT = 
i=n 
∑ DM 
i=1 
Assay 
The drug from pre-weighed SEDDS is extracted by dissolving in a suitable 
solvent. The drug content in the solvent extract was analyzed by suitable analytical 
method against the standard solvent solution of drug using the UV-Visible 
spectrophotometer.   
Stability studies 
Robustness to dilution 
The  robustness  of  SEDDS  to  dilution  was  studied  as  per  Date  et al., the 
method with slight modification36. SEDDS were diluted to 10, 100 and 1000 times 
with various media of water, 0.1N hydrochloric acid and pH 7.4 phosphate buffers. 
The diluted micro emulsions were stored for 12 hours and observed for any signs of 
phase separation or drug precipitation. 
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Thermodynamic stability studies 
The objective  of  thermodynamic  stability  is  to  evaluate  the  phase  separation  
and effect of temperature variation on SEDDS formulations. The SEDDS were diluted 
to 100 times with double distilled water and centrifuged at 10,000 rpm for 20 minutes 
and formulations were observed visually for phase separation. To evaluate the effect 
of temperature, the formulations were subjected to freeze–thaw cycles (- 20°C for 2 
days followed by +25°C for 2 days) 37. At the end of the cycle, the formulations were 
diluted and centrifuged as described above and phase separation and the change in 
droplet size were determined. 
Physical and chemical stability 
Physical and chemical stability was evaluated by storing the L- and S-
SMEDDS samples at 4-8°C (refrigerator) and 25°C for up to 6 months. Samples were 
withdrawn  at  predetermined  time  intervals  after  1,  2,  3  and  6  months.  The  clarity,  
phase separation, particle size and ZP after dilution with double distilled water at 
1:100 were measured for physical stability of SEDDS. In addition, chemical stability 
of SEDDS was determined by UV spectrometric method/ HPLC assay and dissolution 
method. 
In vitro permeability studies 
The diffusion studies were executed in a Franz diffusion cell using cellophane 
membrane as a barrier38. The ex-vivo studies were carried out by replacing cellophane 
membrane with goat intestine sac/stomach. The stomach/intestinal part are rinsed with 
cold ringer’s solution to remove the mucous and lumen contents. The SEDDS sample 
is diluted with 1 ml of distilled water (outside mixing for 1 minute by vortex mixer). 
The resultant sample (2mg/ml) is injected into the lumen of the stomach/duodenum 
using a syringe and both the sides of the intestine are tightly closed. Then the tissue is 
placed in a chamber of organ bath with continuous aeration and a constant 
temperature of 37 0C. The receiver compartment is filled with 30 ml of phosphate 
buffer solution pH 7.4). The aliquots arre collected at periodical intervals of time up 
to 6 hours. The absorbance is measured using a UV-VIS spectrophotometer at the 
specific wavelength, keeping the respective blank. The percent diffusion of the drug is 
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calculated against time and plotted on a graph. The results are compared with that of 
pure drug.  
Everted sac technique  
An albino rat (male) was fasted for 24 hours and anesthetized with 
chloroform. The ileum was removed and transferred into the beaker containing ice 
cold phosphate buffer pH 7.4 and was aerated. The contents were removed by 
flushing with buffer using 2 ml glass syringe using a glass rod designed specifically. 
The intestine was everted, tied at one end. The fresh buffer was filled in the sac and 
tied at another end. The sac was suspended in the receptor fluid (saline phosphate 
buffer of pH 7.4) of 200 ml which contains drug solution. 
 This method can be used to determine kinetic parameters with high reliability 
and reproducibility. The oxygenated tissue culture media and specific preparation 
techniques ensure tissue viability for up to 2 hours. The technique can be used to 
study drug transport across the intestine and into the epithelial cells, provided that 
sensitive detection methods are employed 39.  
Determination of flux 
The cumulative amount of drug permeated was plotted against time and the 
angular coefficient of that curve provides the flux (J) value. The following equation 
was used to calculate the permeability coefficient (Kp) 40 
Kp = J/C 
where C is the initial concentrations of drug in the SMEDDS formulation. 
In vivo Pharmacokinetic study 
The relative bioavailability studies performed in SEDDS were compared with 
marketed formulations and standard drug. The drug plasma concentration values were 
determined from the calibration curve. The trapezoidal method was employed to 
calculate the area under the curve (AUC) of plasma concentration as a function of 
time (t). The Mean residence time (MRT) was calculated as area under the first 
moment  curve  (AUMC)  divided  by  AUC.  AUMC  was  determined  from  the  plot  of  
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plasma concentration multiplied by time (C x t) versus time. All the pharmacokinetic 
parameters were calculated using MS-Excel software. The maximum plasma 
concentration (Cmax) and the time to reach maximum plasma concentration (tmax) 
were determined by the plasma concentration curve using MS-Excel software. The 
elimination  rate  constant  (Kel)  was  calculated  by  the  regression  analysis  from  the  
slope of the line and the half-life (t1/2) of the drug was obtained by 0.693/Kel. Other 
parameters, clearance (Cl) and volume of distribution at steady state (Vss) were 
calculated using the following equations: Cl = Dose/AUC and Vss = Dose X AUMC/ 
(AUC) 41. 
Evaluation of S-SEDDS 
Flow properties of S-SEDDS 
Angle of repose 
The angle of repose of S-SEDDS was determined by funnel method. 
Accurately weighed sample was taken in a funnel. The height of the funnel was 
adjusted in such a way that the tip of the funnel just touches the apex of the heap of S-
SEDDS powder. The powder was allowed to flow through funnel freely onto the 
surface. The diameter of the powder cone was measured and angle of repose 
calculated using the following equation42.  
q = tan-1 h/r 
where h and r are the height and radius of the heap of powder 
Bulk density 
Both loose bulk density (LBD) and tapped bulk density (TBD) were 
determined for       S-SEDDS. A quantity of 2 g of S-SEDDS was introduced into a 10 
ml measuring cylinder. The initial volume was observed, the cylinder was allowed to 
fall under its own weight onto a hard surface from a height of 2.5 cm at 2-second 
intervals. The tapping was continued until no further change in volume was noted. 
LBD and TBD were calculated using the following formulae   
LBD =Weight of powder/Volume of packing 
TBD =Weight of powder/Tapped volume of packing.  
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Compressibility Index 
The compressibility of the granules was determined by Carr’s Compressibility 
Index. 
Carr's compressibility index (%) = TBD-LBD/TBD× 100. 
Hausner ratio 
A similar index like compressibility index has been defined by Hausner. 
Hausner ratio can be calculated by a formula:  
Hausner ratio =TBD/LBD 
Reconstitution properties of S-SEDDS 
Dilution study by visual observation 
The dilution study was done to study the effect of dilution on S-SEDDS, 
because  dilution  may  better  mimic  the  condition  of  the  stomach  after  oral  
administration. In this method, S-SMEDDS (100 mg) was introduced into 100 ml of 
double distilled water in a glass beaker that was maintained at 37ºC and the contents 
were mixed gently using a magnetic stirrer. The tendency to emulsify spontaneously 
and progress of emulsion droplets were observed with respect to time. The 
emulsification ability of S-SMEDDS was judged qualitatively “good” when clear 
micro emulsion formed and “bad” when there was turbid or milky white emulsion 
formed after stopping of stirring43. 
Hausner ratio  
Pellets (100g) are placed in a 10 ml volumetric cylinder and their volume is 
determined. The bulk density is calculated as g/cm3.The cylinder was then tapped 
1250 times and the volume is determined again afterward to calculate the tapped 
density. 
Hausners ratio = Tapped density/Bulk Density 
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Water content  
The residual water content present in the pellets after drying was determined 
by thermo gravimetric or IR-LOD apparatus (Infra Red- Loss on drying) connected to 
a sample analyzer. The moisture content was determined using IR-LOD apparatus. A 
specified amount (3 g) of pellets was kept so as to cover the full surface of the pan. 
The equipment was operated at 105o C for 15 min. After 15 min, the percentage 
moisture content was recorded from the digital recorder.  
Friability  
About  5  gm  accurately  weighed  pellets  were  taken  from  the  modal  class  
fraction of the pellets and placed in a Roche friabilator and tumbled for 200 
revolutions at 25 rpm. Twelve steel balls (diameter 6.3 mm, weighing 1.028 gm each) 
were used as attrition agents. After friability testing, the pellets were sieved through a 
series  of  sieves.  The  weight  loss  (%  F)  after  friability  testing  was  calculated  by  
formula given below  
% Friability = Initial weight –Final Weight/Final weight×100 
where the initial weight of the pellets before friability testing and the final weight of 
pellets retained above the sieve with 0.355 mm aperture size after friability testing 
were determined.  
Disintegration time 
 The disintegration time of pellets in size fraction mode value was studied in 
deionised water at 370C using a disintegration test apparatus. Six pellets from each 
formulation were evaluated. The end point was taken as the time for the disintegration 
of the pellets. The mesh size used is 35 (500 μm) in place of 10 (2000 μm) mesh.  
DSC analysis 
The physical state of the drug in S-SEDDS/SMEDDS was characterized by 
Differential Scanning Calorimetry). The thermograms of standard drug powder, 
aerosil 200, their physical mixture (PM) and S-SMEDDS were recorded in order to 
characterize the physical state of a drug. A heating rate of 10°C/min was employed in 
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the range of 25-300°C with nitrogen atmosphere supplied at 40 ml/min. Each sample 
was taken (∼4-8 mg) in an aluminum pan, crimped and sealed. An empty aluminum 
pan was used as a reference.   
XRD analysis 
XRD diffractograms of standard drug powder, aerosil 200, their physical 
mixture and S-SMEDDS were obtained using Bruker AXS D8 Advance X-ray 
diffractometer. Scans were performed between 5º < 2θ < 80º. 
Scanning electron microscopy  
The pellets morphology is evaluated by scanning electron microscopy (SEM). 
Samples are examined using a scanning electron microscope at 10 kV accelerating 
voltage using the secondary electron technique. 
Stability studies  
The optimized self-emulsifying pellet or tablet dosage forms containing the 
lipid formulation are subjected to accelerated stability studies. Two ounce amber 
colored glass containers, each containing 5 gm pellets are stored at 40C in temperature 
controlled ovens at 250 and 300C; light stability chamber at 250C UV irradiation (350 
nm) using a 60W black light; and in humidity chambers at 250C/60% RH, 300C /60% 
RH, and 400C/75% RH. These conditions are selected to facilitate comparison of 
stability data without strictly adhering to the ICH guidelines which recommend 
300C/65%  RH  as  the  intermediate  storage  condition.  The  saturated  salt  solutions  of  
sodium bromide (for 60% RH) and sodium chloride (for 75% RH) are used to 
maintain the humidity conditions. An equivalent amount of pellets is removed at each 
time point (15 days, 1 month, 1.5 months and 4 months) and evaluated for their 
hardness and dissolution profiles.  
1.7   DESIGN OF EXPERIMENTS (DOE) FOR SEDDS 
The primary goal of the pharmaceutical investigator is to develop an optimally 
performing product or process through various techniques such as experimental 
design, modeling, and optimization strategies with the efficient determination of a set 
of conditions. There are numerous literature references for solid dosage form 
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development, relatively little has been published concerning solution or disperse 
systems44 using these techniques which are useful for determining rational limits for 
critical formulation or processing variables, outside of which unacceptable product 
would be produced. The "design" of an experiment is simply defined as the plan that 
governs the performance of the experiment. The use of properly designed reduce the 
procedural errors in data collected. The observations resigned from a designed 
experiment are examined using analysis of variance (ANOVA) techniques in which 
the variance associated with a particular independent variable or interaction between 
independent variables is compared with a variance associated with the random error 
occurs in the experiment. If there is a difference between the treatment and error 
variances, then the treatment being tested is considered to have a significant effect on 
the measured response. The comparisons between variances are used in F test or F 
distribution test. Orthogonal designs are two perpendicular lines, neither having an 
effect on the direction of the other. For experimental design, orthogonality is defined 
as follows  
N                                                                                                                                                             
∑ xiu xju = 0 (i ≠ j) where independent variable levels are coded such that  
u=1 
 
N     N 
∑ xiu = 0 for = 1,2…k. and ∑ x2iu = N  
u=1          u=1                                                                                                                
where N is the number of experimental trials and xiu and xju represents the uth level 
of variables i and j for k variables. For factorial designs, the variable levels are fixed 
equally spaced and coded at -1(low level), +1(high level) and 0 (midpoint). 
In many fields45 the problem of experimental design or design of experiments 
(DOE) is encountered. The terms of factors or design variables (Xi,  X2 ...Xn), set at 
specified levels (predefined values) and response variables of interest or responses 
(Yi, Y2 ...Ym) constitute an experimental design which is represented by the sequence 
of experiments to be performed. The relationship between design variables and 
responses is complicated and requires statistically designed experiments in many 
cases. In DOE ‘n' is the total number of design variables in which each of design 
variables combination could be visualized as a point in the n-dimensional design 
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space. An experimental design is a design of experiments in which the particular 
arrangement of points is designed in the design space. In pharmaceutical 
development, DOE can be used to underline the relationship between formulation or 
process variables and their influence in obtaining the optimized formulation. When 
the responses are influenced by the design variables and the exact relationship is 
unknown, it is often helpful to approximate this relationship with an empirical model: 
Yi= f (Xi, X2... Xn). Usually, the function f(X) is a first- or second-order polynomial. 
When this empirical model is second order then it is called a response surface model 
(RS Model), response surface methodology (RSM), or curve fit.  
Response surface methodology 
A useful tool for developing, improving and optimizing processes46 is 
response surface methodology which is termed as a collection of statistical and 
mathematical techniques useful for building an empirical model and model 
exploration. To obtain a regression model and to find a suitable approximation for the 
time functional relationship between the responses and the set of independent 
variables response surface methodology was devised. The basic idea is to screen 
several variables and identify a few variables to perform RSM. 
Screening 
Screening experiments are used to reduce the set of factors to those that are 
most influential to the responses being investigated, when the number of factors is 
large or when experimentation is expensive. 
First-order experimentation: 
A first order polynomial model is employed as a response surface model, 
when the objective of an experimental design is to identify the most significant design 
variables, ignoring possible interactions between these variables. The mathematical 
relationship in this model is, 
Y1 = Ao+ A1Xl + A2X2 + ... AmKm. 
where Ao is the intercept and A1, A2 and Am are the coefficients of factors X1, X2 and 
Xm. 
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Second-order experimentation: 
A second-order polynomial model is used if there is curvature in the system 
and the interactions between design variables play a significant role in the underlying 
relationship between a particular response and the design variables. The mathematical 
form of the model is, 
Y1=Ao + A1X1 + A11X1' + A2X2 + A22X22 + A12X1X2 +…. 
where A12 is the interaction coefficient of X1 and X2.  
The experimental runs should be must be greater than or equal to the number 
of coefficients in the model, when at least three levels of the factors are required to 
construct this model. The first- or second-order models are utilized to solve all 
problems.  
Design of experiments by factorial and fractional factorial designs 
The simultaneous main effects and their interactions are estimated by most 
basic experimental factorial designs. In this design, a polynomial model is used as a 
response surface model where the coefficients of the polynomial can be estimated 
using the method of least squares. The RS model, however, should not be used to 
predict the values of the responses far outside the points that are used to construct this 
RS model. Therefore, in order to estimate the relationship between the response and 
the design variables within a multidimensional box in the design space, the box 
should be defined by the upper and lower limits of the design variables, in this case, 
the responses are estimated at the vertices of this multidimensional box. The 
arrangement of points in the design space is called a full factorial experimental 
design. 
It’s because design variables are involved in the RS model often are referred 
to as factors in statistics, the design is called a factorial. The product of the number of 
levels for each factor is the number of design points dictated by a full factorial design. 
The most common are 2n (for evaluating main effects and interactions) and 3n designs 
(for evaluating main and quadratic effects and interactions) for n factors at 2 and 3 
levels, respectively. Factorial designs are often used in pharmaceutical applications 
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when design variables or factors are five or less. A factorial design was employed for 
the evaluation, optimization of the operating parameters and the HLB value of 
different oil in water emulsions47. A full factorial design was also used to evaluate the 
effect of plasticizer concentration and the volume of coating dispersion on the release 
of propranolol from pellets coated with Eudragit RS48. Lipps and Sakr49 used a 
randomized full factorial (32) design to investigate the effects of processing conditions 
on granulation of acetaminophen powder using 5% polyvinyl pyrrolidone as the 
binder. The 32 factorial design was successfully applied to the optimization of process 
variables for the preparation of ibuprofen coprecipitates50. To make the factorial 
designs more practical, it is possible to estimate the responses, not at all the vertices 
of the box, but at a subset of the vertices only51. The experimental design obtained is 
called a fractional factorial design and is denoted according to the number of points in 
the design, 2(n-m), where n is the total number of design variables and m is an integer 
number smaller than n. Fractional factorial designs are used when experiments are 
costly and many factors are required. The most common fractional factorial designs 
are 2(n-m) designs in which the fraction is 1/2m. 
The 23 full factorial design illustrated in figure 2 (a) shows the estimation of 
all main effects (X1,  X2,  X3),  all  two factor  interactions  (X1X2,  X1X3,  and  X2X3) as 
well as the three factor interaction (X1X2X3). The 2(3-1) fractional factorial is indicated 
by the solid dots in figure 2(b), the main effects, however are biased with the two 
factor interactions. The screening of important factors is identified by using 2n and 2(n-
m) designs. The system is assumed to be dominated by main effects and low-order 
interactions when there are numerous factors. The greatest effects are identified by 
two level fractional factorial designs which are also used to screen them. 
 
Fig. 2a 23 Full Factorial Fig. 2b 23-1 Fractional Factorial 
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Statistical software tools for designing SEDDS 
Selecting the appropriate design is essential for effective experimentation 
where the desire is to gain as much information as possible about the response-factor. 
There are several interactive statistical software packages that support phase of 
experimental  design  which  include  Design  Ease  (Stat-Ease  Inc.,  Minneapolis,  MN),  
Jass (Joiner Associates, Inc., Madison, WI), X-STAT (Wiley Professional Software, 
New York, NY) and CADE (International Quality Technology, Ltd Plymouth, MN), 
ECIP (Expert in a chip Inc., Hockessin, DE) and RS/Discover (BBN Software 
products Corp., Cambridge, MA) are useful software packages for classic, mixture 
and optima  designs52.  
Commercially available Lipid formulations in market53  
The currently estimated oral lipid based formulations are 2- 4 % which are 
commercially available in the market above 20 years. 
Sand immune® (Cyclosporine) 
Category: Immunosuppressant for organ transplantation. 
Molecular weight: 1202.61 
Log P: 2.92 (approx) 
Dose: 25-700 mg (2-10 mg/kg) 
Formulation and ingredients: Soft gel: 25-100 mg cyclosporine in ethanol, 
corn oil, Labrafil M 2125 CS, gelatin, glycerol. Oral solution: 100 mg/ml in 12.5 % 
ethanol, olive oil, Labrafil M 1944. 
Norvir ® (Ritonavir) 
Category: Antiretroviral agent 
Molecular weight: 720.9 
Log P: 5.28 
Dose: 1200 mg (600 mg BID) 
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Formulation and ingredients: Soft gel: 100 mg Ritonavir, ethanol, oleic acid, 
polyoxyl 35 castor oil, butylated hydroxytoluene. Oral Solution: 80 mg/ml drug in 
ethanol (43%w/v), polyoxyl 35 castor oil, propylene glycol, citric acid. 
Fortovase ® (Saquinavir)  
Category: Antiretroviral agent 
Molecular weight: 670.84 
Log P: 4.40 
Dose: 1200 mg 
Formulation and ingredients: Soft gel: 200 mg drug in medium chain mono 
and diglycerides and povidone. 
Aptivus ® (Tipranavir) 
Category: Antiretroviral agent 
Molecular weight: 602.66 
Log P: 7.2 
Dose: 1000 mg (with 400 mg Ritonavir) 
Formulation and ingredients: Soft gel: 250 mg Tipranavir, polyethylene glycol 
400, vitamin E polyethylene glycol succinate, purified water, and propylene glycol 
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1.8 DRUG PROFILE 
Drug I: Atorvastatin Calcium54-56  
Chemical structure: 
 
Category:  Cardiovascular agent and antihyperlipoproteinemic 
Chemical name: Atorvastatin calcium is (βR, δR)-2-(p-fluorophenyl) – β,δ- 
dihydroxy -5-isopropyl-3-phenyl-4-(phenyl carbamoyl) pyrrole-1-heptanoic acid (1:2) 
trihydrate2. 
Molecular formula: C66H68CaF2N4O103H2O 
Molecular weight: 1209.4 
BCS Class: Class II (Low solubility high permeability) 
Physical state and appearance: White to off-white crystalline powder  
Description 
 Atorvastatin belongs to the drug class known as statins. It is used for lowering 
cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase which is the rate-determining enzyme in 
cholesterol biosynthesis through the mevalonate pathway. HMG-CoA reductase 
catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in 
the liver. The decreased hepatic cholesterol levels increase hepatic uptake of 
cholesterol and reduce plasma cholesterol levels.  
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Solubility 
The drug is freely soluble in methanol, soluble in dimethylsulphoxide 
(DMSO), dimethyl formamide (DMF) and insoluble in aqueous solution with pH less 
than  4.0.  It  is  very  slightly  soluble  in  distilled  water,  phosphate  buffer  (7.4)  and  
acetonitrile. It is slightly soluble in ethanol. 
Pka: 4.46  
Log p (Octanol/Water): 5.39 
Melting point: 159.2-160.7 °C 
Mechanism of Action 
Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting 
HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the 
number of hepatic LDL (low density lipoprotein) receptors on the cell-surface to 
enhance uptake and catabolism of LDL. Atorvastatin also reduces LDL production 
and the number of LDL particles. 
Absorption  
Atorvastatin is rapidly absorbed after oral administration with maximum 
plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of 
atorvastatin (parent drug) is approximately 14% and the systemic availability of 
HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic 
bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-
pass metabolism in the liver. 
Volume of distribution: 381 L. 
Protein binding:  More than 98% bound to plasma proteins 
Metabolism 
Atorvastatin is extensively metabolized to ortho- and para-hydroxylated 
derivatives and various beta-oxidation products. The in vitro inhibition of HMG-CoA 
reductase by ortho and para-hydroxylated metabolites is equivalent to that of 
atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA 
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reductase is attributed to active metabolites. CYP3A4 is also involved in the 
metabolism of atorvastatin.  
Half-life:  The  half-life  of  the  drug  is  14  hours,  but  the  half-life  of  HMG-CoA  
inhibitor activity is 20-30 hours due to longer-lived active metabolites.   
Toxicity: The side effects are myalgia, constipation, asthenia, abdominal pain and 
nausea. The other possible side effects include myotoxicity (myopathy, myositis, and 
rhabdomyolysis) and hepatotoxicity. The toxicity in Asian patients can be avoided by 
lowering the doses.  
Dose: The starting dose of the drug is 10mg/day and maximum recommended dose is 
20mg/day. A dose of 10-80 mg daily is given depending upon the diseased conditions. 
Drug II: Glibenclamide 54-58 
Chemical structure 
 
Category: Antidiabetic 
Chemical name: Glibenclamide is 1-{4-[2-(5-chloro-2-methoxybenzamido) ethyl} 
benzenesulphonyl}-3-cyclohexylurea. 
Molecular formula: C23H28ClN3O5S 
Molecular weight: 494 
BCS Class: Class II (Low solubility high permeability) 
Physical state and appearance: A white or almost white crystalline powder 
Description: Glibenclamide is an oral anti hyperglycemic agent used for the 
treatment of noninsulin dependent diabetes mellitus (NIDDM). It belongs to the 
sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the 
pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and 
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meal-stimulated insulin release. Sulfonylureas also increase peripheral glucose 
utilization, decrease hepatic gluconeogenesis and may increase the number and 
sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though 
less so than insulin.  
Solubility: The drug is practically insoluble in water, slightly soluble in alcohol and 
in methyl alcohol. It is sparingly soluble in dichloromethane. 
Pka: 5.3 
Log p (Octanol /Water): 4.8 
Melting point: 172-174°C  
Mechanism of Action: Sulfonylureas such as glibenclamide bind to ATP-sensitive 
potassium channels on the pancreatic cell surface, reducing potassium conductance 
and causing depolarization of the membrane. The depolarization stimulates calcium 
ion influx through voltage sensitive calcium channels, raising intracellular 
concentrations of calcium ions, which induces the secretion or exocytosis of insulin. 
Absorption: The drug absorption is significant within 1 hour and peak plasma levels 
are reached in 2 to 4 hours and the onset of action occurs within one hour. 
Volume of distribution (Vd): Steady state Vd =0.125 L/kg; Vd during elimination 
phase=0.155 L/kg.  
Protein binding: The unchanged drug is approximately 99% bound to serum proteins 
and 4-trans-hydroxyglyburide is greater than 97% bound to serum proteins.  
Metabolism: The metabolism of the drug occurs by the liver (mainly cytochrome 
P450 3A4). The major metabolite is 4-trans-hydroxy derivative. The retention of 
major metabolite 4-trans-hydroxyglyburide may prolong the hypoglycemic effect in 
patients with severe renal impairment.  
Half-life: The half-life of the unchanged drug is 1.4-1.8 hours and 10 hours with 
metabolites included. The duration of effect is 12-24 hours.   
Dose: The oral dose of the drug is 2.5 mg-5 mg daily with breakfast. The increments 
may be of 2.5 – 5 mg daily up to 15 mg daily. 
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1.9 EXCIPIENT PROFILE 
Sunflower oil 59  
Nonproprietary Names: 
BP: Refined Sunflower Oil 
Ph Eur: Sunflower Oil, Refined 
USP-NF: Sunflower Oil 
Chemical name: Sunflower oil 
Structural Formula: Sunflower oil is classified as the oleic linoleic acid oil. The 
composition of oil includes linoleic acid (66%), oleic acid (21.3%), palmitic acid 
(6.4%), arachidic acid (4.0%), stearic acid (1.3%), and behenic acid (0.8%). The USP 
32–NF-27 describes sunflower oil as a refined fixed oil obtained from the seeds of 
Helianthus Annuus Linne (Fam. Asteraceae alt. Compositae). The Ph Eur 6.2 
describes sunflower oil as the refined fatty oil obtained from the seeds of Helianthus 
Annuus C. by mechanical expression or by extraction. A suitable antioxidant may be 
added.  
Description: Sunflower oil occurs as a clear, light yellow-colored liquid with a bland, 
agreeable taste. 
Boiling point: 40–60°C 
Density: 0.915–0.919 g/cm3 
Hydroxyl value: 14–16 
Iodine number: 125–140 
Melting point: -18°C 
Refractive index: 1.472-1.474 
Specific gravity: 0.914-0.924 
Saponification value: 180-200 
Solubility: Miscible with benzene, chloroform, carbon tetrachloride, diethyl ether and 
light petroleum; practically insoluble in ethanol (95%) and water. 
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Functional Category: Diluent, emollient, emulsifying agent, solvent and tablet 
binder.  
Stability and storage conditions: Sunflower oil should be stored in an airtight, well-
filled container, protected from light. Stability may be improved by the addition of an 
antioxidant such as butylated hydroxytoluene. 
Coconut Oil 59 
Nonproprietary Names:  
BP: Coconut Oil, 
JP: Coconut Oil 
Ph Eur: Coconut Oil, Refined 
USP-NF: Coconut Oil 
Chemical name: Coconut oil 
Structural Formula: Coconut oil contains triglycerides, the fatty acid constituents of 
which are mainly lauric and myristic acids with smaller proportions of capric, caproic, 
caprylic, oleic, palmitic and stearic acids. The PhEur 6.2 and USP32–NF27 state that 
the fatty acid composition for coconut oil is caproic acid (41.5%), caprylic acid (5.0–
11.0%), capric acid (4.0–9.0%), lauric acid (40.0–50.0%), myristic acid (15.0–
20.0%), palmitic acid (7.0–12.0%), stearic acid (1.5–5.0%), arachidic acid (40.2%), 
oleic acid (4.0–10.0%), linoleic acid (1.0–3.0%), linolenic acid (40.2%) and 
eicosenoic acid (40.2%). 
Description: Coconut oil generally occurs as a white to light-yellow mass or colorless 
or light yellow clear oil, with a slight odor characteristic of coconut and a mild taste. 
Boiling point: > 450°C 
Density: 0.915–0.919 g/cm3 
Flash point: 216°C 
Hydroxyl value: 14–16 
Iodine number: 8-9.5 
Melting point: 23-26°C 
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Refractive index: 1.448-1.450 
Specific gravity: 0.918-0.923 
Saponification value: 180-200 
Solubility: Practically insoluble in water; freely soluble in dichloromethane and in 
light petroleum, soluble in ether, carbon disulfide, and chloroform; soluble at 60°C in 
2 parts of ethanol (95%) but less soluble at lower temperatures. 
Functional Category: Emollient; ointment base. 
Stability and Storage Conditions: Coconut oil remains edible and mild in taste and 
odor for several years under ordinary storage conditions.  
Corn Oil 59 
Nonproprietary Names: 
BP: Refined Maize Oil 
JP: Corn Oil 
PhEur: Maize Oil, Refined 
USP-NF: Corn Oil 
Chemical name: Corn oil 
Structural Formula: Corn oil is composed of fatty acid esters of glycerol known 
commonly as triglycerides. Typical corn oil produced in the USA contains five major 
fatty acids such as linoleic 58.9%; oleic 25.8%; palmitic 11.0%; stearic 1.7% and 
linolenic 1.1%. Corn grown outside the USA yields corn oil with lower linoleic and 
higher oleic and higher saturated fatty acid levels. Corn oil also contains small 
quantities of plant sterols. The USP 32 describes corn oil as the refined fixed oil 
obtained from the embryo of Zea mays Linne (Fam. Gramineae).  
Description: Clear, light yellow colored, oily liquid with a faint characteristic odor 
and slightly nutty, sweet taste resembling cooked sweet corn. 
Boiling point: > 450°C 
Density: 0.915–0.918 g/cm3 
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Flash point: 321°C 
Hydroxyl value: 8–12 
Iodine value: 109-133 
Melting point: -18 to -10°C 
Refractive index: 1.470-1.474 
Specific gravity: 0.914–0.921 
Saponification value: 187-193 
Solubility: Miscible with benzene, chloroform, dichloromethane, ether, hexane and 
petroleum ether; practically insoluble in ethanol (95%) and water. 
Functional Category: Oleaginous vehicle; solvent. 
Stability and Storage Conditions: Corn oil should be stored in an airtight, light-
resistant container in a cool, dry place. The exposure to excessive heat should be 
avoided and prolonged exposure to air leads to thickening and rancidity. Corn oil may 
be sterilized by dry heat, maintaining it at 150°C for 1 hour60. 
Sesame oil59 
Nonproprietary Names 
BP: Refined Sesame Oil 
JP: Sesame oil 
PhEur: Sesame oil, Refined 
USP-NF: Sesame oil 
Chemical name: Sesame oil 
Structural Formula: A typical analysis of refined sesame oil indicates the 
composition of the acids, present as glycerides, to be as arachidic acid 0.8%; linoleic 
acid 40.4%; oleic acid 45.4%; palmitic acid 9.1% and stearic acid 4.3%. Sesamin, 
complex  cyclic  ether,  and  sesamolin,  a  glycoside  are  also  present  in  small  amounts.  
The monographs for Sesame Oil in the USP32 NF27 and Refined Sesame Oil in the 
PhEur 6.3 specify the acceptable range of eight triglycerides found in sesame oil.  
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Description: Refined sesame oil is a clear, pale yellow colored liquid with a slight, 
pleasant odor and a bland taste. It solidifies to a soft mass at about -48°C. 
Density: 0.916–0.920 g/cm3 
Flash point: 338°C  
Freezing point: -58°C 
Refractive index: 1.4650–1.4665 
Specific gravity: 0.916–0.921 
Iodine value: 103-116. 
Saponification value: 188-195. 
Solubility: Insoluble in water; practically insoluble in ethanol (95%); miscible with 
carbon disulfide, chloroform, ether, hexane and light petroleum. 
Functional Category: Oleaginous vehicle and solvent. 
Stability and Storage Conditions: Sesame oil should be stored in a well filled, 
airtight, light resistant container, at a temperature not exceeding 40°C. The Ph Eur 6.3 
permits  the  addition  of  a  suitable  antioxidant  to  sesame  oil. Sesame oil may be 
sterilized by aseptic filtration or dry heat. It has been demonstrated that dry heat 
sterilization of sesame oil at 150°C for  1  hour  is  sufficient  to  kill  all  added  bacillus  
subtilis spores61.  
Mustard oil 62 
Description: The oil is obtained from good quality of mustard cake or from clean and 
sound seeds of Brassica Compestris Linn, Brassica juncea Linn, Czern or the mixture 
of seed all belonging to the family Cruciferae, by a process of solvent extraction or 
from the mustard seeds by the process of expression.  
Types and Grades: 
The oil can be classified as following types and grades. 
a) Expressed type i) Refined grade ii) Raw grade I iii) Raw grade II 
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b) Solvent extracted i) Refined, ii) Semi refined iii) Raw grade I iv) Raw grade II. 
The refined grade mustard oil of the expressed and solvent extracted types and 
the raw grades of expressed types are suitable for direct edible consumption. 
Refractive Index: 1.4646 – 1.4666 
Saponification value: 169-177 
Iodine value: 98-110 
Acid value:  
i) Refined grade mustard oil -0.5 
ii)  Raw grade I mustard oil -1.5 
iii)  Raw grade II mustard oil - 60 
Storage Conditions: Mustard oil must be stored in well closed container 
Rice bran oil 63 
Description: The rice bran oil shall be obtained from the layer around the endosperm 
of rice obtained from paddy of Oryza sativa Linn of family Gramineae and which is 
removed during the process of rice milling and is generally known as rice bran. 
Grades: The  oil  shall  be  of  the  following  three  grades:  a)  Refined  Grade,  b)  Raw  
Grade I, and c) Raw Grade II. The Refined Grade is suitable for edible purposes.  
Refractive index: Refined Grade: 1.460 to 1.470  
Specific gravity: Refined Grade: 0.910 to 0.920 
Saponification value: Refined Grade: 180-195 
Iodine value: Refined grade: 90-105. 
Acid value: Refined grade: Maximum of 0.5. 
Flash point: 250 
Storage Conditions: Rice bran oil must be stored in a well closed container.  
Olive oil 59 
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Nonproprietary Names 
BP: Refined Olive Oil 
JP: Olive Oil 
PhEur: Olive Oil, Refined 
USP-NF: Olive Oil 
Chemical Name: Olive oil  
Structural formula: Olive oil is a mixture of fatty acid glycerides. The analysis of 
olive oil shows a high proportion of unsaturated fatty acids, and a typical analysis 
shows that the composition of the fatty acids such as Myristic acid  £ 40.5%, Palmitic 
acid of 7.5–20.0%, Palmitoleic acid of 0.3–5.0%, Heptadecanoic acid  £  40.3%, 
Stearic acid - 0.5–5.0%, Oleic acid- 55.0–83.0%, Linoleic acid -3.5–21.0%, Linoleic 
acid £  40.9%, Arachidic acid £  40.6%, Eicosaenoic acid £ 40.4%, Behenic acid £  
40.2% and Lignoceric acid £ 41.0%. Sterols are also present. 
Description: Olive oil is the fixed oil obtained by cold expression or other suitable 
mechanical means from the ripe drupes of Olea europaea. It occurs as a clear, 
colorless or yellow, transparent oily liquid. It may contain suitable antioxidants. 
Refined olive oil is obtained by refining crude olive oil such that the glyceride content 
of the oil is unchanged. A suitable antioxidant may be added. 
Flash point: 225°C 
Refractive index: 1.4657–1.4893 
Smoke point: 160–188°C 
Saponification value: 190–195 
Iodine value: 79–88 
Solubility: Slightly soluble in ethanol (95%), miscible with ether, chloroform, light 
petroleum (50–70°C) and carbon disulfide.  
Specific gravity: 0.910–0.915 
Functional Category: Oleaginous vehicle. 
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Stability and Storage Conditions: When cooled, olive oil becomes cloudy at 
approximately 10°C and becomes butter like mass at 0°C. Olive oil should be stored 
in a cool, dry place in a tight, well filled container, protected from light. 
Peceol 59 
Source: Gattefosse 
Nonproprietary Names 
BP: Glycerol Mono oleate 
PhEur: Glyceryl Mono oleate 
USP-NF: Glyceryl Mono oleate 
Chemical Name: 9-Octadecenoic acid (Z), monoester with 1, 2, 3-
propanetriol 
Structural Formula: 
            H                 O 
 
H         C         O      C        C17H33 
 
H         C         OH 
 
H         C            OH 
 
            H 
Description: The PhEur 6.3 describes glyceryl monooleate as being a mixture of 
monoacylglycerols, mainly monooleoylglycerol, together with variable quantities of 
di and triacylglycerols. They are defined by the nominal content of monoacylglycerols 
and obtained by partial glycerolysis of vegetable oils mainly containing 
triacylglycerols  of  oleic  acid  or  by  esterification  of  glycerol  by  oleic  acid,  this  fatty  
acid being of vegetable or animal origin. A suitable antioxidant may be added. 
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Glyceryl monooleates occur as amber oily liquids, which may be partially solidified at 
room temperature and have a characteristic odor. 
Boiling point: 238–240°C 
Density: 0.942 g/cm3 
Flash point: 216°C 
HLB value: 1 
Melting point: 35°C  
Refractive index: 1.4626 
Iodine value: 65.0–95. 
Saponification value: 150–175  
Solubility: Soluble in chloroform, ethanol (95%), ether, mineral oil and vegetable 
oils; practically insoluble in water. The self - emulsifying grade is dispersible in 
water. 
Functional Category: Bioadhesive material, emollient, emulsifying agent, emulsion 
stabilizer, gelling agent, mucoadhesive, nonionic surfactant and sustained- release 
agent. 
Stability and Storage Conditions: Glyceryl monooleate should be stored in an 
airtight container, protected from light in a cool, dry place. 
Table 4 : Certificate of analysis for Peceol 
Parameters Specifications Values 
Acid value < = 3.00 mg KOH/g 0.93mg KOH/g 
Saponification value 150-175 mg KOH/g 166 mg KOH/g 
Palmitic Acid % < = 12.0  3.9 
Stearic acid (%) < = 6.0 1.8 
Oleic acid (%) > = 60.0 78.9 
Linoleic acid (%) < = 35.0 12.2 
Linolenic acid (%) < = 2.0 < 2.0 
Arachidic acid (%) < = 2.0 0.2 
Eicosenoic acid (%) < = 2.0 0.7 
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Labrasol (64-67) 
Source: Gattefosse 
Non-proprietary name: Caprylo caproyl macrogol glyceride. 
Chemical name: Caprylocaproyl macrogol–8 glycerides EP; Caprylocaproyl 
Polyoxy–8 glycerides NF. 
Description: Labrasol is odourless and tasteless white transparent liquid. Labrasol is 
chemically Caprylocaproyl macrogol glycerides (polyoxyl glycerides) and confirms to 
EP, USPNF, and FDA IIG specification.  
Solubility: Soluble in water, ethyl alcohol, n propyl alcohol and isopropyl alcohol.  
HLB value: 12 
Functional category: Labrasol improves water solubility of major water insoluble 
products. Labrasol is an excellent and versatile emulsifying agent. It emulsifies major 
hydrophobic substances like fatty acids, fatty alcohols, mineral oil. Labrasol improves 
the bioavailability of liquid and semi-solid lipid systems. It can be incorporated in a 
number of dosage forms including granules, pellets, tablets and capsules using the 
conventional equipment. Labrasol in aqueous solutions is stable towards electrolytes 
e. g. acids and salts, provided that their concentration is not too high. Mercury (II) 
chloride is an exception and forms a precipitate with the product. Labrasol can be 
sterilized by heating in an autoclave for 1 hour at 170°C. Acute and chronic toxicity 
test in animals has shown Labrasol is essentially nontoxic and non- irritant material. 
Labrasol  with  the  concentration  of  0.1  and  1  %  was  shown  to  increase  the  
permeability of mannitol by 4.6-fold and 33.8-fold, respectively68.  
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Table 5 : Certificate of analysis for labrasol 
Parameters Specifications Values 
Specific gravity at 20°C 1.060 to 1.070 1.064 
Refractive index at 20°C 1.450 to 1.470 1.461 
Viscosity at 20°C 80-110 mPa.s 89 
Acid value < = 2.00 (mg KOH/g) 0.48 
Saponification value (mg KOH/g) 85-105 mg KOH/g 100 
Hydroxyl value(mg KOH/g) 170-205 mg KOH/g 189 
Caproic acid (%) < = 2.0 0.1 
Caprylic acid (%) 50-80 56.6 
Capric acid (%) 20-50 42.3 
Lauric acid (%) < = 3.0 0.4 
Myristic acid (%) < = 1.0 < 0.1 
Capryol PGMC 
Source: Gattefosse 
Chemical name: Propylene glycol monocaprylate (type I) NF 
Description: A water insoluble surfactant used in self - emulsifying systems to obtain 
a coarse dispersion of SEDDS or a fine dispersion of SMEDDS. 
Functional Category: It’s an oral bioavailability enhancer which inhibits the 
enterocytic drug metabolizing enzyme CYP3A4.  
Physical form: Liquid 
HLB value: 6 
Formulation techniques and dosage forms: It  is  suitable  for  hard  and  soft  gelatin  
capsules. It can be adsorbed onto neutral carrier powders for use in tablets, capsule 
filling  and  sachets.  It's  used  in  a  formulation  of  topical  ointments,  micro  emulsions,  
and emulsions.   
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Table 6 : Certificate of analysis for Capryol PGMC 
Parameters Specifications Values 
Specific gravity at 20°C 0.930-0.945 0.938 
Acid value < = 0.50 mg KOH/g 0.16 
Saponification value 285 to 310 mg KOH/g 296 
Caprylic acid (%) > = 99.0 99.6 
Capric acid (%) < = 3.0 0.1 
Lauric acid (%) < = 3.0 0.1 
Labrafil M 1944CS 
Source: Gattefosse 
Chemical name: Oleoyl macrogol-6 glycerides EP / Oleoyl polyoxyl-6 glycerides 
NF. 
Description: It's a water dispersible surfactant composed of well characterized PEG-
esters and a glyceride fraction. It can self-emulsify on contact with aqueous media 
forming a coarse dispersion and due to the good miscibility with labrasol and Gelucire 
44/14, it forms the microemulsion. It's a powerful surface active agent which 
improves the solubility of drugs for invitro and invivo studies.  
Functional category: It is a bioavailability enhancer. It increases the bioavailability 
of poorly water soluble drug because of its composition of long chain triglyceride and 
the highly hydrophobic drugs are selectively absorbed by the lymphatic system which 
reduces the hepatic first pass metabolism.  
Physical form: Liquid 
HLB value: 9 
Formulation techniques and dosage forms:  It is suitable for hard and soft gelatin 
capsules. It's used in the formulation of topical ointments, micro emulsions, and 
emulsions.   
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Table 7 : Certificate of analysis for Labrafil M 1944CS 
Parameters Specifications Values 
Specific gravity at 20°C 0.930-0.945 0.938 
Acid value < = 0.50 mg KOH/g 0.16 
Saponification value 285 to 310 mg KOH/g 296 
Caprylic acid (%) > = 99.0 99.6 
Capric acid (%) < = 3.0 0.1 
Lauric acid (%) < = 3.0 0.1 
 
Labrafil M2125 CS 
Source: Gattefosse 
Chemical name: Linoleoyl macrogol-6 glycerides EP / Linoleoyl polyoxyl-6 
glycerides NF 
Description: It's a water dispersible surfactant composed of well characterized PEG-
esters and a glyceride fraction. It can self-emulsify on contact with aqueous media 
forming a coarse dispersion and due to the good miscibility with labrasol and Gelucire 
44/14, it forms microemulsion. It's a powerful surface active agent which improves 
the solubility of drugs for invitro and invivo studies.  
Functional category: It is a bioavailability enhancer.  
Physical form: Liquid.        
HLB value: 9 
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Table 8 : Certificate of analysis for Labrafil M 2125 
Parameters Specifications Values 
Specific gravity at 20°C 0.935-0.955 0.943 
Refractive index at 20°C 1.465-1.475 1.473 
Viscosity at 20°C 70-90 mPa.s 83 
Acid value < = 2.00 mg KOH/g 0.73 
Hydroxyl value 45-65 mg KOH/g 55 
Saponification value 150 to 170 mg KOH/g 166 
Palmitic acid (%) 4.0-20.0 11.3 
Stearic acid (%) < = 6.0 1.9 
Oleic acid (%) 20-35 30.2 
Linoleic acid (%) 50-65 54.3 
Linolenic acid (%) < = 2.0 0.9 
Arachidic acid (%) < = 1.0 0.4 
Eicosenoic acid (%) < = 1.0 0.3 
 
Transcutol HP 
Source: Gattefosse 
Chemical name: Highly purified diethylene glycol monoethyl ether EP/NF 
Description: It is used as a powerful solvent for poorly water soluble pharmaceutical 
ingredients.  
Functional category: Transcutol HP is used as hydrophilic cosolvent for producing 
self - emulsifying lipid formulations and fine dispersions of the micro emulsion.  
Physical form: Liquid 
Solubility: Miscibility with water 
Boiling point: > 198°C 
Flash point: 940°C 
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Table 9 : Certificate of analysis for Transcutol HP 
Parameters Specifications Values 
Specific gravity at 20°C 0.985-0.991 0.988 
Refractive index at 20°C 1.426-1.428 1.427 
Acid value < = 0.10 mg KOH/g < 0.01 
Water content < = 0.10 % 0.04 
2-Methoxy ethanol < = 20ppm < 10 
2-Ethoxy ethanol < = 50 ppm < 10 
Ethylene glycol < = 20ppm < 10 
Diethylene glycol < = 50 ppm < 10 
Diethylene glycol monoethylether > = 99.900 % 99.987 
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CHAPTER 2 
AIM AND OBJECTIVES OF THE STUDY 
The  aim  of  the  proposed  research  work  was  to  develop  a  novel  o/w  self-
emulsifying drug delivery system (SEDDS) for poorly soluble BCS system class II 
drugs of Atorvastatin calcium and Glibenclamide with novel manufactured oils, an 
assortment of edible natural oils and surfactants/co-surfactants with the utilization of 
Design of Experiments and factorial designing. The proposed investigated work was 
selected because of simplicity in the basic procedure of creation and to scale up with 
the least framework. 
The purpose of the present research work was to systematically investigate the 
interaction, the quadratic effects of formulation variables (independent variables) of 
SEDDS on desired responses; to develop a model that would yield an optimized 
SEDDS of Atorvastatin calcium and Glibenclamide. A 13 run factorial design with 2 
factors and 3 levels, including 4 replicates at the centre point was used for fitting a 
second order response surface. The estimation of the coefficients for the second order 
polynomial model was performed by regression analysis. The model adequacy was 
checked by an F-test and the determination of correlation coefficient (R2). All the 
responses were optimized simultaneously by using desirability function.  
The major objectives of the present investigation include 
Ø Formulation of Atorvastatin calcium and Glibenclamide SEDDS by improving 
their solubility, dissolution characteristics thereby enhancing their relative 
bioavailability. 
Ø Selection of oil, surfactant, co-surfactant through equilibrium solubility and 
ternary  phase  diagram  study  for  the  development  of  SEDDS  loaded  with  
Atorvastatin calcium and Glibenclamide  
Ø Optimization of the various formulations by factorial design study. 
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Ø Evaluation of prepared formulations for cloud point measurement, 
emulsification time, particle size, polydispersity index (PDI), zeta potential, 
viscosity, spectroscopic optical clarity, refractive index, turbidity measurement 
and percentage drug loading.  
Ø In vitro release behaviour studies to be performed and compared with standard 
drug and marketed formulation for optimized formulations of Atorvastatin 
calcium and Glibenclamide SEDDS. 
Ø  In vitro drug diffusion studies and stability studies for optimized 
formulations. 
Ø To administer the L-SEDDS by filling them in soft gelatin capsules. 
  
55 
CHAPTER 3 
REVIEW OF LITERATURE 
Abdalla et al.,69 developed a new Progesterone self-emulsifying drug delivery 
system in which lipid mixtures composed of Solutol HS 15 and optimized their self-
emulsifying properties. The liquid SE lipid was mixed with microcrystalline cellulose 
and transformed into pellets by extrusion/spheronization technique and they were 
characterized by size, shape, surface characteristics and friability. In vitro dissolution 
and digestion experiments were carried out using physiological dissolution media. 
The study concluded extrusion/spheronization is a suitable process to produce solid 
self-emulsifying pellets with up to 40% load of a liquid SE mixture.  
Akhter et al., 70 studies considered a solubility enhancing technique of self-
emulsifying drug delivery system (SEDDS) for Ibuprofen, a poorly soluble drug using 
Capmul PG 8 as a co-solvent and hydrophilic surfactant Cremophor EL. In the study, 
a 3-level factorial design was carried out to optimize the formulation using design 
expert software trial version 8.0.3.1 and Capmul PG8 and Cremophor EL was used as 
independent variables and percent drug release as the dependent variable. The study 
found a possibility of increased release of Ibuprofen by using Capmul PG8 and 
Cremophor EL.  
Albertini B et al., 71 developed a novel preparation approach of solid Self-
Emulsifying Drug Delivery System (S-SEDDS) based on spray congealing as 
potential drug delivery technology for poorly water-soluble drug Glibenclamide with 
different solid excipients of HLB such as Myverol, Myvatex, Gelucire®50/13 and 
Gelucire®44/14, Cremophor®EL and Poloxamer 188 as surfactants and PEG 4000 as 
co-solvent. The screening of the best carrier for S-SEDDS manufacturing revealed 
that Gelucire®50/13 had greater performance. The dissolution studies showed that the 
formulation containing Gelucire®50/13 and PEG 4000 increased the drug 
solubilisation of five times and the microparticles showed self-dispersibility within 
60 min and micelles dimensions around 360 nm. 
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Bachhav YG et al., 72 investigated the development and evaluation of self-
micro emulsifying drug delivery system (SMEDDS) for improving the delivery of a 
BCS class II antidiabetic agent, Glyburide. The solubility of Glyburide in oils, 
cosurfactants, and surfactants was evaluated to identify the components of the 
microemulsion. The ternary diagram was plotted to identify the area of microemulsion 
existence. The in vitro dissolution profile of Glyburide SMEDDS was evaluated in 
comparison to the marketed Glyburide tablet and pure drug in pH 1.2 and pH 7.4 
buffers. The chemical stability of Glyburide in SMEDDS was determined as per the 
International Conference on Harmonisation guidelines. The area of microemulsion 
existence increased with the increase in the cosurfactant (Transcutol P) concentration. 
The Glyburide microemulsion exhibited globule size of 133.5 nm and polydispersity 
index of 0.94. The stability studies indicated that Glyburide undergoes significant 
degradation in the developed SMEDDS.  
Balakrishnan et al., 73 studied prepared a solid form of lipid-based self-
emulsifying drug delivery system (SEDDS) by spray drying liquid SEDDS with an 
inert solid carrier Aerosil 200 to improve the oral bioavailability of poorly water-
soluble drug Dexibuprofen. The liquid SEDDS was a system that consisted of 
Dexibuprofen, Labrasol, Capryol 90 and Labrafil M 1944 CS. The solid SEDDS was 
characterized by Scanning electron microscopy, Differential scanning calorimetry and 
X-Ray diffraction studies. The in vivo study of solid SEDDS and Dexibuprofen 
powder in rats at the dose of 10 mg/kg showed that the initial plasma concentrations 
of drug in solid SEDDS were significantly higher than those of Dexibuprofen powder. 
The study result suggested that solid SEDDS could be used as an effective oral solid 
dosage form to enhance rate and extent of absorption of lipophilic drugs. 
Bandivadeka et al., 74 studies demonstrated the use of smaller molecular oil 
(Capmul MCM) for developing self-micro emulsifying drug delivery system with 
Atorvastatin calcium using the combination of Tween 20 and Labrasol surfactants and 
proved for better in vitro and in vivo performance. The formulations were evaluated 
for percentage transmittance, droplet size, polydispersity index, Zeta potential, 
refractive index and cloud point measurement. Of all the oils accessed for drug 
solubility, Capmul MCM showed better higher solubility capacity for Atorvastatin 
calcium.  
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Bandivadekar  et al., 75 has studied developed that formulation of a single 
non-ionic surfactant of Tween 20 based self-nano emulsifying drug delivery system 
(SNEDDS) enhanced dissolution and absorption of a poorly soluble drug of 
Atorvastatin calcium using Capmul MCM as an oil phase. The study assessed that 
none of the formulation showed cytotoxicity and permeation enhancement of the 
drug.  
Bandyopadhyay et al.,76 developed systematically optimized self-nano 
emulsifying drug delivery systems (SNEDDS) using long chain triglycerides (LCT's) 
and medium-chain triglycerides (MCT's) of Ezetimibe employing using 32 Central 
Composite design and the optimized formulations located using overlay plot and the  
in vitro and in vivo performance were evaluated. The study indicated the successful 
formulation development of self-nano emulsifying systems with distinctly improved 
bioavailability potential of Ezetimibe.  
Barrable K et al., 77 studies used established methodologies to assess the 
inhibitory effect of the excipients on the Pgp-mediated efflux of the probe, Rh123 and 
tested the hypothesis that long-term treatment of Caco-2 cells with the lipid 
excipients, Peceol(c) and Gelucire(c) 44/14 decreased Pgp protein expression. The 
results suggested a new mechanism which contributed to the improved bioavailability 
for drugs formulated with lipid-based excipients. 
Basalious., 78 studies  reported  SNEDDS  formulations  of  Lacidipine  (LCDP)  
containing surfactants were bioenhancer for improvement of dissolution and oral 
absorption. The study applied D-optimal mixture experimental design to optimize an 
SNEDDS containing a minimum amount of surfactant, a maximum amount of lipid 
and possesses enhanced emulsification and dissolution rates. The study included three 
formulation variables; the oil phase X1 (a mixture of Labrafil /Campus, the surfactant 
X2 (a mixture of Cremophor /Tween 80) and the co-surfactant X3, in the design and 
the systems, were assessed for droplet size, light absorbance, optical clarity, and drug 
release and emulsification efficiency. The optimized formulation of LCDP showed a 
significant increase in dissolution rate compared to drug suspension under the same 
conditions.  
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Bhattacharya et al., 79 proved the oral bioavailability of Self-emulsifying 
formulation of Ketoconazole was significantly greater than aqueous suspension of 
Ketoconazole and mostly unaffected by concurrent administration of Ranitidine and 
Antacid. The study has concluded that Self-emulsifying formulations can be utilized 
as an alternative to conventional dosage forms to overcome pH dependent absorption 
of weakly basic drugs such as Ketoconazole.  
Buyukozturk et al., 80 established an initial foundation for relating emulsion 
function to formulation design and enabled bioavailability optimization across a 
broad, representative range of SEDDS formulations using surfactants with HLB 
values ranging from 10 to 15 and three structurally different oils (long chain 
triglyceride, medium chain triglyceride, and propylene glycol dicaprylate/dicaprate) 
were combined at three different weight ratios (1:1, 5:1, 9:1). The release coefficients 
for each emulsion system were calculated and finally the study indicated that 
incorporation of a long chain triglyceride (Soybean oil) as the oil phase increased the 
drug release rate constant. 
Cirri M et al.,81 studies developed effective fast-dissolving tablet formulations 
of Glyburide, endowed with improved dissolution and technological properties, 
investigating the actual effectiveness of the solid-self micro emulsifying drug delivery 
system (S-SMEDDS) approach. The selected liquid SMEDDS formulations (Capyol 
90 as oil, Tween 20 as surfactant and Glycofurol or Transcutol as cosurfactant) were 
converted into solid-SMEDDS, by adsorbing them onto Neusilin (1:1 and 1:0.8w/w 
S-SMEDDS: carrier), and fully characterized in terms of solid state (DSC and X-ray 
powder diffraction), morphological and dissolution properties, particle size and 
reconstitution ability. Finally, the 1:1 S-SMEDDS containing Glycofurol as 
CoSurfactant, showed the best performance, was selected to prepare two final tablet 
formulations.  The  ratio  test  and  pair-wise  procedures  (difference  (f1)  and  similarity  
(f2) factors) highlighted the similarity of the new developed tablets and the marked 
difference between their drug dissolution profiles and those of formulations based on 
the micronized drug.  
Date et al., 36 employed a method for screening of self-nano emulsifying drug 
delivery  systems  (SNEDDS)  and  selected  of  various  surfactants  based  on  the  
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emulsiﬁcation efficiency for selected oily phase of Cefpodoxime proxetil (CFP). The 
study also helped in rapid screening of the large pool of co-surfactants available for 
per oral delivery. The study on ternary phase diagrams has indicated that CFP and pH 
of the dilution medium significantly affected the area of the nanoemulsion formation 
for the selected system. SNEDDS of CFP accommodated high dose of CFP (130mg) 
and exhibited rapid release independent pH of dissolution media.  
Devani et al., 82 revealed the emulsification properties of Labrafil/Tween 
based self-emulsifying systems of two hydrophobic drugs Danazol and Mefenamic 
acid formed the emulsion of small particle size with greater solubilisation. The study 
also highlighted the dilution of the emulsion resulted in the change in particle size.  
Dixit et al., 25 prepared and optimized Valsartan containing self-micro 
emulsifying drug delivery system (SMEDDS) using Capmul MCM as the oil phase, 
Tween 80 as a surfactant, and PEG 400 as cosurfactant. The study evaluated in vitro 
parameters like particle size, polydispersity index (PDI) zeta potential, in vitro 
release, and bioavailability. The combination of all three components, 
oil/surfactant/cosurfactant in the ratio of 10:45:45 was formulated in SMEDDS yield 
lower particle size 12.3, PDI 0.138 and zeta potential of −0.746. This optimized 
SMEDDS showed good in vitro release which increased more than 90% when 
compared with marketed formulation and drug suspension. The in vivo study has 
revealed signiﬁcant improvement in the extent of absorption of Valsartan in rabbit to 
1.78-fold compared to with conventional capsule formulation.  The study illustrated 
the potential use of self-microemulsiﬁed drug delivery system to dispense lipid-
soluble drug by the oral route.  
Elnaggar et al., 83 prepared a self- nano emulsifying drug delivery system 
using capryol 90 and maisine 35-1 as oils, cremophor RH 40 and propylene glycol as 
surfactant and cosurfactant. Tamoxifen citrate is a highly lipophilic drug and having 
first-pass metabolism and Pgp pump efflux in an intestine. The prepared SNEDDS 
showed a significant increase in release rate compared to the drug suspension and 
anticipated to solve oral problems of Tamoxifen citrate.  
Fernandez et al., 84 investigated the lipolytic activity of pancreatic extracts and 
human pancreatic juice on Labrasol taken orally is due to the combined action of 
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pancreatic lipase-related protein 2 (PLRP2) and carboxyl ester hydrolase (CEH). The 
study has revealed about the lipolysis of lipidic excipients proceeded along with the 
gastrointestinal tract and the lipolytic process affecting the physico chemistry of lipid 
vehicles and the bio-availability of hydrophobic drugs.  
Franceschinisa et al., 85 showed the experimental design approach applied to 
the study of solid pharmaceutical dosage forms, such as the self-emulsifying pellets 
produced by wet granulation, led to a mathematical model describing the effects of 
formulation components on the product characteristics. The study has demonstrated 
the mathematical equations; the response behavior can be predicted over the whole 
experimental field for the development of a self-emulsifying system for Nimesulide as 
a poorly water-soluble model drug allowed to find different formulations with 
improved drug solubility and permeability characteristics.  
Gao.P et al., 86 applied Response surface methodology (RSM) and optimized 
the self-emulsifying drug delivery system (SEDDS) containing 25% (w/w) model 
drug, with a high lipophilicity and low water solubility. The dispersion experiment 
results confirmed the prediction identified potential optimal formulations for further 
development. The work has demonstrated that RSM is an efficient approach for 
optimization of the SEDDS formulation. 
Hashem FM et al., 87 utilized custom fractional factorial design with 14 
experimental runs of highly solubilizing SNEDDS components: oleic acid, Tween 80 
and propylene glycol and characterized the formulations. Optimized SNEDDS 
formula exhibited mean globule size of 73.5 nm, a zeta potential magnitude of -24.1 
mV and 13.5 μs /cm of electrical conductivity. The release behavior of the optimized 
SNEDDS formula showed 56.78% of cumulative ATR release after 10 minutes. The 
bioavailability estimation in Wistar albino rats revealed an augmentation in ATR 
bioavailability, relative to ATR suspension and the commercial tablets, from 
optimized ATR SNEDDS was found to be 193.81%. The findings of the work showed 
that the optimized nanocarriers enhanced the oral delivery and pharmacokinetic 
profile of ATR. 
Kadu PJ et al., 88 formulated a self-emulsifying drug delivery system of 
Atorvastatin calcium and determined its solubility in various vehicles such as Captex 
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355, Captex 355 EP/NF, Ethyl oleate, Capmul MCM, Capmul PG-8, Gelucire 44/14, 
Tween 80, Tween 20 and PEG 400. Prepared formulations were tested for micro 
emulsifying properties and evaluated for clarity, precipitation, viscosity 
determination, drug content and in vitro dissolution. The optimized formulation was 
further evaluated for particle size distribution, zeta potential, stability studies and in 
vivo potential. In vivo performance of the optimized formulation was evaluated using 
a Triton-induced hypercholesterolemia model in male Albino Wistar rats. The 
formulation significantly reduced serum lipid levels as compared 
with Atorvastatin calcium. The study has illustrated the potential use for 
the delivery of the hydrophobic drug such as Atorvastatin calcium by the oral route.  
Khan et al., 89 studies explained an incorporation of the maximum of 12.5% of 
the  Atorvastatin  (ATV) into  the  formulation  of  SEDDS with  Oleic  acid,  Tween 80,  
and PEG 400 oil, enhanced dissolution of the drug. Pseudo-ternary phase diagram 
construction was generated to the optimized ratio of oil/surfactant/co-surfactant. A 32 
factorial  design  without  replication  was  proved  to  correlate  the  dependant  and  
independent variables. The study further revealed that the potential possible gastric 
irritation due to the use of a large amount of surfactants of these formulations for 
bioavailability enhancement and the study needed to be further evaluated by in vivo 
studies. 
Kishore R et al., 38 studies enhanced the solubility of Atorvastatin by 
designing the suitable solid self-micro emulsifying drug delivery systems (S-
SMEDDS).The clear and transparent self-micro emulsifying drug delivery 
system (SMEDDS) were formulated using coconut oil and isopropyl myristate as lipid 
phases, tween 80 as a surfactant and PEG 400 and glycerin as co-surfactant at 2:1, 
3:1, 1:2 and 1:3 ratio. The pseudo-ternary phase diagrams were constructed to identify 
the micro emulsion region. The SMEDDS were evaluated for zeta potential, poly 
dispersity index, globule size, pH, viscosity and drug release. The solid SMEDDS 
were developed by employing adsorption and melt granulation methods. The S-
SMEDDS were evaluated for micromeritics, morphology, solid state property, 
reconstitution ability, drug release and stability. The micro formulations formed with 
the particle size of 25 nm had shown a 3-folds rise in drug release. The solid 
SMEDDS had reconstituted to a good micro emulsion rapidly in 1-3 min, with a 
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release of 94.62% at the end of 30 min and behaved as immediate releasing capsules. 
Their shelf-life was found to be 1.3 years. The 1:3 ratio SMEDDS had shown 
more drug release owing to their less particle size. The solid SMEDDS had shown an 
increased dissolution profiles than Atorvastatin. 
Kosnik A et al., 90 designed and characterized liquid and solid self-
emulsifying drug delivery systems (SEDDS) for poorly soluble Atorvastatin. The 
studies demonstrated the possibility of formulating liquid and solid SEDDS as 
promising carriers of Atorvastatin and SEDDS, with their unique solubilization 
properties, provided the opportunity to deliver hydrophobic drugs to the 
gastrointestinal tract in a solubilized state, avoiding dissolution as a restricting factor 
in absorption rate of BCS Class 2 drugs of Atorvastatin. 
Liu et al., 91 focused on the development of an improved formulation 
screening and optimization method for a Bufalin self-micro emulsifying drug delivery 
system (SMEDDS). The study concluded on solubility and ternary phase diagrams 
combined with experimental design may offer a valuable and efficient strategy for 
developing and optimizing a SMEDDS to obtain optimal formulations with desired 
characteristics 
Mantri SK et al., 92 designed the self-nano emulsifying drug delivery systems 
(SNEDDS) of Atorvastatin calcium (ATV) using naturally occurring different 
vegetable oils, various surfactants and co-surfactants and identified ATV solubility 
for improving the dissolution thereby oral bioavailability and to minimize the gastric 
degradation. The prepared SNEDDS were evaluated for visual observations, turbidity, 
the effect of pH of the dispersion media on globule size and zeta potential, robustness 
to dilution and in vitro dissolution study and optimized. The review summarized that 
FT-IR and DSC study revealed no interaction between drug and excipients and 
accelerated stability studies showed no significant changes in the mean globule size, 
zeta potential, drug content and drug release before and after storage of optimized 
SNEDDS.  
Marasini et al.,93 studies prepared solid self-micro emulsifying drug delivery 
system (SMEDDS) for Flurbiprofen loaded liquid SMEDDS dispersed in dextran by 
spray-drying at different factorial combinations of processing parameters by using 
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three-factor, three-level Box–Behnken design. The study results suggested that design 
of experiments (DOE) was considered the best approach for the production of 
pharmaceutical products with required quality attributes as a cost-effective approach 
with the minimum number of experiments.   
Miriyala et al.,94 developed an optimized formulation of self-nano 
emulsifying drug delivery system (SNEDDS) consisting of oleic acid, Tween 80 and 
Brij 30 offered the advantage of good solubilisation of Atorvastatin. The study 
confirmed that SNEDDS can be used as a possible alternative to a conventional oral 
formulation  of  Atorvastatin.  The  results  further  concluded  that  SNEDDS  can  be  
explored  as  a  potential  drug  carrier  for  dissolution  enhancement  of  Atorvastatin  and  
other insoluble drugs.  
Mohsin et al., 95 showed the effects of different components of lipids and 
different ratios on the particle size. They studied the effect of lipid surfactant ratio and 
the presence of cosolvents on the performance of formulations. The report showed 
that mono and di-glycerides in the formulation systems lead to increase efficiency of 
emulsification system 
Nagarsenker et al., 36 clearly explained about the screening of surfactants and 
cosurfactants for peroral delivery to achieve optimum emulsification for selected oil. 
The prepared SNEDDS were tested for robustness to dilution with various media. In 
vitro release of SNEDDS was assessed by filling it  into size 4 hard gelatin capsules 
using type I dissolution apparatus. The prepared SNEDDS were robust to all dilutions 
and can accommodate high dose of Cefpodoxime proxetil and exhibited rapid release 
independent of pH of dissolution media  
Nekkanti et al., 43 formulated SMEDDS formulation of Candesartan cilexetil 
a poorly water-soluble drug for direct filling into hard gelatin capsules for oral 
administration and evaluated their parameters. The study demonstrated the utility of 
SMEDDS to enhance solubility and dissolution of sparingly soluble compounds like 
Candesartan which may result in improved therapeutic performance. 
Patel et al ., 96 studies developed  and characterized self-micro emulsifying 
drug delivery system (SMEDDS) of the poorly water-soluble drug, Glibenclamide 
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using captex 200P (oil), cremophor RH40 (surfactant), capmul MCM C8 (co-
surfactant). The formulations were prepared according to 32 full factorial design using 
two variables oil: Smix (X1) and S: Cos (X2) and their effects were evaluated for three 
responses of droplet size, self-emulsification time and % drug release at 15 min. All 
the nine batches were assessed for dispersibility, emulsification time, % transmission, 
viscosity, zeta potential, particle size, electro conductivity, drug content and 
dissolution studies. In vitro drug dissolution was carried out using USP type-II 
apparatus and compared with that of marketed GBD tablet (Daonil®) and dissolution 
was found to be increased in the case of SMEDDS than marketed tablet formulation. 
Effects of various formulation variables on different responses were extracted out by 
using  Design  Expert®  software.  The  result  of  the  study  proved  that  X1 variable 
negatively affects self-emulsification time while droplet size was negatively affected 
by X2 variable. 
Patil et al.,97 study formulated a gelled self-emulsifying drug delivery system 
(SEDDS) containing Ketoprofen of sustained release solid dosage form with Captex 
200 (an oil), Tween 80, Capmul MCM (a co-surfactant) and silicon dioxide was used 
as a gelling agent, aided in solidification and retardation of drug release. The effect of 
concentrations of co-surfactant and gelling agent on emulsification process and in 
vitro drug diffusion was studied using 32 factorial design. Multiple regression analysis 
data and response surfaces obtained showed that liquid crystal phase viscosity 
increased significantly with increasing amount of silicon dioxide which in turn caused 
an increase in average droplet size of resultant emulsion and slower drug diffusion. 
The study indicated the potential applications of gelled SEDDS for transformation in 
sustained release solid dosage forms 
Poudel et al., 93 study worked on Valsartan self micro emulsifying drug 
delivery system (SMEDDS) using 3-level, 3-factor level Box-Behnken design (BBD) 
on the effects of three formulation factors (Labrafil  M 2125 CS as oil,  Tween 20 as 
surfactant and Capryol 90 as co-surfactant) showed significant effect on particle size 
and equilibrium solubility while the amount of co-surfactant exhibited the main effect 
on dissolution profile after 15 min). The study concluded that the optimized 
formulation showed significantly increased bioavailability compared to that of 
Valsartan powder and BBD facilitated in the better understanding of the inherent 
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relationship  of  formulation  variables  with  the  responses  and  in  the  optimization  of  
Valsartan SMEDDS in relatively cost, time and labor effective manner.  
Pouton.,98 described strategies used for the formulation of self-emulsifying 
drug  delivery  system  (SEDDS),  methods  used  for  assessment  of  efficiency  of  
emulsification and practical consideration regarding the use of SEDDS for 
enhancement of the bioavailability of drugs from the gastro-intestinal tract.  
Prajapathi et al., 99 concluded that self-micro emulsified drug delivery 
systems (SMEDDS) would be a promising drug delivery system for the poorly water-
soluble drug of Olmesartan in various oils, surfactants and co surfactants by the oral 
route. The study further compared the in vitro and ex vivo diffusion rate of the drug 
from the SMEDDS was significantly higher than that of the plain drug suspension.  
Selvam et al.,100 developed SNEDDS for lipophilic Efavirenz using labrafac 
PG(oil), tween 80(surfactant), PEG 200(Co-surfactant) had sufficient drug loading, 
rapid self-micro-emulsification in aqueous media and forming droplet size in the 
range of nanoemulsion. The study revealed that drug solubility was achieved and thus 
overcome dissolution rate-limited absorption of Efavirenz with in vitro drug release. 
The stability study of prepared SNEDDS showed same physicochemical properties as 
compare to initial SNEDDS after 3 months stored in stability chamber at 40°C and 
75%RH.  
Sha et al., 101 designed a self micro emulsifying drug delivery system 
(SMEDDS) of Probucol composed of olive oil, Lauroglycol FCC, Cremophor EL, 
Tween-80, and PEG-400. The study evaluated and compared the pharmacokinetics 
and bioavailability of Probucol suspension, oil solution and SMEDDS in rats. The 
study has concluded that relative bioavailability of SMEDDS was dramatically 
enhanced in an average of 2.15- and 10.22-fold that of oil solution and suspension.  
Shaji et al., 102 studies prepared, evaluated and optimized, self-micro 
emulsifying drug delivery system of Celecoxib using 3 factor, 3 level factorial with 
different amounts of Labrafil 2609 WL, Labrasol and Cremophor EL as independent 
variables. The response variable was selected on particle size (nm) of the droplets 
after dilution in 0.1N HCl. Mathematical equation and response surface plots were 
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used to relate the dependent and independent variables. The regression equation was 
generated for the particle size after dilution. The study has concluded that the 
observed response was in close agreement with the predicted values of the optimized 
formulation and demonstrated the reliability of the optimization procedure in 
predicting particle size of the self micro-emulsifying delivery system for Celecoxib.  
Shakeel F et al.,103 studied the impact of various combinations of nonionic 
surfactants on the self-nano emulsifying performance of two grades of Lauroglycol 
(Lauroglycol-90 and Lauroglycol-FCC) in Glibenclamide nanoemulsion by 
spontaneous emulsification method. The results of thermodynamic stability and self-
nano emulsification tests were confirmed by further characterization of these 
formulations in terms of droplet size, viscosity, refractive index and % transmittance. 
The study revealed that formulations prepared with Labrasol, HCO-60 and Gelucire-
44/14 were found to be suitable for self-emulsifying drug delivery system only 
whereas those prepared with Tween-80 and Cremophor-EL were found to be suitable 
for self-nano emulsifying or self-micro emulsifying drug delivery system of 
Glibenclamide with respect to Lauroglycol-90 or Lauroglycol-FCC.  
Sharma et al .,104 studies involved preparation and evaluation of self-
emulsifying drug delivery system (SEDDS) of Ibuprofen using peanut oil composed 
of varying concentrations of peanut oil (solvent), tween 80 (surfactant) and span 20 
(co-surfactant). The study has investigated the influence of the concentration of 
surfactant/co-surfactant and globule size on dissolution rate. The dissolution rate of 
self  the  emulsifying  capsule  was  found  to  be  significantly  faster  than  that  from  
conventional tablet from the study.  
Shen H, et al., 105 successfully prepared self-micro emulsifying drug delivery 
systems (SMEDDS) of Atorvastatin calcium to improve its bioavailability. The 
release of Atorvastatin from SMEDDS capsules was studied using the dialysis bag 
method in 0.1 M HCl and phosphate buffer (pH 7.4), compared with the release 
of Atorvastatin from a conventional tablet. The study resulted in bioavailability 
of Atorvastatin SMEDDS capsules was significantly increased when compared with 
that of the conventional tablet. 
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Singh SK et al., 106 developed and characterized self-nano emulsifying drug 
delivery system of the poorly water-soluble drug, Glibenclamide (GBD). The result of 
the study has indicated that the self-nano emulsifying drug delivery system of GBD, 
owing to nanosize, has potential to enhance its absorption and without interaction or 
incompatibility between the ingredients.  
Smita et al., 107 explored the multifunctionality of Rice Germ Oil (RGO) in 
self-micro emulsifying drug delivery system (SMEDDS) formulation of lipophilic 
drug such as Tacrolimus (TAC). The antioxidant potential and solubilization capacity 
of RGO was significantly higher than Rice Bran Oil (RBO) The Tacrolimus (TAC 
SMEDDS formulation using RGO showed significantly higher dissolution profile as 
well as improvement in oral pharmacokinetic parameters of TAC in comparison with 
plain TAC and marketed capsule. The study has concluded that gamma-oryzanol-
enriched natural RGO is a multifunctional excipient for lipid drug delivery system 
like SMEDDS.  
Subramanian R et al., 108 studied  the  effects  of  two  lipid  
excipients, Peceol and Gelucire 44/14 on the in vitro pancreatic lipase activity. The 
results from this study suggested that these lipid excipients inhibit in vitro pancreatic 
lipase activity and should be taken into consideration when developing oral 
formulations using these agents  
Vithlani et al., 109 improved the aqueous solubility and modified in 
vitro dissolution profile of hydrophobic drug using self-emulsifying drug delivery 
systems (SEDDS) of Cinnarizine using Capmul PG-12, Cremophor RH 40 and Tween 
20 at different weight ratios and incorporated with Cinnarizine. The drug 
incorporation into pre-concentrate, drug solubility in phosphate buffer, (pH 7.2) the 
mean droplet size and drug release profile of the SEDDS were also determined. The 
SEDDS with 30% w/w of Capmul PG-12 provided the greatest enhancement in drug 
solubility in phosphate buffer as well as rapid drug release despite forming larger 
droplets upon emulsification. The combination of Capmul PG-12, Tween 20 and 
Cremophor RH 40 can produce SEDDS which can be used as an alternative dosage 
form for poorly water soluble drug.  
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Wang et al., 110 developed and evaluated the new solid self-emulsifying (SE) 
pellets of poorly soluble Nitrendipine (NTD) prepared by extrusion/spheronization 
technique, using liquid SEDDS (NTD, Miglyol® 812, Cremophor® RH 40, Tween 80, 
and Transcutol® P), adsorbents (silicon dioxide and crospovidone), microcrystalline 
cellulose and lactose, and studies further illustrated that extrusion/spheronization 
technique could be a useful large-scale producing method to prepare the solid SE 
pellets from liquid SEDDS.  
Yeom D W et al., 111 successfully developed an optimized Atorvastatin (ATV) 
loaded self-micro emulsifying drug delivery system (SMEDDS) formulation by using 
the D-optimal mixture design containing 7.16% Capmul MCM (oil), 48.25% Tween 
20 (surfactant), and 44.59% Tetraglycol (cosurfactant) which significantly enhanced 
the dissolution rate of ATV in different types of medium, including simulated 
intestinal fluid, simulated gastric fluid, and distilled water and compared with ATV 
suspension. The good agreement was observed between predicted and experimental 
values for mean droplet size and percentage of the drug released in 15 minutes that 
could potentially be used for improving the oral absorption of poorly water-soluble 
drugs.  The pharmacokinetic studies in rats showed that the optimized SMEDDS 
formulation considerably enhanced the oral absorption of ATV, with 3.4-fold and 4.3-
fold increased in the area was observed under the concentration-time curve and time 
taken to reach peak plasma concentration when compared with the ATV suspension. 
Zhaoa et al., 112 demonstrated the potential utility of SNEDDS for formulation 
of Zedoary turmeric oil (ZTO) with improved aqueous dispersibility, stability and oral 
bioavailability. The study illustrated in the formulated SNEDDS, the essential oil 
ZTO served as a partial lipid phase with the dual advantages of increasing drug 
loading and minimizing the amount of the inert oils required. The study served as a 
prototype  approach  for  the  formulation  development  of  other  essential  oils  or  
hydrophobic drugs in liquid form.  
  Zhong et al.,113 studies developed a self-double-emulsifying drug delivery 
system (SDEDDS) for a Hydroxysafflor yellow A (HSYA) the main active ingredient 
of the safflower plant (Carthamus tinctorius L) and improved oral absorption through 
inhibition of p-glycoprotein efflux. The final study demonstrated that SDEDDS were 
promising technique for improving the oral absorption of drugs with high solubility 
and low permeability with no significant toxicity in vitro and in vivo. 
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CHAPTER 5 
MATERIALS AND METHODS 
5.1 LIST OF MATERIALS 
S.No. Name Source 
1. Atorvastatin calcium Goodman Pharmaceuticals, Pondicherry.  
2. Glibenclamide Goodman Pharmaceuticals, Pondicherry. 
3. Capryol PGMC Gattefosse  (Saint-Priest Cedex, France) 
4. Transcutol HP Gattefosse (Saint-Priest Cedex, France) 
5. Peceol Gattefosse (Saint-Priest Cedex, France) 
6. Labrasol Gattefosse (Saint-Priest Cedex, France) 
7. Labrafil M 1944 CS Gattefosse (Saint-Priest Cedex, France) 
8. Labrafil M 2125 CS Gattefosse (Saint-Priest Cedex, France) 
9. Virgin sesame oil  Vama oil industries, Coimbatore. 
10. Sunflower oil  Vama oil industries, Coimbatore. 
11. Olive oil Shaah Enterprises, Chennai. 
12. Mustard oil Green spice products, Coimbatore. 
13. Virgin coconut oil Vama oil industries, Coimbatore. 
14. Rice bran oil Jupiter Manufacturing industry, Chennai. 
15. Corn oil Arumuga group of industries, 
TamilNadu. 
16. Potassium dihydrogen ortho 
phosphate 
Loba Chemie Pvt Ltd, Mumbai. 
17. Sodium hydroxide pellets Loba Chemie Pvt Ltd, Mumbai. 
18. Methanol Loba Chemie Pvt Ltd, Mumbai. 
19. Dialysis membrane (Molecular 
mass cut off 12,000-14,000 daltons) 
Himedia, Mumbai. 
20. Dialysis membrane clips Himedia, Mumbai. 
21. Anhydrous potassium bromide Loba Chemie Pvt Ltd, Mumbai. 
22. Hydrochloric acid Loba Chemie Pvt Ltd, Mumbai. 
23 Potassium dichromate Loba Chemie Pvt Ltd, Mumbai. 
24. Potassium iodide Loba Chemie Pvt Ltd, Mumbai. 
25. Iodine Crystals  resublimed Loba Chemie Pvt Ltd, Mumbai. 
26. Starch Loba Chemie Pvt Ltd, Mumbai. 
27. Mercuric iodide Loba Chemie Pvt Ltd, Mumbai. 
28. Sodium thiosulphate Loba Chemie Pvt Ltd, Mumbai. 
29. Iodine monochloride Loba Chemie Pvt Ltd, Mumbai. 
30. Iodine trichloride Loba Chemie Pvt Ltd, Mumbai. 
31. Carbon tetra chloride Loba Chemie Pvt Ltd, Mumbai. 
32. Phenolphthalein  indicator Loba Chemie Pvt Ltd, Mumbai. 
33. Rectified Spirit Loba Chemie Pvt Ltd, Mumbai. 
34. Ethanol Loba Chemie Pvt Ltd, Mumbai. 
35. Distilled water Prepared in laboratory 
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5.2 LIST OF EQUIPMENTS 
S.No. Instrument/Equipment Model / Manufacturer 
1. UV-Visible Spectrophotometer Shimadzu 1700 Pharmaspec, Japan. 
2. Electronic balance Shimadzu BL-220H, Japan. 
3. Bath sonicator  Sonica 2200MH, Soltech srl, Soluzioni 
Tecnologirhe, Milano, Italy. 
4. Magnetic stirrer Remi instruments. 
5. Vortex mixer Spinix, Japan 
6 Humidity chamber Labtech, Ambhala. 
7. Digital pH meter Elico scientifics-L1610, Mumbai. 
8. Eppendorff 5415D centrifuge Marshall scientific, New Hampshire. 
9. Brookfield viscometer Brookfield engineering Laboratories, 
USA. 
10. USP dissolution tester  Electrolab, India. 
11. Turbidimeter Elico D-10-model 331, Japan. 
12. Abbe refractometer Remi instruments 
13. Malvern Nano Zeta sizer-90 Malvern Instruments Ltd., Malvern, UK 
14. Refrigerator  Samsung 
15. Fourier transform infrared 
spectrophotometer 
FT/IR- 8400S Shimadzu 
16. IR-Hydraulic pellet press Techno search instruments 
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5.3 METHODOLOGY 
5.3  Development and Evaluation of Atorvastatin calcium and Glibenclamide 
SEDDS Preformulation Study  
Identification test for Atorvastatin calcium and Glibenclamide 
5. 3.1 Melting Point  
The melting point of Atorvastatin calcium and Glibenclamide were tested by 
using laboratory melting point apparatus with capillary tube method and the 
procedure followed as per Indian Pharmacopeia 2007125.  
5.3.2 Fourier transform infrared (FT-IR) spectroscopy of Atorvastatin calcium 
and Glibenclamide 57 
The drug sample was mixed with anhydrous potassium bromide (KBr) in 1:4 
ratio. Briefly about 100 mg of this mixture was made into fine powder using mortar 
and pestle followed by compression to form transparent KBr pellet using Techno 
search hydraulic press set at 15 tons pressure. Each KBr pellet was scanned at 4mm/s 
at a resolution of 2cm over a wave number region from 4000 to 400 cm-1 in an FTIR 
spectrophotometer (8400S Shimadzu, Japan).  
5.3.3 Identification test for oils 
Specific gravity  
The  specific  gravity  of  the  oils  was  tested  by  specific  gravity  bottle  method  
and the procedure followed as per Bureau of Indian standards IS 548-1126. 
5.3.4 Determination of iodine value by WIJS method 126 
Preparation of potassium iodide solution  
About 10 g of potassium iodide free from potassium iodate was dissolved in 
90ml of water. 
  
72 
Starch Solution 
About 5 g of starch and 0.01 g of mercuric iodide was triturated with 30 ml of 
cold water and slowly poured it with stirring into 1 litre boiling water. The solution 
was boiled for three minutes. It was allowed to cool and the supernatant liquid was 
decanted. 
Standardization of sodium thiosulphate solution  
About 0·1Normal solution of sodium thiosulphate was prepared by dissolving 
24·8 g of sodium thiosulphate crystals in 1 litre of distilled water and made up to 
1000ml. About 0.5 g of finely ground potassium dichromate which has been 
previously dried to a constant weight at105 ± 2°C was weighed accurately and 
transferred into a 1litre volumetric flask. It was dissolved in distilled water and made 
up to the mark. About 25 ml of above solution was pipetted into the 250ml conical 
flask. To the conical flask solution, 5 ml of concentrated hydrochloric acid and 15 ml 
of a 10% potassium iodide solution was added. It was allowed to stand in the dark for 
5  minutes  and  the  resultant  mixture  was  titrated  with  the  0.1Normal  solution  of  
sodium thiosulphate using the starch solution as an indicator towards the end. The end 
point is the change of blue to green colour. 
The normality of the sodium thiosulphate solution was calculated as follows 
                                                25W 
                                              49.03V 
Where W is weight in g of the potassium dichromate and V is a volume of ml of 
sodium thiosulphate solution required for the titration. 
Preparation of Wijs solution 
The solution was prepared by dissolving 13g of iodine in 1litre of acetic acid 
and the strength of solution was determined by titrating with standard sodium 
thiosulphate solution. The chlorine gas was introduced into 50 ml of the solution until 
the characteristic colour change was occurred and the halogen content was nearly 
doubled as ascertained again by titration. 
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Procedure 
About 0.2 g of the sample was weighed accurately and transferred into a 500 
ml iodine flask or well to which 25 ml of carbon tetrachloride have been added and 
agitated to dissolve the contents. 25 ml of the Wijs solution was added and the glass 
stopper was replaced after wetting with potassium iodide solution. It was swirled for 
intimate mixing and allowed to stand in the dark for 30 minutes in the case of non-
drying and semi-drying oils and one hour in the case of drying oils. The blank test 
was carried out under similar experimental conditions. After standing 15 ml of 
potassium iodide solution and 100 ml of water were added and the liberated iodine 
was titrated with standard sodium thiosulphate solution. Then 1 ml of starch solution 
was added to the above solution until the formation of blue colour disappeared after 
thorough shaking. 
Iodine value was calculated as shown below 
12.69 (B-S) N 
Iodine value =  
                               W 
where   
B = volume of ml of standard sodium thiosulphate solution required for the 
blank 
S = volume in ml of standard sodium thiosulphate solution required for the 
sample 
N  =  normality of the standard sodium thiosulphate solution  
W  =  weight in g of the material taken for the test. 
5.3.5 Determination of saponification value126  
Preparation of alcoholic potassium hydroxide Solution  
 About 35 to 40 g of potassium hydroxide was dissolved in 20 ml of distilled 
water and sufficient aldehyde free rectified spirit was added to make up to 1000 ml. 
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Then the solution was allowed to stand overnight. The clear liquid was decanted and 
kept in a bottle closed tight with a cork or rubber stopper. 
Preparation of 0.5N hydrochloric acid 
 About 42.5 ml of hydrochloric acid was diluted and made up to 1000 ml of 
distilled water. 
Procedure 
  About 1 to 2 g of the oil was weighed accurately and transferred in a conical 
flask.  To the flask, 25 ml of the alcoholic potassium hydroxide solution was added 
and refluxed with air condenser connected to the flask. The flask was heated on a 
water-bath for not more than one hour. Then the contents of the flask were boiled 
gently until the sample is completely saponified as indicated by an absence of any oily 
matter and appearance of the clear solution. The flask was allowed to cool. To the 
above solution, 1 ml of phenolphthalein indicator was added and titrated with the 
standard hydrochloric acid.   
The saponification value is calculated as follows 
56.1 (B-S) N 
Saponification value =      
      W 
where  B is the volume in ml of standard hydrochloric acid required for the blank 
S is the volume in ml of standard hydrochloric acid required for the sample 
N is the normality of the standard hydrochloric acid 
W is the weight in g of the material taken for the test. 
5.3.6 Determination of acid value126 
Preparation of 0.1N sodium hydroxide  
About 5.611g of potassium hydroxide was dissolved in sufficient water to 
produce 1000ml.  
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Procedure 
 About 1 g of oil was weighed and transferred into 200 ml conical flask. To the 
solution added 50 ml of freshly neutralized hot ethyl alcohol and 1 ml of 
phenolphthalein indicator solution. The mixture was boiled for five minutes and 
solution was titrated with 0.1N sodium hydroxide solution. 
The acid value was calculated as given below 
                       5.61 V N 
Acid value =  
                           W 
where V = volume of ml of standard sodium hydroxide solution used. 
N = normality of standard potassium hydroxide or sodium hydroxide solution. 
W = weight in g of the oil taken for the test. 
5.4 DEVELOPMENT OF STANDARD CALIBRATION CURVE OF 
ATORVASTATIN CALCIUM IN METHANOL 
UV Spectroscopy (λ max)  
The absorption maximum of the standard solution of Atorvastatin calcium was 
scanned between 200- 400 nm regions on UV- visible spectrophotometer.  
5.4.1 Preparation of standard stock solution  
An accurately weighed quantity of about 50 mg of Atorvastatin calcium was 
taken in 50 ml volumetric flask and dissolved in sufficient quantity of methanol 
followed by sonication127 in a bath sonicator (Sonica 2200MH) provided with a power 
supply of 305 Watts during heating at a temperature of 60°C for 10 minutes and 
finally diluted to 50 ml with methanol to obtain the concentration of 1000 μg/ml. 
From this solution, 5 ml was pipetted out in a 50 ml volumetric flask and volume was 
made up with methanol to obtain the concentration of 100 μg /ml. 
5.4.2 Preparation of calibration curve  
From the stock solution, 2, 4, 6, 8,10 and 12 ml appropriate aliquots were 
pipetted out from standard stock solution into the series of 100 ml volumetric flask 
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and the volume was made up to the mark with methanol to get the concentration of 2-
12 μg/ml of the drug. The absorbance at various concentrations was measured against 
methanol as blank at 247 nm using a UV-visible spectrophotometer. 
5.5 PREPARATION OF BUFFER SOLUTIONS  
5.5.1  Preparation of 0.2M Potassium dihydrogen phosphate 
Accurately weighed 27.218g of potassium dihydrogen orthophosphate was 
dissolved in 1000ml of distilled water.  
5.5.2  Preparation of 0.2M sodium hydroxide 
 Accurately weighed 8.0g of sodium hydroxide was dissolved in 1000 ml of 
distilled water.  
5.5.3  Preparation of Phosphate Buffer pH 6.8 
 Phosphate buffer pH 6.8 was prepared according to I.P. 2007. A measured 
quantity of 50 ml of 0.2M potassium dihydrogen phosphate and 22.4 ml of 0.2M 
sodium hydroxide were taken in 200ml volumetric standard flask and diluted with 
freshly prepared distilled water to produce the required volume. 
5.5.4  Preparation of phosphate buffer pH 7.4 
 Phosphate buffer pH 7.4 was prepared according to I.P. 2007. A measured 
quantity of 50 ml of 0.2M potassium dihydrogen phosphate and 39.1 ml of 0.2M 
sodium hydroxide were added in 200ml volumetric standard flask and diluted with 
freshly prepared distilled water to produce the required volume. 
5.6 DEVELOPMENT OF CALIBRATION CURVE OF ATORVASTATIN 
CALCIUM IN PHOSPHATE BUFFER pH 6.8 
5.6.1  Preparation of standard stock solution  
An accurately weighed quantity of about 10 mg of Atorvastatin calcium128 was 
taken in 100 ml volumetric flask and dissolved in sufficient quantity of phosphate 
buffer of pH 6.8 and finally diluted with the same buffer to obtain the concentration of 
100 μg/ ml.  
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5.6.2  Preparation of calibration curve  
From the stock solution 2, 4, 6, 8,10 and 12 ml appropriate aliquots were 
pipetted out from standard stock solution into the series of 100 ml volumetric flask 
and  the  volume  was  made  up  to  the  mark  with  phosphate  buffer  pH  6.8  to  get  
concentration of 2-12 μg/ml of the drug. The absorbance at various concentrations 
was measured against blank (phosphate buffer pH 6.8)  
5.7  DEVELOPMENT OF STANDARD CALIBRATION CURVE OF 
GLIBENCLAMIDE IN METHANOL129 
UV Spectroscopy (λ max)  
The absorption maximum of the standard solution of glibenclamide was 
scanned between 200- 400 nm regions on UV- visible spectrophotometer. 
5.7.1  Preparation of standard stock solution  
An accurately weighed quantity of about 50 mg of glibenclamide was taken in 
50 ml volumetric flask and dissolved in sufficient quantity of methanol to obtain the 
concentration of 1000 μg/ml.  From this solution, 5 ml was pipetted out in a 50 ml 
volumetric flask and volume was made up with methanol to obtain the concentration 
of 100 μg /ml. 
5.7.2  Preparation of calibration curve  
From the stock solution, aliquots 1, 2, 3, 4, 5 and 6 ml appropriate aliquots 
were pipetted out from standard stock solution into the series of 100 ml volumetric 
flask and the volume was made up to the mark with methanol to get concentration of 
1-6 μg/ml of drug. The absorbance at various concentrations was measured with 
methanol as blank at 226.5 nm using UV-visible spectrophotometer. 
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5.8  DEVELOPMENT OF CALIBRATION CURVE OF GLIBENCLAMIDE 
IN PH PHOSPHATE BUFFER 7.4 
5.8.1  Preparation of standard stock solution  
An accurately weighed quantity of about 10 mg of Glibenclamide130, 131 was 
taken in 100 ml volumetric flask and dissolved in sufficient quantity of phosphate 
buffer pH 7.4 to obtain the concentration of 100 μg /ml.  
5.8.2 Preparation of calibration curve  
From the stock solution, aliquots of 2, 4, 6, 8, 10 and 12 ml were pipetted out 
from standard stock solution into the series of 100 ml volumetric flask and the volume 
was made up to the mark with phosphate buffer pH 7.4 to get concentration of 2-12 
μg/ml of drug. The absorbance at various concentrations was measured with 
phosphate buffer pH 7.4 as blank at 226.5 nm using UV spectrophotometer. 
5.9  SOLUBILITY STUDIES  
The solubility for Atorvastatin calcium were determined in aqueous solutions 
of various pH (pH 4 and 7.4), distilled water, organic solvents such as 
dimethylsulphoxide and dimethylformamide. Aqueous solution of pH 4.0 and 7.4 was 
obtained by adding suitable amount of dilute hydrochloric acid and dilute sodium 
hydroxide. The solubility of Glibenclamide was determined in distilled water, 
methanol,  ethanol and dichloromethane. About 2 ml of each solvent was transferred 
into 5 ml glass vial and an excess quantity of drug (150 mg) was added to the vial. 
The solubility of the drug samples were also analyzed by adding excess amount 
(150mg) of the drug to 2 ml of various oils, surfactants and co-surfactants in screw 
capped glass vials followed by vortex mixing for 30 secs using vortex mixer (Sphinx, 
Japan).  The  mixtures  were  shaken  for  48  h  at  300C in a thermostatically controlled 
shaking water bath, followed by equilibrium for 24 hr. The sample mixtures were then 
centrifuged at 3000 rpm132 for 10 min and the supernatant liquid was filtered through 
a millipore membrane filter (0.45μ). Samples were suitably diluted with methanol 
followed by sonication for 10 min and finally diluted with the same solvent. The final 
drug concentration was quantified by UV-visible spectrophotometer at 247 nm for 
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Atorvastatin calcium and 226.5nm for Glibenclamide. The experiment was repeated 
in triplicates. The results are represented as mean value (mg/ml) ± SD. 
5.9.1 Construction of Ternary Phase Diagram: (Following method was used for 
both the two drugs individually)  
Based on the results of saturation solubility studies in Table 12, sunflower oil, 
labrasol and transcutol HP for Atorvastatin calcium and peceol, labrasol and 
transcutol HP for Glibenclamide were selected as oil, surfactant and co-surfactant 
respectively. The percentage limit of surfactant, co-surfactant and oil used herein was 
selected by considering their acceptable safe dose and decided on the basis of the 
requirements stated according to the lipid formulation classification system (LFCS) 
introduced by Pouton8.  A  ternary  phase  diagram  was  constructed  for  the  system  
containing oil-surfactant-co-surfactant by Chemix School software version 3.51. The 
grading method reported by Craig et al.133 was modified and adopted in this study. A 
series of self-emulsifying systems were prepared with varying weight percentage of 
oil, surfactant, and co-surfactant. Since the drug incorporated in the SEDDS may have 
some effect  on  self  emulsion  boundary,  every  system in  the  series  also  consisted  of  
10% w/w for Atorvastatin calcium and 5% w/w for Glibenclamide. The extreme and 
middle level of the independent variables consisting of oil, surfactant and co-
surfactant were selected for further study. 0.2 ml of each formulation was introduced 
into 200 ml of water in a glass beaker maintained at 37°C and was mixed gently about 
200 rpm with a magnetic stir bar. The tendency to emulsify spontaneously and the 
progress of emulsion droplets spread were observed. The tendency to form an 
emulsion was judged as ‘good’ when droplets spread easily in water and formed a fine 
milky or slightly bluish emulsion within 1 min133. It was judged ‘bad’ when there was 
poor, slow or no emulsion formation or when oil droplets coalesced when stirring was 
stopped or when dull, grayish white emulsion was formed. All studies were repeated 
thrice.  
5.10  PREPARATION OF SEDDS 
Optimum ratios of oil and Smix were selected from the phase diagrams. 
SEDDS formulations were prepared by dissolving the drug in Smix mixtures along 
with gentle vortexing and sonicating and then by adding oil134. The effects of the 
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formulation variables for different batches were studied by preparing with each batch 
of SEDDS formulation containing single dose of Atorvastatin and Glibenclamide with 
varying amounts of oil and Smix using 32 factorial designs as illustrated in Table 14a 
and Table 14b. Then the final formulation was equilibrated in water bath at 37°C for 
48 h before carrying out the droplet size, polydispersity index and dissolution. The 
optimized formulations are prepared by the same method.  
5.11  EXPERIMENTAL DESIGN: 32 FULL FACTORIAL DESIGN 
A  32 full factorial design factor  was  used  to  explore  and  optimize  the  main  
effects, interaction effects and quadratic effects of the formulation ingredients on the 
in-vitro performance of liquid SEDDS. A total of 13 experimental runs, including 4 
replicates at the centre were generated and evaluated by using Design-Expert software 
(version 10.0.2.0, Stat-Ease Inc., Minneapolis, U.S.A.) which are summarized in 
Table 14a and Table 14b. The purpose of the replication was to estimate experimental 
error and increase the precision by computing a model independent estimate of the 
process standard deviation. The significant response factors studied for assessing the 
quality of the SEDDS formulation were particle/globule size (Y1) and  drug loading 
(Y2).The data obtained after the each response was fitted to quadratic polynomial 
model explained by the following non-linear equation Y = β0 +  β1X1 +  β2X2 + 
β12X1X2+ β1X12 + β2X22 + E. where Y is the response of the dependent variables; β0 to 
β2 are the regression coefficients; and X1,  X2 are independent variables. All the two 
responses were optimized by using the desirability function approach by fixing the 
constraints in range and minimizing the particle size (Y1) and maximizing the drug 
load (Y2). 
5.12  EVALUATION OF PREPARED SEDDS  
5.12.1 Self-emulsification and drug precipitation studies 
The efficiency of self-emulsification of oral micro/nanoemulsion is assessed 
by dispersibility test using a standard USP dissolution apparatus II25. One ml of each 
formulation is added to 500 ml of water at 37 ± 0.5°C. A standard stainless steel 
dissolution  paddle  rotating  at  50  rpm tends  to  provide  gentle  agitation.  The  in vitro 
performance of the formulations is visually assessed from such dispersion using a 
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suitable grading system. The grading system has been reported to be based on the 
formation  of  a  micro  emulsion  (o/w  or  w/o),  micro  emulsion  gel,  emulsion  or  
emulgel. The drug/excipient precipitation was evaluated by visual inspection of the 
resultant emulsion after 24 h. The in vitro performance of the formulations is visually 
assessed using the following grading system:  
Grade I: Rapidly forming (within 1 min) nano emulsion, having a clear or bluish 
appearance. (Micro emulsion) 
Grade II: Rapidly forming, slightly less clear emulsion, having a bluish white 
appearance. (Micro emulsion gel)  
Grade III:  Fine milky emulsion that formed within 2 min. (Emulsion) 
Grade IV: A dull grayish white emulsion having slightly oily appearance that is slow 
to emulsify is formed (longer than 2 min). (Emulgel) 
Grade V: Formulation, exhibiting either poor or minimal emulsification with large oil 
globules present on the surface with phase separation is observed.  
Grade VI: The drug is precipitated. 
Grade  I  and  Grade  II  formulation  will  remain  as  nano  emulsion  when  
dispersed in GIT while formulation falling in Grade III could be recommended for 
SEDDS formulation. The primary means of self-emulsification is a visual evaluation. 
The effectiveness of self-emulsification can be optimized by rate of emulsification, 
droplet size distribution and turbidity measurements. 
5.12.2  Phase separation study  
The self-emulsifying formulation was diluted with distilled water up to 5 times 
and the temperature was maintained at 25°C. The mixture was then mixed for 2 min, 
stored for about 2 hr and visually observed for any phase separation 
5.12.3  Determination of emulsification time 
The emulsification time (the time for a preconcentrate to form a homogeneous 
mixture upon dilution) was monitored by visually observing the disappearance of 
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SEDDS and the final appearance of the emulsion in triplicate. A dissolution apparatus 
USP II (Electrolab) was employed with 500 ml water and with a paddle speed of 50 
rpm at 37°C. The SEDDS (1 ml) was added drop wise to the medium by dropping the 
pipette and time required for the disappearance of SEDDS was recorded 135.  
5.12.4  Spectroscopic characterization of optical clarity 
SEDDS formulations disperse in aqueous phase forming the emulsion or 
micro emulsions and can be detected by the final appearance and droplet size. In 
practice, the key difference between the emulsion and micro emulsions concerns with 
their appearance. Emulsions are cloudy while micro emulsions are clear or translucent 
and the reason for their transparency appearance is due to very small droplet size. The 
optical clarity may be checked visually. But in order to measure it quantitatively, a 
UV-visible spectrophotometer was used to measure the amount of light of a given 
wavelength absorbed by the solution. The cloudier solutions will absorb more of the 
incident light resulting in higher absorbance values and lower absorbance is obtained 
with optically clear solutions. 
The  optical  clarity  of  aqueous  dispersions  of  SEDDS  formulations  was  
measured  spectroscopically.  About  l  ml  of  SEDDS  formulations  were  diluted  to  50  
times with double distilled water. The absorbance values of each formulation were 
measured by a UV-visible spectrophotometer (Shimadzu) at 400 nm136. 
5.12.5  Turbidity measurement 
The measurement of turbidity is to analyze whether the dispersion reaches 
equilibrium rapidly and in a reproducible time. The growth of emulsification is done 
by nepheloturbidimetric evaluation. The turbidity measurements in nephelometric 
turbidity unit (NTU) were performed on the resultant emulsion stored in a screw 
capped sample vials using a turbid meter (Elico D-10-model 331). About 0.5 ml of the 
SEDDS formulation was introduced into 250 ml of distilled water in 500 ml conical 
flask under an action of magnetic stirrer rotating at constant speed. The emulsification 
was done at room temperature137. 
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5.12.6  Viscosity determination 
The viscosity studies are necessary for SEDDS to characterize the system 
physically  and  to  control  its  stability.  If  the  system has  low viscosity  then,  it  is  o/w 
type of the system and if a high viscosity then it is w/o type of the system. SEDDS 
preconcentrate (10 ml) was taken and its viscosity was measured by using Brookfield 
viscometer (Brookfield engineering Laboratories, USA) using spindle C 16-1 at 
25±0.5 ◦C 138 with a shear rate of 50 rpm.  
5.12.7 Cloud point measurement 
Cloud point temperatures (Tc) was determined by visual observation. 0.5 ml 
of preconcentrate was diluted to 50 ml with distilling water in a glass beaker. The 
sample was heated at the rate of about 0.5°C/min. A close observation was made at 
the appearance of the dispersion with the increase in temperature. The temperature at 
which the dispersion became turbid was taken as Tc. After the temperature exceeds 
the cloud point, the sample was cooled below Tc, and then it was heated again to 
check the reproducibility of the measurements. It mainly insists about the stability of 
micro emulsion at body temperature139. 
5.12.8  Determination of refractive index 
The refractive index, n, of a medium is defined as the ratio of the speed, c, of a 
wave such as light or sound in a reference medium to the phase speed, vp, of the wave 
in the medium represented by n=c/vp. It was determined using an Abbes type 
refractometer140. The clarity of micro emulsion could be estimated by measuring the 
refractive index of the formulations141.The SEDDS formulations were diluted 100 
times with water. The refractive index of the system was measured by an Abbe 
refractometer by placing 1 drop of solution on the slide and it compares with distilled 
water.  
5.12.9 Droplet size and polydispersity index (PDI) analysis  
The droplet size of the micro/nano emulsions is determined by photon 
correlation spectroscopy (which analyses the fluctuations in light scattering due to a 
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brownian motion of the particles) using a Zetasizer  which can measure sizes between 
10 and 5000 nm.  
Polydispersity was determined according to the equation:  
Polydispersity = D (0.9) – D (0.1) /D (0.5)  
where D (0.9) corresponds to particle size immediately above 90% of the 
sample, D (0.5) corresponds to particle size immediately above 5% of the sample and 
D (0.1) corresponds to particle size immediately above 10% of the sample. PDI is a 
measure of particle homogeneity and it varies from 0.0 to 1.0. The closer to zero the 
PDI  value  the  more  homogenous  are  the  particles.  The  mean  droplet  size  and  
polydispersity index of formulations were determined by using Malvern Nano Zeta 
sizer-90. The resultant SEDDS 0.5 ml, was diluted to 100 ml with double distilled 
water. The samples were loaded into a cuvette placed in a thermostatic chamber and 
light scattering was monitored at 25oC at a 90o angle142 after external standardization 
with spherical polystyrene beads.  
Each  determination  was  done  in  triplicate.  The  nanometric  size  range  of  the  
particle is retained even after 100 times dilution with water which proves the systems 
compatibility with excess water143.  
5.12.10 Zeta potential measurement 
The zeta potential of prepared SEDDS formulations was determined using a 
Zeta sizer ZS 90 (Malvern Instruments UK) by using laser Doppler micro-
electrophoresis. An electric field is applied to a solution which will cause the particles 
to move to the electrodes with a velocity related to their zeta potential calculated 
using Helmholtz–Smoluchowski equation. A suitable amount of the sample (50-
100µl) was diluted with 5 ml of distilled water and after sonicating in a bath sonicator 
to achieve a homogeneous state. Measurements were carried out at 25ºC using 
disposable polystyrene cuvette with a zeta dip cell. All the measurements were 
performed in triplicate and the data presented is mean ±SD144.  
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Zeta potential determination using following equation  
V           η 
ζ =             
E          ε·ε0 
where ζ  zeta – potential  ,  E electrical  intensity,  v particle velocity,  η viscosity,  ε·ε0 
dielectric constant 
5.12.11 Drug loading efficiency145 
The drug efficiency was done to investigate the effect of drugs on a self-
emulsifying performance of SEDDS. Approximately 10 mg of Atorvastatin calcium 
was added to 1 ml of boundary formulations of SEDDS and checked for a formation 
of the clear solution. 
5.12.11a Prototype formulation for Atorvastatin calcium 
Prototype formulations of Atorvastatin calcium were prepared by varying 
sunflower oil in 3:1 ratios of the mixture of labrasol and transcutol HP as per the 
formula composition mentioned in Table 14a. In the first trial, the oil was used at 40% 
and increased up to 80%. The ratio of surfactant to co-surfactant was maintained at 
3:1. Then drug of one dose equivalent of 10 mg atorvastatin calcium was added and 
stirred for 15 min. The mixture was heated to 30-40°C till the drug was solubilized. 
The drug loading capacity of each mixture was determined by adding the excess of 
atorvastatin calcium to each prototype mixture till the clear solution was obtained. 
The solution was filtered. 
The drug content of the SEDDS formulation was determined by diluting the 
solution in methanol and the volume was made up to 10 ml with methanol (1mg/ml). 
From the above stock solution, 0.2 ml (200µg/ml) was withdrawn and diluted up to 10 
ml with methanol (20 µg /ml). From the above solution 0.2ml (20 µg/ml) diluted up to 
10 ml  with methanol (2µg/ml) Samples were prepared in triplicate and absorbance 
was measured at 247 nm using UV-visible Spectrophotometer146 (Shimadzu UV-
1700) using methanol as a reference solution.  
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5.12.11b Prototype formulation for Glibenclamide 
Prototype formulations of glibenclamide were prepared by varying peceol in 
1:1 ratios of the mixture of labrasol and transcutol HP as per the formula composition 
mentioned in Table 14b. In the first trial, the oil was used at 15% with an interval of 5 
% and increased up to 25%. The ratio of surfactant to co-surfactant was maintained at 
1:1. Then drug of one dose equivalent of 5 mg glibenclamide was added and stirred 
for 15 min. The mixture was heated to 30-40°C till the drug was solubilized. The drug 
loading capacity of each mixture was determined by adding the excess of 
glibenclamide to each prototype mixture till the clear solution was obtained. The 
solution was filtered. 
The drug content was determined by repeating the same procedure as 
mentioned  above  with  the  SEDDS  formulation  equivalent  to  5mg  of  glibenclamide  
and the absorbance was measured at 226.5 nm using UV-Visible spectrophotometer 
(Shimadzu UV-1700). 
Drug loading efficiency was calculated by equation 
Drug loading efficiency = Amount of drug in known amount of formulation x 100 
                                                           Initial drug load 
5.12.12 In vitro dissolution studies for Atorvastatin calcium 
The in vitro studies were performed to find out the dissolution rate of SEDDS. 
The in vitro drug release147 profiles of optimized Atorvastatin of SEDDS, API 
Atorvastatin calcium and marketed Atorvastatin calcium tablet (Storvas 10mg 
Ranbaxy Laboratories Ltd) were carried out using  USP type II dissolution test 
apparatus (Electrolab) in 900 ml of Phosphate buffer (pH 6.8). The temperature was 
maintained at 37 ± 0.5°C and the speed of the paddle was set at 100 rpm. About 120 
mg of each optimized SEDDS formulations (AF1, AF5, AF11, AF13 and OPFA) 
were filled into soft gelatin capsules (size ‘3') and used for dissolution studies. The 
capsules were held to the bottom of the vessel using copper sinkers. At predetermined 
time intervals of 5, 10, 20, 30, 40, 50, 60, 75 and 90 min, an aliquot (5ml) of a sample 
were collected and filtered through the membrane filter (0.45µm, Whatman). The 
withdrawn samples were diluted suitably with phosphate buffer (pH 6.8) and analyzed 
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for the drug content by standard calibration curve method as described in section 5.6.1 
and 5.6.2 by UV-visible spectrophotometer (Shimadzu UV-1700) at 247 nm. An 
equal volume of the dissolution medium was replaced in the vessel after each 
withdrawal to maintain the sink condition. Each test  was performed in triplicate and 
calculated mean values of cumulative drug release were used while plotting the 
release curves as illustrated in Fig.16a. The dissolution profile of the API Atorvastatin 
calcium and marketed tablet (Storvas 10 mg) were assessed by the same method.  
5.12.13 In vitro dissolution studies for Glibenclamide 
The in vitro drug release profiles of optimized SEDDS formulations of 
Glibenclamide, API Glibenclamide and marketed Glibenclamide tablet (Daonil 5mg, 
Aventis  Pharma Ltd)  were  carried  out  using   USP type  II  dissolution  test  apparatus  
(Electrolab) in 900 ml of phosphate buffer (pH 7.4) as dissolution media148. The 
temperature was maintained at 37 ± 0.5°C and the speed of the paddle was set at 50 
rpm. About 70 mg of each optimized SEDDS formulations (GF1, GF2, GF7, GF12 
and OPFG) were filled into soft gelatin capsules (size‘3') and used for dissolution 
studies. The capsules were held to the bottom of the vessel using copper sinkers. At 
predetermined time intervals of 5, 10, 15, 20 and 30 min, an aliquot (2 ml) of a 
sample was collected and filtered through the membrane filter (0.45µm, Whatman). 
The withdrawn samples were diluted suitably with phosphate buffer (pH 7.4) and the 
drug content was analyzed by standard calibration curve method as described in 
section 5.8.1 and 5.8.2 by UV-visible spectrophotometer (Shimadzu UV-1700) at 
226.5 nm. An equal volume of the dissolution medium was replaced in the vessel after 
each withdrawal to maintain the sink condition. Each test was performed in triplicate 
(n = 3) and calculated mean values of cumulative drug release were used while 
plotting the release curves as illustrated in Fig.16b. The dissolution profile of the API 
Glibenclamide and marketed tablet (Daonil 5mg) were assessed by the same method.  
5.12.14 Kinetic modeling and Mechanism of drug release of optimized 
formulations 
The drug release data of optimized formulations were evaluated for various 
kinetic models viz. zero order, first order, Higuchi model, Hixson-Crowell model and 
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Korsmeyer-Peppas model. The study was carried out to determine the mode of drug 
release from the formulation by using DD Solver software. 
The kinetics of in vitro drug release 
Zero order:  
                         C = K0 t 
Where K0 - is  the  zero-order  rate  constant  expressed  in  units  of  concentration/time  
and t -is the time in h.  
First order:  
           Log C = Log C0 – K1t / 2.303  
Where C0 - is the initial concentration of drug, K1 - is the first order constant and t - is 
the time in h 
Higuchi:                 
                      Qt = Kt1/2  
Where Qt - is the amount of the released drug in time t, 
K- is the kinetic constant and t- is the time in h. 
Korsmeyer-Peppas: 
                      Mt / M∞ = Kt no  
where  Mt  - represents amount of the released drug at time t,  
M∞ - is the overall amount of the drug (whole dose) released after 12 h  
K is the diffusional characteristic of drug/polymer system constant  
n  is  a  diffusional  exponent  that  characterizes  the  mechanism  of  release  of  a  
drug.  
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The diffusion exponent and solute release mechanism are given below 
Diffusion exponent (n) Overall solute diffusion mechanism 
< 0.5  Quasi-Fickian diffusion  
   0.5  Fickian diffusion  
  0.5 < n < 1.0  Anomalous (non-Fickian) diffusion  
  1.0  Case-II transport  
> 1.0  Super case-II transport  
 
5.12.15 In vitro diffusion release study for Atorvastatin calcium and 
Glibenclamide 
The conventional dissolution testing can only provide a measure of 
dispersibility of SEDDS in the dissolution medium of SEDDS. Alternatively, in vitro 
performance of SEDDS can be evaluated by drug diffusion studies using the dialysis 
technique. The in vitro diffusion was performed using the dialysis membrane 
diffusion technique by a dialysis membrane method. The dialysis membrane of 
molecular weight cut off 12000 daltons was soaked in distilled water for four hours 
and  then  rinsed  thoroughly  with  distilled  water.  One  end  of  pretreated  cellulose  
dialysis bag (7cm tubing) was sealed firmly with clamp and 0.5 ml of optimized self-
emulsifying formulation was introduced in it along with 0.5 ml of dialyzing medium 
(phosphate buffer pH 6.8).The other end of the bag was also secured with clamp and 
was allowed to rotate freely. The bags were incubated in beakers containing 500 ml 
phosphate buffer (pH 6.8) at 37± 0.5°C and shaken at a speed of 100 rpm149 for 
atorvastatin calcium and the procedure was repeated with phosphate buffer 7.4 for 
glibenclamide. About 5 ml of samples were withdrawn individually at 0.5, 1, 2, 4, 6, 
8, 10 and 12 hour for Atorvastatin calcium and at 0.5, 1, and 2 hours for 
Gglibenclamide, which was simultaneously replaced with equal volumes of fresh 
medium at the same time. The drug content was determined spectrophotometrically at 
247 nm as described in section 5.6.1 and 5.6.2 for Atorvastatin calcium and at 227.5 
nm under section 5.8.1 and 5.8.2 for glibenclamide. The diffusion of the drug from 
optimized formulation was compared with the API and marketed tablet. 
  
90 
5.13 STATISTICAL ANALYSIS 
The  ANOVA  provision  available  in  the  software  was  used  to  establish  the  
statistical validation of the polynomial equations generated by Design Expert. A total 
of  13  runs  for  Atorvastatin  calcium  SEDDS  and  Glibenclamide  SEDDS  were  
generated by optimal design. All the responses were evaluated by a sum of squares, 
mean of squares, F values and p values. Various feasibility and grid searches were 
conducted over the experimental domain to find the optimized SEDDS formulations. 
Three-dimensional response surface plots and 2D contour plots were provided by the 
Design Expert software 10.0.2.0, where by intensive grid search performed over the 
whole experimental design. 
5.14  STABILITY STUDIES150  
A pharmaceutical product needs to be physical, chemically, therapeutically 
toxicologically and microbiologically stable throughout its shelf life. The 
pharmaceutical companies do stability testing for estimating the shelf life and based 
on this, the expiry data is given for the product. The real time studies (Long term 
testing) at recommended storage condition are the ideal method for predicting shelf 
life. Often the studies are designed to increase the rate of chemical degradation or 
physical change of pharmaceutical products by using exaggerated storage conditions. 
This is known as accelerated stability testing. The Pharmaceutical products are 
subjected to higher temperature and humidity conditions for accelerating the 
degradation. However, the results of accelerated testing are not always predictive of 
physical changes and potency. The international Conference on Harmonization (ICH) 
guidelines for stability testing of new drug substances and products (QIA) describes 
the stability test requirements for drug registration application in the European Union, 
Japan and Unites states of America. ICH specifies the length of study and storage 
conditions as follows 
Long term testing: 25°C±2°C at 60% RH± 5% for 12 months. 
Accelerated testing: 40°C ± 2°C at 75% RH ± 5% for 6 months.  
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The pharmacopeia specifies certain storage conditions. The details of the 
storage condition as specified in Indian pharmacopeia I.P 2007125 are given below:  
 
Storage condition Meaning 
Cold  Any temperature not exceeding 8ºC (2-8ºC)  
Cool  Any temperature not between 8-25ºC  
Warm  Any temperature not between 30-40ºC  
Excessive heat  Any temperature not above 40ºC  
 
The SEDDS formulations were filled in soft gelatin capsules (size 3) and were 
subjected to stability studies. The optimized SEDDS was stored under cold condition 
(4-8°C) at refrigerator and room temperature. The samples were charged at elevated 
temperature (50±2°C) in stability chamber (Labtech) under ambient humid conditions. 
After 1 month and 6 months, samples were analyzed for self-emulsification, phase 
separation, emulsification time, globule size and % drug loading151.  The  %  drug  
loading of the capsules was analyzed using the standard calibration curve method as 
described under 5.12.11a for Atorvastatin calcium and 5.12.11b for Glibenclamide.  
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CHAPTER 6 
RESULTS AND ANALYSIS 
6.1 PREFORMULATION STUDY 
6.1.1 Melting point determination 
The melting point of Atorvastatin calcium and Glibenclamide determined as 
per standard IP procedure were found to be 160°C and 173°C, respectively. The 
results obtained were within the melting point range as mentioned in The Merck’s 
Index55 (Atorvastatin calcium melting point is 159.2-160.7°C and Glibenclamide 
melting point is 172-174°C). 
6.1.2 FT-IR studies for Atorvastatin calcium 
From Figure 3a it was illustrated that the IR spectrum of Atorvastatin calcium 
showed the characteristic peaks of aromatic N-H stretching at 3364.93 cm-1 and the 
asymmetric stretching of C=O of amide group at 1651.12cm1. However, similar peaks 
of symmetric C=O stretching were observed at 1579.75 cm-1 and  O-H  stretching  at  
3566.50 cm-1. The characteristic peaks were observed at the wave numbers  
1510.31 cm-1 and 1424.48 cm-1 due to the C=C ring stretching.  The peak found at 
1317.43 cm-1 was  due  to  CH3/CH3 deformation bending vibration at the plane. The 
two characteristic bands were observed at 3735.28 cm-1 and 3055.35 cm-1due to the 
O-H stretching associated with the hydrogen bond. From the above study, it was 
inferred that the drug sample was identified as Atorvastatin calcium. 
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Figure 3a FT-IR spectrum of Atorvastatin calcium
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6.1.3 FT-IR studies for Glibenclamide 
From the Figure 3b, the IR spectrum of Glibenclamide showed the 
characteristic bands of N-H stretching of amide group at 3315.41 cm-1. The bands 
observed at 3033.82 cm-1 and 1714.60 cm-1 indicated CH=CH stretching and C=O 
stretching of the spectrum. The characteristic three bands observed at 1593.09 cm-1, 
1618.17 cm-1, 1523.66 cm-1 were exhibited due to ring C=C stretching, N-H bend 
scissoring, and N-H bending. A secondary weaker band formed by interaction 
between the N-H bending and C-N stretching was found to be at 1247.86 cm-1. From 
the characteristic peaks of IR spectrum, as shown in Figure 3b, it was confirmed that 
the drug was Glibenclamide.  
The melting point and FTIR studies revealed that the drug samples are pure 
API of Pharmacopoeial standard. 
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Figure 3b FT-IR spectrum of glibenclamide
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Identification test for oils 
6.1.4 Specific gravity 
The  specific  gravity  of  the  oils  were  determined  as  mentioned  in  Bureau  of  
Indian standards of Indian standard specification given under the methods of sampling 
and test for oils and fats IS 548- 1.The results obtained were within specific gravity 
range are given as follows 
Name of oil                 Specific gravity         Specific gravity limits as per standards 
Virgin sesame oil  0.917 0.916-0.921(Complies as per USP 2009)152     
Sunflower oil  0.916  0.914-0.924 (Complies as per USP 2009) 152 
Corn oil                          0.915        0.914-0.921(Complies as per USP 2009) 152 
Mustard oil                    0.920   0.914-0.923 (Complies to USP twelfth 
       revision 1942)153                                                                                              
Rice bran oil                  0.912  0.910-0.920  
  (Complies as per BIS IS 3448- 1984)67          
Olive oil                        0.913 0.910-0.915 (Complies as per USP 2009) 152 
Virgin coconut oil          0.918  0.915-0.920   
  (Complies as per BIS IS 542 1968)154  
Peceol                            0.942  0.942 (Complies as per USP 2009) 152 
6.1.5 Determination of saponification value, Iodine value and acid value for oils 
The oils were identified by performing any two assessment tests for oils 
among saponification value, Iodine value and acid value according to the Bureau of 
Indian standards for Indian standard specification specified under the methods of 
sampling and test for oils and fats IS 548-1. The results obtained were given as 
follows 
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Virgin sesame oil     
Saponification value –191 (complies within the range of 188-195 as per USP 2009) 152                       
Iodine value – 110 (complies within the range of 103-116 as per USP 2009) 152    
Virgin coconut oil     
Saponification value - 190 (complies within the range of 180-200 as per USP 2009)152 
Acid value -0.6   (Complies as per BIS IS 542 1968) 154 
Sunflower oil  
Saponification value – 192 (complies within the range of 180-200 as per USP 
2009)152 
Iodine value – 110 (complies within the range of 100-140 as per BIS IS 4277-1975)155 
Corn oil 
Saponification value - 189 (complies within the range of 187-193 as per USP 2009)152 
Iodine value – 110 (complies within the range of 109-133 as per USP 2009) 152 
Mustard oil 
Saponification value  - 172 (complies within the range of 169-177 as per BIS IS: 546-
1975)62 
Iodine value – 100 (complies within the range of 98-110 as per BIS IS: 546-1975) 62  
Rice bran oil                  
Saponification value – 188 (complies within the range 180-195 as per BIS IS 3448 
1984) 63 
Iodine value – 102 (complies within the range 90-105 as per BIS IS 3448 1984) 63 
Olive oil 
Saponification value– 194 (complies within the range of 190-195 as per USP 2009)152 
Iodine value – 84 (complies within the range of 79-88 as per USP 2009) 152 
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Peceol 
Saponification value - 164 (complies within the range of 150-175 as per USP 2009)152 
Iodine value – 75 (complies within the range of 65-95 as per USP 2009) 152 
From the above results, it was analyzed that the natural and synthetic oils used 
for  development  of  SEDDS  are  of  the  pure  quality  which  complies  with  the  tests  
given under standard specifications.                  
6.1.6  UV spectroscopic method analysis of Atorvastatin calcium 
Linearity and range for calibration curve of Atorvastatin calcium in methanol  
The straight line calibration graph was obtained in the concentration of  
2-12μg/ml of the Atorvastatin calcium in methanol. The linear regression equation 
was found to be y=0.045x+0.003 with the correlation co efficient (r2) of 0.999. The 
calibration curve was illustrated in Fig. 4a and from the linear regression data (r2 
value) of Table 10a, it can be concluded that the analyzed concentration of the drug 
solution followed linearity.  
 
Table 10a : Calibration data for Atorvastatin calcium in methanol 
S.No. Concentration (µg/ml) Absorbance 
1. 2 0.0913 
2. 4 0.1908 
3. 6 0.2836 
4. 8 0.3774 
5. 10 0.4625 
6. 12 0.5465 
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               Fig.4a Calibration curve of Atorvastatin calcium in methanol 
6.1.7 Linearity and range for calibration curve of Atorvastatin calcium in 
phosphate buffer pH 6.8 
The straight line calibration graph was obtained in the concentration 2-12 
μg/ml of the Atorvastatin calcium phosphate buffer pH 6.8.The linear regression 
equation for Atorvastatin calcium in phosphate buffer pH 6.8 is y=0.012x+0.001 with 
the correlation co efficient of 0.999. The calibration curve was illustrated in Fig.  4b 
and from the linear regression data (r2 value) of Table 10b, it can be concluded that 
the analyzed concentration of the drug solution followed linearity.  
Table 10b : Calibration data for atorvastatin calcium in phosphate buffer pH 6.8 
S.No. Concentration (µg/ml) Absorbance 
1. 2 0.0265 
2. 4 0.0529 
3. 6 0.0795 
4. 8 0.1046 
5. 10 0.1279 
6. 12 0.1535 
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Fig.4b Calibration curve of Atorvastatin calcium in phosphate buffer pH 6.8 
6.1.8 Linearity and range for calibration curve of Glibenclamide in methanol 
The straight line calibration graph was obtained in the concentration 1-6 μg/ml 
of the Glibenclamide in methanol. The linear regression equation of Glibenclamide in 
methanol was y=0.118x+0.002 with the correlation coefficient of 0.999. The 
calibration curve was illustrated in Fig.5a and from the linear regression data (r2 
value) of Table 11a, it can be concluded that the analyzed concentration of the drug 
solution followed linearity.  
Table 11a : Calibration data for glibenclamide in methanol 
S.No. Concentration (µg/ml) Absorbance 
1. 1 0.1186 
2. 2 0.2472 
3. 3 0.3558 
4. 4 0.4774 
5. 5 0.5980 
6. 6 0.7116 
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Fig.5a Calibration curve of Glibenclamide in methanol 
6.1.9 Linearity and range for calibration curve of Glibenclamide pH phosphate 
buffer 7.4 
The straight line calibration graph was obtained in the concentration 2-12 or 1-
6μg/ml of the Glibenclamide in pH phosphate buffer 7.4. The linear regression 
equation for Glibenclamide in phosphate buffer pH 7.4 is y=0.018x+0.001 with the 
correlation co efficient of 0.999. The calibration curve was illustrated in Fig.5b and 
from the linear regression data (r2 value) of Table 11b, it can be concluded that the 
analyzed concentration of the drug solution followed linearity.  
Table 11b : Calibration data for glibenclamide in phosphate buffer pH 7.4 
S.No. Concentration (µg/ml) Absorbance 
1. 2 0.038 
2. 4 0.076 
3. 6 0.112 
4. 8 0.152 
5. 10 0.188 
6. 12 0.221 
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Fig.5b Calibration curve of glibenclamide in phosphate buffer pH 7.4 
6.2 SOLUBILITY STUDY 
6.2.1  Solubility of Atorvastatin calcium in various excipients 
Atorvastatin calcium was found to be insoluble in aqueous acidic solutions of 
pH 4.0. It was very slightly soluble in water, pH 7.4 phosphate buffer, acetonitrile and 
ethanol as indicated in Table 12. The drug was found to be freely soluble in methanol, 
dimethylsulphoxide and dimethylformamide. Further, as Atorvastatin calcium is 
classified as class II drug of BCS classification it can be considered an ideal candidate 
for formulation into SEDDS. 
The most important criterion for the screening of components for lipid based 
formulation, is the solubility of the drug in oil, surfactant and cosurfactant. The 
solubility of a drug in oil is more important because the ability of lipid based 
formulation to maintain the drug in solubilized form is greatly influenced by the 
solubility of the drug in the oil phase. At least one dose of the drug should be soluble 
in the oil phase otherwise it becomes necessary to add the higher amount of surfactant 
and co-surfactant to dissolve the drug. The drug was found to be more soluble in oils 
with high HLB value. The function of the oil phase in the self-emulsifying system is 
to solubilize the hydrophobic/lipophilic active moiety in order to improve both drug 
loading and bioavailability of the hydrophobic active moiety. Therefore selection of 
oil plays a vital role in the formulation as it determines the amount of drug that can be 
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solubilized in the system. A lipid molecule with a large hydrophobic portion 
compared to hydrophilic portion is desirable as it maximizes the amount of drug that 
can be solubilized.  
The solubility of the Atorvastatin calcium in the various oils, surfactants and 
co-surfactants were tabulated in Table 12 and the solubility graph was illustrated in 
Fig.6a. Sunflower oil of solubility of 30.13 mg/ml showed the best solubility for 
Atorvastatin calcium and it can be seen that one dose of the drug can be successfully 
dissolved in sunflower oil. The sunflower oil which is a long chain triglyceride 
consisting of linoleic acid as a major component has been used as a carrier for poorly 
soluble drugs thus it was selected as oil phase for further study. The hydrophilic 
surfactants of labrasol tend to show higher solubility for Atorvastatin calcium than the 
hydrophobic surfactants such as capryol PGMC, labrafil M 1944CS, labrafil M 2125 
CS as indicated in Table 12. However, labrasol having caprylic (C8) and capric (C10) 
fatty acid esters of glycerol in its composition showed the highest solubility of 89.23 
mg/ml than the other surfactants. Transcutol HP which showed highest solubilization 
capacity of 38.62mg/ml was chosen as cosurfactant for further study. The drug 
content of Atorvastatin calcium was calculated using the Beer Lambert’s equation (y 
= 0.045 × concentration + 0.003). 
6.2.2.  Solubility of Glibenclamide in various excipients 
Glibenclamide was found to be practically insoluble in water as indicated in 
Table 12. It was found to be slightly soluble in methanol. The drug was found to be 
sparingly soluble in dichloromethane. It was confirmed that Glibenclamide is 
classified as class II drug of BCS classification due to poor aqueous solubility and it 
can be considered as an ideal candidate for formulation into SEDDS. Peceol which is 
a long chain monoglyceride showed a maximum solubilization capacity of 7.83 
mg/ml was selected as oil phase for the drug. The labrasol showed the maximum 
solubilization capacity of 9.52 mg/ml was selected as surfactant among the other 
hydrophobic surfactants as indicated in Table 12. The transcutol HP showed the 
maximum solubilizing capacity of 38.62mg/ml and it was selected as cosurfactant for 
further study. The drug content of Glibenclamide was calculated using the Beer 
Lambert’s equation (y =0.118× concentration + 0.002). 
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Table 12 : Solubility of Atorvastatin calcium  and Glibenclamide in various 
excipients 
S.No. Excipients 
Atorvastatin calcium 
Solubility (mg/ml) 
Glibenclamide 
Solubility (mg/ml) 
   Oils 
1. Virgin sesame oil 15.36±0.006 3.5±0.012 
2. Virgin coconut oil 25.37±0.015 6.30±0.007 
3. Sunflower oil 30.13±0.02 2.28±0.001 
4. Corn oil 4.86±0.030 4.89±0.009 
5. Mustard oil 10.35±0.01 2.34±0.002 
6. Rice bran oil 12.29±0.040 4.25±0.001 
7. Olive oil 17.62±0.010 5.65±0.003 
8. Peceol 12.84±0.021 7.83±0.015 
  Surfactants 
9. Labrasol 89.23±0.015 9.52±0.016 
10. Labrafi   Labrafil 1944CS    1.78±0.011 6.24±0.004 
11. Labrafil 2125 1.62±0.012 1.26±0.011 
12 Capryol PGMC 2.22±0.006 2.26±0.052 
   Co-surfactant   
13. Transcutol HP 38.62±0.28 18.12±0.018 
  Solvents  
14. Distilled water 0.0096±0.012  0.0001±0.008 
15.. Methanol 0.666±0.002 0.0092±0.002 
16. pH Phosphate buffer 7.4 0.0095±0.013 - 
17. Acetonitrile 0.0092±0.003 - 
18. Ethanol 0.0089±0.014 0.0085±0.012 
19. Dimethyl sulphoxide 0.0793±0.022 - 
20. Dimethyl formamide 0.0757±0.003 - 
21. Dichloromethane - 0.0305±0.004 
22. Aqueous solution of pH 4 0.02± 0.005 - 
    * Values are mean ±S.D (n=3) 
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Fig. 6a Solubility profile of Atorvastatin calcium 
 
 
Fig. 6b Solubility profile of Glibenclamide 
6.3 CONSTRUCTION OF TERNARY PHASE DIAGRAM 
Ternary phase diagrams were designed in order to demonstrate regions of 
nanoemulsion formation. Variable proportions of oil, surfactant and co-surfactant 
were tested. The shaded darker region in the ternary phase diagram (Fig.7a and 
Fig.7b) represents the efficient self-emulsifying region where desired visual 
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observation characteristics were observed for clarity  of  the  solution,  no  phase  
separation, rapidity and spontaneity of the emulsion formation. The range and level 
for each component (independent variables) was selected as oil (40–80%), surfactant 
(22.5–52.5%), co-surfactant (7.5–17.5%) for Atorvastatin calcium and oil (15-30%) 
surfactant (15-25%), cosurfactant (15-25%) for Glibenclamide as shown in Table 13a 
and Table 13b. The border lines are shown in the Fig. 7a and Fig. 7b which is 
surrounded by  the shaded region indicate the boundary of the level used in the 32 
factorial design study and the polygonal area bounded by all the border lines indicate 
the region from which optimum formulation is to be selected. During emulsification, 
the surfactant molecules migrate to the o/w interface and lower the interfacial tension. 
By adding cosurfactant, the interfacial tension further decreases and the induction of 
ideal curvature of an interfacial film takes place. The droplet size decreases and the 
net outcome is the negative value for the free energy of microemulsion formation 
which means spontaneous microemulsion formation. As the water is always in 
considerable abundance and oil volume fraction is low, it was safely supposed that 
only o/w emulsion was formed and no other dispersed and bicontinuous pseudo 
phases were formed.  
 
Fig. 7a Ternary phase diagram of Atorvastatin calcium SEDDS 
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Fig. 7b Ternary phase diagram of Glibenclamide SEDDS 
6.3.1 Variables selected for development of Atorvastatin calcium and 
Glibenclamide SEDDS 
Based on the feasibility of micro emulsion formation at extreme values, the 
range for each component was selected as follows: oil (40-80%), Smix (30-70%) for 
Atorvastatin calcium and oil (15-25%), Smix (30-50%) for Glibenclamide 
respectively. The slack variable was taken as water content as it is present in the 
larger amount in a gastrointestinal tract. The dependent variables which are significant 
response factors studied for assessing the quality of SEDDS are particle size (Y1) and 
% drug loading (Y2).  The  optimization  of  the  SEDDS was  done  using  by  3  level  2  
factorial design. From the preliminary solubility and ternary phase diagram studies the 
amount of sunflower oil (X1) as lipophile and the amount of surfactant mixture (X2) of 
labrasol and transcutol HP were selected as the two independent variables  for the 
development of Atorvastatin calcium SEDDS. The amount Peceol (X1) and surfactant 
mixture (X2) of Labrasol and transcutol HP were the two independent variables 
selected for the formulation of Glibenclamide SEDDS. The three levels of each factor 
were used to construct experimental design. The levels for sunflower oil (40, 60 80), 
labrasol and transcutol HP (30, 50, 70) for a formulation of Atorvastatin calcium 
SEDDS were selected from the preliminary study as depicted in Table 13a.  The 
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levels for peceol (15, 20, 25), labrasol and transcutol HP (30, 40, 50) were chosen for 
development of Glibenclamide SEDDS as illustrated in Table 13b. 
Table 13a : Variables for Atorvastatin calcium in 32 full factorial Design 
Independent Variables(a) 
Levels 
Low (-1) Middle (0) High (-1) 
X1: Amount of oil added (mg) 40 60 80 
X2:Amount of Smix in ratio of 3:1 
added (mg) 
30(22.5:7.5) 50(37.5:12.5) 70(52.5:17.5) 
Dependent Variables 
Constraints 
Range  Goal 
Y1: Particle size (Globule Size in nm) In the range   Minimize 
Y2: % drug loading  In the range  Maximize 
(a) Oil: Sunflower oil; Surfactant: Labrasol; Cosurfactant: Transcutol HP 
 Table 13b : Variables for Glibenclamide in 32 full factorial Design 
Independent Variables(a) 
Levels 
Low (-1) Middle (0) High (-1) 
X1: Amount of oil added (mg) 15 20 25 
X2: Amount of Smix in ratio of 
1:1added (mg) 
30(15:15) 40(20:20) 50(25:25) 
Dependent Variables 
Constraints 
Range  Goal 
Y1: Particle size(Globule Size in nm) In the range   Minimize 
Y2: % drug loading  In the range  Maximize 
(a) Oil: Peceol; Surfactant: Labrasol; Cosurfactant: Transcutol HP 
6.4 STATISTICAL ANALYSIS OF THE DESIGNED EXPERIMENT 
The range of oil  (X1),  Smix (X2) were delimited as independent variables; 32 
full factorial design was performed to optimize SEDDS with constraints on globule 
size and drug load as the Response Surface methodology (RSM) requires 13 
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experiments and the observed responses are summarized in Table 14a and Table 14b. 
All the data were fitted to the second order quadratic model and validation of the 
model was carried out by analysis of variance (ANOVA) test, lack of fit test and 
correlation coefficient (R2). The significance of the ratio of mean square variation due 
to regression and residual error was tested using analysis of variance (ANOVA). The 
ANOVA indicated a significant (p<0.05) effect of factors on a response. Various 
statistical evaluations of models for each response are depicted in the Tables 15a, 
Table 16a and Table 15b, Table 16b for Atorvastatin calcium and Glibenclamide. As 
shown in Table 15a, 15b at 5% significance level, it was observed that for responses 
Y1,  and Y2, quadratic fitting was significant (p-value <0.05). For the Y1 response of 
Atorvastatin calcium, the "Lack of Fit F-value" of 32.97 implies the Lack of Fit is 
significant. There is only a 0.28% chance that a "Lack of Fit F-value" this large could 
occur due to noise. For the Y2 response of Atorvastatin calcium response, the lack of 
fit  was  The  "Lack  of  Fit  F-value"  of  1.93  implies  the  Lack  of  Fit  is  not  significant  
relative to the pure error. There is a 26.69% chance that a "Lack of Fit F-value" this 
large could occur due to noise. For the Y1 response of Glibenclamide, the "Lack of Fit 
F-value" of 182.64 implies the Lack of Fit is significant. There is only a 0.01% 
chance that a "Lack of Fit F-value" this large could occur due to noise. For the Y2 
response of The "Lack of Fit F-value" of 2.02 implies the Lack of Fit is not significant 
relative to the pure error. There is a 25.33% chance that a "Lack of Fit F-value" this 
large could occur due to noise. Non-significant lack of fit is good while calculating 
the correlation coefficient (R2) for the responses Y1,  and  Y2 the confidence that the 
regression equations would predict the observed value better than mean were more 
than 83.22%, 93%, respectively (Table 16a) for Atorvastatin calcium and 
79.6%,79.37% for Glibenclamide (Table 6b). The corresponding coefficients which 
showed the quantitative effects of independent variables (X1 and  X2) and their 
interactions  on  the  responses  are  shown  in  the  Tables  17a  and  Table  17b.  The  
coefficients (Factor intercepts) (X1·X2,)  and  those  with  the  higher  order  terms  (X12, 
X22)  indicate the interactions and quadratic effects, respectively. For all the models 
the predicted R2 value is reasonable agreement with the adjusted R2 value. Adequate 
precision values higher than 4 for all responses confirmed that the predicted models 
can be used to navigate the design space defined by full factorial design. A positive 
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value represents an effect that favors the optimization and negative value indicates an 
inverse relationship between the factor and response.  
Table 14a : Execution of 32 Experimental Design and coding of actual values of 
independent variables for factorial design with the observed responses for 
Atorvastatin calcium 
Std Run 
Formulation 
Code (FC) 
Oil 
(mg) 
Smix 
(mg) 
Y1(Particle 
size) (nm) 
Y2(%Drug 
Loading) 
7 1 AF1 -1(40) +1 (70) 106.8±4.08 81.8±6.63 
4 2 AF2 -1(40) 0 (50) 172±7.5 83.1±4.54 
6 3 AF3 +1(80) 0 (50) 290±4.9 91.5±2.78 
10* 4 AF4* 0 (60) 0 (50) 112.4±8.5 85.1±2.71 
13* 5 AF5*   0 (60) 0 (50) 128.5±5.68 84.3±3.05 
9 6 AF6 +1(80) +1 (70) 285±8.6 87.6±1.65 
5 7 AF7   0 (60) 0 (50) 137.9±5.5 88.7±1.1 
2 8 AF8  0(60) -1 (30) 197.6±5.65 75.1±2.75 
8 9 AF9 0 (60) +1 (70) 233.1±3.44 86.1±4.37 
3 10 AF10 +1 (80) -1 (30) 229.7±4.98 89.1±4.53 
11* 11 AF11* 0 (60) 0 (50) 140.2±3.0 85.7±4.70 
1 12 AF12 -1 (40) -1 (30) 415±8.7 70.1±2.25 
12* 13 AF13* 0 (60) 0 (50) 114.9±7.1 86.9±1.21 
Y1: Particle size; Y2: Drug Load;   *Centre point Formulations 
The coded and actual values for the factors used in the 32 factorial design for 
Atorvastatin calcium at three levels are stated as below 
Factors    Factor Level used  
                                                                Low level      Mid Value      High Value 
Coded value           X1 & X2                         -1                    0                    +1 
Actual value           X1                                  40                   60                   80 
Actual value           X2                                  30                   50                   70 
 
X1 is the % amount of sunflower oil in mg 
X2 is the % amount of Smix (Labrasol and Transcutol) in mg. 
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Table 14b : Execution of 32 Experimental Design and coding of actual values of 
independent variables for factorial design with the observed responses for 
Glibenclamide 
Std Run 
Formulation 
Code 
Oil (mg) 
Smix 
(mg) 
Y1 (Particle 
size) (nm) 
Y2 (% Drug 
Loading) 
10* 1 GF1* 20(0) 40(0) 411.5 87.8 ± 2.25 
13* 2 GF2* 20(0) 40(0) 410.3 90 ± 3.7 
3 3 GF3 25(+1) 30(-1) 415.2 82 ± 1.9 
6 4 GF4 25(+1) 40(0) 233.1 84 ± 4 
5 5 GF5 20(0) 40(0) 402.3 91.2 ± 5.4 
9 6 GF6 25(+1) 50(+1) 229.7 84.6 ±3.7 
12* 7 GF7* 20(0) 40(0) 421.6 89 ± 4.16 
2 8 GF8 20(0) 30(-1) 464.1 85.6 ± 2.64 
8 9 GF9 20(0) 50(+1) 616.3 92.3 ± 4.12 
7 10 GF10 15(-1) 50(+1) 169.7 87.6 ± 1.75 
4 11 GF11 15(-1) 40(0) 222.2 92.3 ± 3.26 
11* 12 GF12* 20(0) 40(0) 401 92 ± 5.26 
1 13 GF13 15(-1) 30(-1) 284.2 88.8 ± 2.38 
 
The coded and actual values for the factors used in the 32 factorial design for 
glibenclamide at three levels are stated as below 
Factors                Factor Level used  
Low level      Mid value      High value 
Coded value           X1 & X2    -1          0     +1 
Actual value           X1              15          20         25 
Actual value           X2                   30     40         50 
 
X1 is the % Amount of Peceol in mg 
X2 is the %Amount of Smix (Labrasol and Transcutol) in mg 
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Analysis of Variation and Regression156, 157 
The observations resulting from a designed experiment are often examined 
using analysis of variance (ANOVA) techniques in which the variance associated 
with a particular independent variable or interactions between the variable or 
interactions between independent variables is compared with the variance associated 
with the random error that occurs in the experiment. If there are a difference variable 
and error variances, then the treatment being tested is considered to have a significant 
effect on the measured response. The comparisons between the variances are made 
typically using an F test or F distribution. The ANOVA was performed to check the 
adequacy of suggested models and identify the significant factors. In statistically the 
mathematical models were evaluated for each response by means of multiple linear 
regression  analysis.  The  regression  analysis  is  a  technique  to  determine  the  
relationship exists between experimental variables and a response variable. The 
specific relationship defined for a response variable (Y) and the experimental or 
independent variables (X) is known as the regression model. The modeling was stated 
with a quadratic model, including linear, squared and interaction term. A linear 
polynomial regression model can be used to approximate the relationship between the 
response variable and independent variables The linear first order polynomial is 
represented as by Y =β0 + β1 X + e where Y is the response, X1,X2 are the independent 
variables and e is the random error term at which the standard deviation is zero. The 
β0 and β1 are the regression model coefficients that estimate the linear or main effects 
of the independent variables. The two level factorial design is suitable for linear first 
order model. For estimation of interaction and quadratic effects the second order 
polynomial model which involve three levels for each variable are chosen in the 
experimental design. The least square method of analysis is employed to fit a 
mathematical model to the data. The estimates of the regression coefficients and the 
predicted values are unbiased with least variance if the following statements are true 
a) The X values are fixed and not random variables 
b) The deviations (ei) are independent, uncorrelated and have a mean of zero. 
c) The variance of the deviations are constant 
d) The deviations are normally distributed 
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The significant term in the model was found by analysis of variance 
(ANOVA) for each response. The significance was judged by determining the 
probability  level  that  the  p-  statistics  calculated  from  the  data  is  less  than  5%.  The  
model accuracy was checked by R2, adjusted R2 and Predicted R2 and prediction error 
sum of squares (PRESS). A good model will have larger predicted R2 and low press 
values. The total data variance is divided into two main contributions, the sum of 
squares explained by the regression, SSR, and  the  residual  sum of  squares  SSr. Both 
summations are taken over all the experimental design levels, j = 1,2… m and all the 
replicates performed at each level, j =1,2……..ni.. SSR is  a  sum  of  squares  of  
differences between values predicted by the regression and the grand average of all 
the response values and has p-1 degrees of freedom where p is the number of 
coefficients in the model. SSr is a sum squares of differences or residuals between all 
the experimental values and the predicted values from the model. It has n-p degrees of 
freedom where n is the total number of experimental data used to determine the 
model. The large SSR and small  SSr values tend to occur for models that accurately 
describe the experimental data. The total sum of squares of differences between the 
experimental values and the grand average of the data set happen when their sum is 
equal to SST. The sum has n-1 degrees of freedom since it represents the total variance 
in  the  data.  The  SSR/SST ratio represents the fraction of explained variation and is 
commonly represented as R2, the coefficient of determination which varies between 0 
and 1. If the pure error exists, it is impossible for R2 to actually attain 1. Although the 
coefficients is a measure of how close the model fits the data and it cannot be used to 
judge the model lack of fit because it does not take in to account the numbers of a 
degree of freedom for model determination. A real statistic R2a = [1-(1-R2) {(n-1)/ (n-
p)}] makes an adjustment for the varying numbers of a degree of freedom in the 
models being compared. The model quality can only be rigorously judged if the SSr is 
decomposed into two contributions, the lack of fit and the pure error sums of squares, 
SSlof and SSpe. The SSpe is a sum of squares of differences between all the individual 
experimental values and the average of the experimental values at the same level. It 
has n−m degrees of freedom where m is the number of distinct levels in the 
experimental design. The SSlof is a sum of squares of differences between the values 
predicted at each level and the average experimental value at that level and has m−p 
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degrees of freedom. The regression lack of fit is determined to perform an F-test by 
comparing the SSlof /SSpe ratio with the tabled F value for m−p and n−m degrees of 
freedom at the desired confidence level, usually 95%. If the calculated quotient is 
greater than the tabled value there is evidence of model lack of fit and the model must 
be discarded. The model can be accepted at this confidence level as providing an 
adequate representation of the data. The regression significance can be tested by 
comparing the calculated SSR/SSr value with the tabled F-distribution value for p−1 
and n−p degrees of freedom. The regression is significant if the calculated value is 
greater than the tabled one. The F-test is only valid for models for which there is no 
evidence of lack of fit. The regression model failed to explain experimental error and 
the maximum % of explainable variation is given by [(SST −SSpe)/SST] ×100%. The 
terminology of the following terms used to calculate the accuracy of the model is 
Standard deviation: (Root MSE) square root of the residual mean square is used to be 
an estimate the standard deviation. 
Mean: The overall average of the all response data 
Co-efficient of variation: It is the standard deviation expressed as the % of mean. It is 
calculated by dividing the standard deviation by the mean and multiplying by 100. 
PRESS: It is the predicted residual error sum of squares and basically it is a measure 
of how well model from this experiment is likely to predict the response in a new 
experiment. The smallest of PRESS are values are desirable.  
Adjusted R2: It is a measure of the amount of variation around the mean explained by 
the model adjusted for the number of terms in the model. The adjusted R2 decreases 
the number of terms in the model increases if those additional terms are not added 
value to the model. 
Predicted R2:   It  is  a  measure  of  the  amount  of  variation  in  new  data  explained  by  
model.   
Adequate  precision:  It  is  basically  a  measure  of  S/N  ratio  (Signal  to  noise).  It  is  
explained by a factor to judge the model if it is adequate to navigate through the 
design space and can able to predict the response. The desired values should be > 4.0. 
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The Analysis of Variance for the least squares fit of a model which is linear in 
its parameters are illustrated below 
Source of variation Sum of squares  Degrees of freedom         Mean square 
                                                                                   
Regression                     m ni   
SSR = ΣΣ (ŷi -y) 2           p-1               MSR = [SSR / (p-1)] 
i    j 
Residual     m ni 
SSR = ΣΣ (yij- ŷi) 2      n-p           MSr = [SSr / (n-p)] 
i    j 
Lack of fit    m ni 
SSlof = ΣΣ (ŷi -y) 2        m-p           MSlof = [SSlof / (m-p)] 
i    j 
Pure error            m ni 
SSpe = ΣΣ (yij-y) 2                   n-m           MSpe = [SSpe / (n-m)] 
i    j 
 
Total                  m ni 
SSR = ΣΣ (yij-yi) 2                 n-1                                    
i    j 
 
ni: number of replicates at the ith level; m: number of distinct levels of the independent 
variables;  n  =  ∑ni  =  total  number  of  observations;  p:  number  of  parameters  in  the  
model. 
The adequacy of the regression model which is fitted to the experimental data 
is tested by F test (test for significance of the regression) is provided by ANOVA. The 
test is comparison of two estimates of the variance. The mean square for error (MSE) 
yields one unbiased estimate s2 of the population variance s2 if the regression 
coefficients are zero. The regression coefficient which differs significantly from zero 
is tested by F test ratio which is given by F = MSR/s2.If the F value is greater than the 
tabulated critical F value it is indicated that the regression is significant. If the F value 
is  less  than  the  critical  F  it  is  suggested  that  both  MSR  and  s2 provided reasonable 
unbiased estimates of s2 and the regression is nonsignificant. 
A literature search revealed an exhaustive number of publications 
characterizing the self-emulsified drug delivery system158. The reported studies used 
different methods for in vitro evaluation such as self-emulsification time, cumulative 
percent release, low frequency dielectric spectroscopy, zeta potential measurement 
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and surface tensiometry. The particle size and drug loading are critical formulation 
parameters used to help maximize the pharmacokinetics of small molecules159. In this 
present work the particle size of SEDDS after dilution was chosen as Y1 variable was 
selected as criteria for in vitro evaluation.  If  the  particle  size  of  SEDDS  is  less,  the  
release of drug will be more resulting with better bioavailability in the formulation of 
SEDDS.  The  particle  size  of  around  20  nm  gives  total  transparent  system  upon  
dilution, which acts as a solution. Drug loading is a critical parameter which affects 
the therapeutic efficacy, pharmacokinetics and toxicity of the drug. Higher drug 
loading is preferable because less non-active excipients are used to produce the same 
quantity of API in the SEDDS formulation. At a higher drug loading, lower quantity 
of oils and surfactants (non active ingredients) need to be manufactured to deliver an 
equivalent dose of API. The benefit of maximum drug loading is that the quantity of 
surfactants incorporated in the SEDDS formulation can be reduced which in turn 
reduces irritation on GIT due to large quantity of the surfactants. It can also reduce the 
manufacturing and processing time, raw material usage. So, particle size was selected 
as criteria for the optimization. The % drug loading was selected as Y2 variable 
because the higher the drug loading in SEDDS formulation reduces final dose of the 
drug and improves patient compliance with minimum GIT irritation and side effects. 
Evaluation of responses in ANOVA 156 
In the design of experiments, it is essential to test the quality of results prior to 
evaluation. The coefficient of variation (CV= standard deviation/mean) for each 
dependent variable should be calculated and if the results are below 10 %, they might 
be considered excellent while values up to 20% are considered acceptable. Once the 
mathematical model has been selected it is important to determine its significance by 
means of a variance analysis (ANOVA). The standard deviations of the main and the 
interactions effects of the selected factors are calculated by ANOVA. If the standard 
deviations present a lower value than the mean values it is possible to assume that the 
mathematical model is significant. If it is not possible, the experimental data should 
be evaluated in order to not presume that the effect is not significant. In the evaluation 
of experimental designs, a mathematical model is provided to relate the response 
variable with the factor effects. In this regard, the goodness of fit of the model needs 
an assessment and the following criteria are analyzed as follows 
117 
· Standard deviation of the estimated parameters and model 
· Statistical significance of the estimated parameters 
· Regression coefficient 
· Value of the objective function 
· Significance of the regression (ANOVA) 
· Analysis of the residuals. 
It is considered a good fit to the experimental data when the standard deviation 
of the parameter presents a lower value than the correspondent effect indicating that 
the standard deviation of the proposed mathematical model is low and the parameters 
of a model need to be significant otherwise they will not contribute to the model. It is 
considered hypothetically that if the model presents a regression coefficient (R2) 
above 90% then it is considered excellent. It is only one criterion to evaluate the 
model goodness of fit. If a regression coefficient is low (<70%), the mathematical 
model is not good and on the other hand if its value is high (>90%), it means that 
other statistical criteria such as t and F test are used. By using an appropriate 
estimation method applied to the chosen model, the regression coefficients will be 
obtained and the estimated response can be easily calculated. For verification of the 
model adequacy, several techniques are used like residual analysis, scaling residuals, 
prediction of error sum of squares residuals and tests of lack of fit. The lack of fit is a 
measure of a model failure in representing data in the experimental domain significant 
lack of fit as indicated by a low probability value (p <0.05) and the response predictor 
is discarded. The overall predictive capability of the model is commonly explained by 
the regression coefficient (R2) but this coefficient alone was not used to measure the 
model accuracy. R2 is defined as the ratio of the explained variation to the total 
variation and is a measure of the degree of fit. The regression coefficient values were 
used to determine whether the mathematical models can be considered good and it is 
suggested that for a good model fit R2 should be at least 80%.  
In this present work, the R2 values for both the drugs were found to be above 
80%  and % CV below 20% as indicated in Table 16a and Table 16b.Therefore it was 
clearly analyzed that quadratic model for both the Atorvastatin calcium and 
Glibenclamide were found to be a good mathematical model. 
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Table 15a : Analysis of Variance in the regression models for Atorvastatin 
calcium 
Source  DF 
Sum of 
Squares 
Mean 
Square 
F 
Value 
p-Value 
 
 
 
Y1(Globule 
Size in nm) 
Model 5 83517.68 16703.54 6.94 0.0122* Significant 
A-Oil 1 2049.80 2049.80 0.85 0.3867  
B-Smix 1 7877.13 7877.13 3.27 0.1133  
AB 1 33033.06 33033.06 13.73 0.0076** Significant 
A2 1 15552.15 15552.15 6.46 0.0385* Significant 
B2 1 9741.60 9741.60 4.05 0.0841  
Residual 7 16841.75 2405.96    
Lack of Fit 3 16187.12 5395.71 32.97 0.0028** Significant 
Pure Error 4 654.63 163.66    
Cor Total 12 1.004E+005     
 
Y2 (Drug 
Loading in 
%) 
Model 5 382.82 76.56 18.59 0.0006** Significant 
A-Oil 1 183.71 183.71 44.60 0.0003** Significant 
B-Smix 1 74.91 74.91 18.19 0.0037** Significant 
AB 1 43.56 43.560 10.58 0.0140* Significant 
A2 1 5.02 5.02 1.22 0.3031  
B2 1 79.10 79.10 19.20 0.0032** Significant 
Residual 7 28.83 4.12    
Lack of Fit 3 17.04 5.68 1.93  0.2669 Insignificant 
Pure Error 4 11.79 2.95    
Cor Total 12 411.65     
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Table 16a : Correlation Coefficients for Two Responses for Atorvastatin calcium 
Quadratic 
model 
R2 
Adjusted 
R2 
Predicted 
R2 
Adequate 
precision 
SD %CV 
Y1 0.8322 0.7123 -0.5672 7.629 49.05 24.88 
Y2 0.9300 0.8799 0.5375 16.864 2.03 2.41 
 
 
Table 17a : Factor coefficients and their corresponding p-values for Atorvastatin 
calcium 
Factors 
Y1 Y2 
Regression 
Coefficient 
Probability 
value (p-value) 
Regression 
Coefficient 
Probability value 
(p-value) 
Intercept 135.117  86.0862  
X1 18.4833 0.3867 5.53333 0.0003** 
X2 -36.2333 0.1133 3.53333 0.0037** 
X1.X2 90.875 0.0076** -3.3 0.0140* 
X12 75.0397 0.0385* 1.34828 0.3061 
X22 59.3897 0.0841 -5.35172 0.0032** 
Significant model terms at: ** p<0.01, * p<0.05. 
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Table 15b : Analysis of Variance in the regression models for Glibenclamide 
Source  DF 
Sum of 
Squares 
Mean 
Square 
F 
Value 
p-Value 
 
 
 
Y1(Globule 
Size in nm) 
Model 5 1.481E+005 29620.87 5.46 0.0230* Significant 
A-Oil 1 6793.93 6793.93 1.25 0.2999  
B-Smix 1 3640.81 3640.81 0.67 0.4395  
AB 1 1260.25 1260.25 0.23 0.6444  
A2 1 1.363E+005 1.363E+005 25.14 0.0015** Significant 
B2 1 22570.73 22570.73 4.16 0.0807  
Residual 7 37946.56 5420.94    
Lack of 
Fit 
3 37671.55 12557.18 182.64 
<0.0001 Significant 
Pure 
Error 
4 275.01 68.75    
Cor Total 12 1.861E+005     
 
Y2 (Drug 
Loading in 
%) 
Model 5 109.20 21.84 5.39 0.0238 Significant 
A-Oil 1 54.60 54.60 13.46 0.0080** Significant 
B-Smix 1 10.93 10.93 2.70 0.1446  
AB 1 3.61 3.61 0.89 0.3769  
A2 1 17.29 17.29 4.26 0.0778  
B2 1 8.00 8.00 1.97 0.2030  
Residual 7 28.39 4.06    
Lack of 
Fit 
3 17.11 5.70 2.02 0.2533 Insignificant 
Pure 
Error 
4 11.28 2.82 
   
Cor Total 12 137.9     
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Table 16b : Correlation coefficients for two responses for Glibenclamide 
Quadratic 
model 
R2 
Adjusted 
R2 
Predicted 
R2 
Adequate 
precision 
SD %CV 
Y1 0.7960 0.6504 -0.9761 7.414 73.63 20.45 
Y2 0.7937 0.6463 -0.3551 7.335 2.01 2.28 
 
Table 17b : Factor coefficients and their corresponding p-values for 
Glibenclamide 
Factors 
Y1 Y2 
Regression 
Coefficient 
p Value 
Regression 
Coefficient 
Probability value 
(p value) 
Intercept 420.9  90.1862  
X1 33.65 0.2999 -3.01667 0.0080** 
X2 -24.6333 0.4395 1.35 0.1446 
X1.X2 -17.75 0.6444 0.95 0.3769 
X12 -222.15 0.0015** -2.50172 0.0778 
X22 90.4 0.0807 -1.70172 0.2030 
Significant model terms at: ** p<0.01, * p<0.05. 
6.5 ANALYSIS OF VARIANCE FOR PARTICLE SIZE (Y1) AND % DRUG 
LOAD (Y2)  
Atorvastatin calcium SEDDS  
The observed values of particle size for 13 formulations as shown in Table 14a 
varied from 106.8 nm to 415 nm and % drug load varied from 70.1% to 91.5% for 
Atorvastatin calcium. Two-way analysis of variance (ANOVA) can be applied to 
determine statistical significance of each model coefficient and least significant 
difference as post hoc test was performed. 
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Effect of formulation variables on particle size (Y1) 
The polynomial equation derived for particle size for Atorvastatin calcium is 
given by 
Y1 =135.12+18.48*X1-36.23*X2 +90.88*X1X2 + 75.04*X12 +59.39 *X22-Equation 1. 
with R2= 0.8322, adjusted R2= 0.7123 and % CV= 24.88. 
For the particle size, the model F value of 6.94 with a low probability value of 
(p value<0.05) implies a high significance for the full regression model which is 
shown in Table 15a. R2 values of full models are 0.8322 indicating the excellent 
correlation between the independent variables in the models. The adjusted R2 value 
was 0.7123 for the full model indicating a better model as illustrated in Table 16a. An 
increase in % CV shows moderate precision and reliability of the conducted 
experiments. The large SSR and  small  SSr values  tend  to  occur  for  models  that  
accurately describe the experimental data as shown in Table 15a. A significant 
(p=0.0076) synergistic interaction between oil and Smix was observed which as 
illustrated in Table 15a and equation 1. The quadratic regression coefficient of A2 was 
statistically significant. The quadratic effect of oil showed significant synergistic 
effect (p=0.0385) influence on particle size of Atorvastatin calcium SEDDS. The % 
CV was found to be 24.88 which were considered to be a high value for the response 
Y1 variable of particle size. It was concluded that the interaction between Smix and 
oil increases the particle size and hence both the factors are highly significant.  
Effect of formulation variables on % drug load (Y2) 
The second order polynomial equation derived for % drug load of Atorvastatin 
calcium is given by 
Y2= 86.09+5.53*X1+3.53*X2-3.30X1X2+1.35* X12-5.35* X22- Equation 2  
with R2= 0.9300, adjusted R2= 0.8799 and % CV= 2.41. 
The model coefficients estimated by quadratic model are shown in Table 17a. 
In the regression model for % drug loading the model F values are 18.59 implying 
that the model is highly significant with the p-value of 0.0006 as shown in Table 15a. 
The  R2 value (0.9300) and adjusted R2 (0.8799) was found to be more than 80 % 
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indicating a good correlation with the independent variable was well correlated with 
the response variable as shown in Table 16a. A significant antagonistic (p=0.0140) 
interaction between oil and Smix was observed which was illustrated in Table 15a and 
equation 2. The lower interaction between oil and Smix showed the higher drug 
loading. The quadratic effect of B2 was statistically significant. The quadratic effect of 
Smix showed significant effect antagonistic (p=0.0385) influence on drug loading of 
Atorvastatin  calcium SEDDS was  shown in  Table  17a.  The  % CV was  found to  be  
2.41 below 10 % which was considered to be an excellent value for the response Y2 
variable of % drug load. It was concluded that the interaction between Smix and oil 
increases the particle size and hence both the factors are highly significant.  
Analysis of variance for particle size (Y1) and % drug load (Y2)  
Glibenclamide SEDDS 
Effect of formulation variables on particle size (Y1) 
The measured values of particle size for 13 formulations as given in Table 14b 
ranged from 169.7nm to 616.3 nm. 
The polynomial regression equation derived for particle size for 
Glibenclamide is  
Y1 = 420.90+33.65*X1-24.63*X2-17.75*X1X2-222.15*X12+90.40*X22 - Equation 3.  
For  the  particle  size,  the  model  F  value  of  5.46  with  a  low  probability  value  of  (p  
value=0.0230) implies a high significance for the full regression model which is 
shown in Table 15b. R2 values of a full model were 0.7960 indicating good 
correlation between the independent variables in the models. The adjusted R2 value 
was 0.6504 for the full model as illustrated in Table 16b. An increase in % CV of 
20.45% showed moderate precision and reliability of the conducted experiments. The 
large SSR and small  SSr values tend to occur for models that accurately describe the 
experimental data as shown in Table 15b. The quadratic regression coefficient of A2 
was statistically significant. The quadratic effect of oil showed significant effect 
antagonistic (p=0.0015) influence on particle size of Glibenclamide SEDDS as 
indicated in Table 15b. The % CV was found to be 20.45 which were considered to be 
a high value for the response Y1 variable of particle size.  
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Effect of formulation variables on % drug load (Y2) 
The observed values of % drug load for 13 formulations as given in Table 14b 
ranged from 82% to 92.3%. The equations derived for % drug load for glibenclamide 
is 
Y2= 90.19+3.02* X1+1.35*X2+0.95* X1X2-2.5* X12-1.7 X22- Equation 4. 
The values of the coefficient X1, X2 were substituted in the equation to obtain 
the theoretical values of Y.  
The model coefficients estimated by quadratic model are shown in Table 17b. 
In the regression model for % drug loading the model F values are 5.39 implying that 
the model is significant with the p-value of 0.0238 as shown in Table 15b. The R2 
value (0.7937) was found to be more than 80 % indicating a good correlation with the 
independent variable was well correlated with the response variable as shown in Table 
16b. There was no significant or quadratic effects of the formulation variables 
observed as shown in Table 17b. The % CV was found to be 2.28 below 10 % which 
was considered to be an excellent value for the response Y2 variable of % drug load.  
The above equations 1 and 3 indicate as the factor X2 increases the response 
Y1 decreases and is indicated by negative coefficient value of dependant variable in 
which the Smix concentration is increased the particle size is decreased. The possible 
explanation is that when the lower concentration of oil and higher concentration of 
Smix added to facilitate the increase in water penetration and the mixture becomes 
hydrophilic causing decrease in particle size. The positive coefficient for independent 
value  X1 indicates the positive effect on dependent variable Y1 that increase in 
concentration of oil increases the particle size from above equations 1 and 3. In 
equations 2 and 4, the positive coefficient for independent value X1 indicates the 
positive effect on dependent variable Y2 that increase in concentration of oil increases 
the % drug load.  
6.5.1 Linear regression and residual plot analysis 
The residual analysis is one method to check model adequacy. After model 
fitting was performed residual analysis was conducted to validate the assumptions 
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used in ANOVA. The residual analysis includes case statistics to identify examine 
diagnostic plots such as normal probability of studentized residuals, a distribution plot 
of studentized residuals against the predicted values, an outlier T plot and a Box cox 
plot. For the normal probability plots of the studentized residuals, the number of 
standard deviations of the actual values from their respective predictive values, a 
straight line is created indicating no abnormalities or significant deviation from the 
linearity. The normal probability plot of the residuals depicted in Fig.8a, Fig. 8c for 
Atorvastatin calcium and Fig. 9a, Fig.9c for Glibenclamide revealed that the 
systematic deviations from the expectations. In residuals plot where the residuals are 
plotted against the normal values of the model depicted that the points are nearby to a 
diagonal line which implied that the errors are normally dispersed and are individually 
independently depicting a homogenous error variances indicating a well fitted model. 
Residuals from the fitted model are normally distributed therefore all the major 
assumptions of the model have been validated. The plots are shown in Fig. 8b, Fig. 8d 
for Atorvastatin calcium and in Fig.9b, Fig.9d for Glibenclamide depicted an 
agreeable correlation between the predicted and actual values of responses. In this 
study, the normality is satisfactory as all residual plots are distributed along a straight 
line. It is inferred that the confidences for the fitness of the regression equations to the 
observed values are more than 95% for all responses. 
6.5.2  Contour plots and response surface analysis 
A polynomial model describing relationship between response and factors of a 
response surface is known as response surface analysis. A model is graphically 
visualized by drawing 2D contour plots or 3D response plots. The 2D contour plots 
show the isoresponse lines as a function of two factors. The 3D response represents 
the response in 3D dimension. Contour plots and surface response plots are 
diagrammatic  representation  of  the  values  of  the  response.  These  plots  are  useful  to  
project the magnitude of effects for each variable and interactions. It can also explain 
the relationship between independent variables and dependent responses. Response 
surface methodology provides a mathematical trend that can find optimum level of 
experimental factors required for a given response. The two dimensional contour plot 
and the three-dimensional response surface plots are graphical representations of the 
regression equation and express two independent variables at once against the for Y1 
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and Y2 responses (Fig. 10a, Fig.10b, Fig.10c and Fig.10d for Atorvastatin calcium and 
Fig.11a, Fig.11b, Fig.11c and Fig.11d for Glibenclamide) which are useful to study 
the effect of the factors on the responses. With the increasing surfactant (coefficient is 
negative) in the formulation, droplet size is decreased. In Table 17a for Atorvastatin 
calcium, it can be seen that all independent variables showed significant main effects 
interaction effects and the quadratic effect of X1 (p < 0.05) for % drug load; the most 
prominent effect being the amount of oil (X1) added (p =0.0003). For particle size, the 
interaction effect was found to be X1X2 being the amount of oil and Smix added (p = 
0.0076) and the quadratic effect of X1 was found to be significant (p=0.0385). In 
Table 17b the independent variable X1 was found to be significant (p=0.0080) and the 
X2 was found to have the p-value of 0.1446 for Glibenclamide. From Fig 10b, Fig 11b 
it was clearly observed when the level of Smix concentration was increased from low 
to high the response Y1 (particle size) was decreased. From Fig.10d, Fig. 11d it was 
illustrated that when the level of oil concentration was increased from low to high the 
response Y1 (% drug load) was increased. The contour plot of Atorvastatin calcium 
showed that the denser central optimum area with good average  particle size between 
150-200nm as shown in Fig.10a.The contour plot Y2 of % drug loading  showed 
denser region between 85% and 90% as illustrated in Fig.10c. Both the responses Y1 
and  Y2 are thus analyzed by the diagrammatic contour plots. The contour plot of 
Glibenclamide showed the denser region of particle size below 200nm as illustrated in 
Fig. 11a. The contour plot Y2 of % drug loading showed denser region between 80% 
and 90% as illustrated in Fig.11c. 
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Fig. 8a Normal Residual plot Y1 of Atorvastatin calcium 
                        
 
 
 
Fig. 8b Linear correlation plot of Y1 of Atorvastatin calcium 
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Fig. 8c Normal Residual plot Y2 of Atorvastatin calcium 
 
 
 
 
Fig. 8d Linear correlation plot Y2 of Atorvastatin calcium 
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Fig. 9a Normal Residual plot Y1 of Glibenclamide 
 
 
 
Fig. 9b Linear correlation plot Y1 of Glibenclamide 
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Fig. 9c Normal Residual plot Y2 of Glibenclamide 
 
 
 
Fig. 9d Linear correlation plot Y2 of Glibenclamide 
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Fig 10a Contour plot Y1 of Atorvastatin calcium 
 
 
Fig 10b Response surface plot Y1 of Atorvastatin calcium 
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Fig 10c Contour plot Y2 of Atorvastatin calcium 
 
 
Fig. 10d Response surface Y2 of Atorvastatin calcium 
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Fig. 11a Contour plot Y1 of Glibenclamide 
 
 
Fig. 11b Response surface plot Y1 of Glibenclamide 
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Fig. 11c Contour plot Y2 of Glibenclamide 
 
                                          
 
Fig 11d Response surface plot Y2 of Glibenclamide 
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6.5.3 Optimization by using Desirability Function 
The two responses were optimized by using the desirability function approach 
(multiple response optimization techniques) introduced by Derringer and Suich160. 
Each response is associated with its partial desirability function (di) scaled from 0 
(furthest  from  the  target  value)  to  1  (closest  to  the  assigned  target)  and  a  utility  
function was computed to provide the overall or global desirability. For the response 
to be maximized the desirability functions can be defined as di = (Yi-Ymin) / (Ymax-
Ymin) where di is individual desirability of the response to be maximized where Yi is 
the experimental result and Ymin and Ymax represent the minimum and maximum 
possible value. If Yi is equal to or less than Ymin, then, di=0, if Yi is higher or equal 
to Ymax, di=1. For the response to be minimized, the desirability function is defined 
as di= (Ymax-Yi) / (Ymax-Ymin). If Yi is higher than or greater than Ymax then di=0 
and if  Yi is less than or below minimum then di=1. Here lower and upper limits for 
the responses were set from the highest and lower limits of the observed responses. 
After obtaining the individual desirability value for each response, the results were 
combined together usually together to give overall desirable function (D) as the 
geometric mean which is given by the following equation 
D = (d1.d2.d3.d4….dn)1/n 
The  optimum  formulation  was  selected  based  on  the  criteria  of  attaining  the  
constraints of variables responses. The total desirability is defined as a geometric 
mean of the individual desirability for particle size (PS) and drug loading (DL). It can 
be calculated by the formula 
D = (dPS × dDL) 1/2. 
where D is the total desirability, dPS and dDL are individual desirabilities for PS and 
DL. If both the quality characteristics reach their ideal values, the individual 
desirability is 1 for both. Consequently, the total desirability is also 1. The 
independent variables were simultaneously optimized for all the responses by using 
the desirability function.  
The optimization criteria included minimum particle size and maximum drug 
loading in the range. The global desirability value was calculated by combining all the 
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individual desirability functions as the geometric mean by using extensive grid and 
feasibility search over the domain. The suggested optimized formulation for 
Atorvastatin calcium consisted of 67.586% oil, 52.529% Smix with the corresponding 
desirability (D) value of 0.856 and the predicted response as Y1=153.651nm, Y2= 
88.582. Further the suggested optimized formulation for Glibenclamide consisted of 
15.046% oil, 41.047% Smix with the corresponding desirability value of 0.921with 
the predicted response Y1= 169.678nm, Y2=90.743. The desirability function plots are 
illustrated in Figures 13a and 13b for Atorvastatin calcium and Glibenclamide. 
Four batches of the optimized formulations were prepared to validate the 
model adequacy for the prediction, and all the responses were evaluated for each 
formulation as indicated in Table 18. It can be concluded that the experimental values 
were in close agreement with predicted values, indicating the success of the design to 
evaluate and optimize the SEDDS formulation.  
Table 18 : Predicted and measured values of responses and corresponding 
biasness 
Atorvastatin calcium responses Glibenclamide responses 
FC Particle size (nm) FC Particle size (nm) 
 
Predicted 
value 
Measured 
value 
Biasness 
% 
 
Predicted 
value 
Measured 
value 
Biasness 
% 
AF4 153.650 169.2±3.23 10.12 GF1 169.699 173±2.29 1.94 
AF5 153.646 169.4±1.97 10.25 GF2 169.695 172.5±1.56 1.65 
AF11 153.649 168.9±4.23 9.93 GF7 169.699 172.1±2.04 1.36 
AF13 153.636 169.8±1.36 10.52 GF12 169.685 173±2.70 1.95 
OPFA 153.651 169.7±3.2 10.45 OPFG 169.678 172±1.12 1.36 
% drug loading  % drug loading  
AF4 88.572 87.2±1.23 1.55 GF1 90.743 89.1±2.1 1.81 
AF5 88.571 87±2.18 1.77 GF2 90.738 89±2.01 1.92 
AF11 88.584 86.9±3.24 1.90 GF7 90.687 88.9±1.98 1.97 
AF13 88.586 87.1±2.27 1.68 GF12 90.607 89.2±1.97 1.55 
OPFA 88.582 87.2±2.25 1.57 OPFG 90.743 89.3±2.23 1.59 
Biasness %= (predicted value-measured value) ×100/predicted value. 
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The canonical analysis in the Design Expert software is a mathematical tool 
for simplifying a second-order polynomial model and simultaneously observing the 
extreme values of several response surface models. Overlaid contour plots of SEDDS 
were constructed by two independent variables. The overlaid plots for two response 
values are illustrated in Fig 12a and Fig 12b for Atorvastatin calcium and 
Glibenclamide. According to the criteria in present study higher drug loading and 
lower particle size of the optimized formulation of Atorvastatin SEDDS containing oil 
and Smix were selected at 67.5761% and 52.5328 %. The particle size and % drug 
loading of the optimized formulation for Atorvastatin calcium were predicted to be 
153.597nm and 88.5782 % as illustrated in Fig.12a. The particle size and % drug 
loading of the optimized formulation for Glibenclamide containing oil and Smix were 
selected at 15.0457% and 41.0467% respectively. The particle size and % drug 
loading of the optimized formulation for Glibenclamide were predicted to be 
169.678nm and 90.7431 % as illustrated in Fig.12b.   
 
 
Fig 12a Overlay plot for Atorvastatin calcium SEDDS 
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Fig. 12b Overlay plot for Glibenclamide SEDDS 
 
 
 
Fig.13a : Desirability plot of Atorvastatin calcium SEDDS optimized formulation 
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Fig.13b. Desirability plot of Glibenclamide SEDDS optimized formulation OPFG 
 
6.6 Self-emulsification, drug precipitation and phase separation studies 
For all the SEDDS formulations the visual observation of self-emulsification 
study was recorded and evaluated on visibility grades142 as explained in section 
5.12.1. The results of graded formulations were shown in 19a and Table 19b.  
In this study, formulations AF4, AF5, AF11, AF13, OPFA (optimized 
formulations) for Atorvastatin calcium, GF1, GF2, GF7, GF12, OPFG (optimized 
formulations) for Glibenclamide good stability without any signs drug/excipient 
precipitation or phase separation were found and the results are shown in Table 19a 
and Table 19b. 
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Table 19a : Self -emulsification and drug precipitation of Atorvastatin calcium 
SEDDS 
Formulation Code Visibility grade Phase separation Precipitation 
AF1 IV + ++ 
AF2 III + ++ 
AF3 IV + ++ 
AF4* I X XX 
AF5* II X XX 
AF6 III + ++ 
AF7 IV X ++ 
AF8 V + ++ 
AF9 III + ++ 
AF10 IV + ++ 
AF11* I X XX 
AF12 III + ++ 
AF13* II X XX 
OPFA I X XX 
X  --  No  phase  separation,  XX  --  No  precipitation,  +  --  phase  separation  and   
++ -- precipitation. 
 
Table 19b : Self- emulsification and drug precipitation of Glibenclamide SEDDS 
Formulation Code (FC) Visibility grade Phase separation Precipitation 
GF1* I X XX 
GF2* II X XX 
GF3 IV + ++ 
GG4 V + ++ 
GF5 II X XX 
GF6 III + ++ 
GF7* I X XX 
GF8 V + ++ 
GF9 III + ++ 
GF10 III + ++ 
GF11 IV + ++ 
GF12* I X XX 
GF13 III + ++ 
OPFG I X XX 
X  --  No  phase  separation,  XX  --  No  precipitation,  +  --  phase  separation  and   
++ -- precipitation. 
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6.7  ASSESSMENT OF EMULSIFICATION TIME STUDIES 
The ease of emulsification was suggested to be related to the ease of water 
penetration into the colloidal or gel phases formed on the surface of the droplet. The 
emulsification time studies as shown in Table 20a and Table 20b indicated the 
spontaneous emulsification for all formulations. 
 
Table 20a : Refractive index, Turbidity, Optical clarity, Polydispersity index, 
Viscosity, Cloud point measurement and Emulsification time of SEDDS 
formulations of Atorvastatin calcium 
FC 
Refractive 
Index  
± SD (n=3) 
 
Turbidity 
(NTU) 
Absorbance 
Polydispersity 
index 
±SD (n=3) 
 
Viscosity 
(cps) 
±SD(n=3) 
 
Cloud point  
measurement 
(°C)  
± SD(n=3) 
Emulsification                
time (sec) 
AF1 1.3343±0.0006 132 0.402 0.171±0.01 253±2.65 78±3.46 132 
AF2 1.3352±0.0003 146 0.487 0.244±0.005 262±2.66 73±3.61 119 
AF3 1.3366±0.0005 210 0.529 1.097±0.2 264±1.73 75±5.57 121 
AF4* 1.3331±0.0002 90 0.455 0.381±0.03 280±2.31 77±3.46 138 
AF5* 1.3334±0.0002 94 0.432 0.377±0.06 291±3.51 74±3.46 126 
AF6 1.3345±0.0003 168 0.517 0.148±0.012 272±4.58 78±5.20 112 
AF7 1.3363±0.0006 320 0.456 0.379±0.06 269±2.89 75±3.61 95 
AF8 1.3358±0.0004 357 0.493 0.292±0.03 254±2.66 75±4.36 82 
AF9 1.3349±0.0004 92 0.501 0.128±0.04 249±2.08 79±4.58 75 
AF10 1.3347±0.0006 96 0.497 0.386±0.04 263±0.56 77±5.20 62 
AF11* 1.3330±0.0003 91 0.466 0.343±0.065 259±1.53 75±3.61 64 
AF12 1.3352±0.0002 93 0.629 0.224±0.005 266±4.04 76±2.65 67 
AF13* 1.3333±0.0002 95 0.452 0.333±0.005 260±3.56 75±1.73 69 
OPFA 1.3330±0.0002 92 0.425 0.2±0.013 258±2.23 72±1.28 61 
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Table 20b : Refractive index, Turbidity, Optical clarity, Polydispersity index 
(PDI), Viscosity, Cloud point measurement and Emulsification time of SEDDS 
formulations of Glibenclamide 
 
FC 
Refractive 
Index 
± SD (n=3) 
Turbidity 
(NTU) 
Absorbance 
PDI 
±SD (n=3) 
Viscosity 
(cps) 
±SD(n=3) 
Cloud point 
measurement 
(°C) 
±SD (n=3) 
Emulsification                
time(sec) 
GF1* 1.3333±0.0006 98 0.583 0.204±0.017 211±2.22 68±2.16 23 
GF2* 1.3332±0.0003 93 0.578 0.315±0.21 215±2.36 69±3.61 32 
GF3 1.3356±0.0005 127 0.598 0.2±0.01 324±3.24 72±2.23 24 
GF4 1.3331±0.0002 134 0.488 0.284±0.01 356±1.72 77±2.46 25 
GF5 1.3334±0.0002 142 0.571 0.438±0.01 318±2.34 71±2.76 27 
GF6 1.3335±0.0003 132 0.472 0.224±0.02 365±3.24 79±4.20 20 
GF7* 1.3333±0.0006 95 0.614 0.282±0.018 232±2.45 65±2.51 28 
GF8 1.3358±0.0004 125 0.687 0.423±0.06 348±1.89 73±2.36 30 
GF9 1.3349±0.0004 132 0.708 0.328±0.015 298±2.97 78±4.28 22 
GF10 1.3347±0.0006 133 0.419 0.418±0.06 288±3.68 76±4.29 24 
GF11 1.3330±0.0003 128 0.448 0.327±0.02 272±2.65 76±2.61 26 
GF12* 1.3352±0.0002 93 0.523 0.217±0.03 223±1.98 66±2.65 25 
GF13 1.3333±0.0002 124 0.506 0.324±0.02 294±2.54 76±2.73 24 
OPFG 1.3330±0.0002 92 0.494 0.244±0.04 200±1.95 62±2.25 21 
 
6.8 SPECTROSCOPIC CHARACTERIZATION OF OPTICAL CLARITY 
As shown in Table 20a and Table 20b the absorbance of the studied aqueous 
dispersion of Atorvastatin calcium SEDDS ranged between 0.402 to 0.529 and 0.419 
to 0.708 for Glibenclamide which indicates that optically clear and oil droplets 
formed are to be in a state of finer dispersion. 
6.9 TURBIDITY MEASUREMENT 
The turbidity of SEDDS was performed determined as per procedure and 
turbidity for all optimized formulations were found to below 100NTU which shows 
the stability of SEDDS and the results were shown in Table 20a and Table 20b. 
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6.10  VISCOSITY DETERMINATION 
From viscosity determination, it was observed that as the concentration of oil 
increased, viscosity of formulations decreased as shown in Table 20a and Table 20b. 
Overall, the viscosity of the undiluted liquid SNEDDS was found less than 10,000 cps 
which imply that the developed SEDDS can be filled in soft gelatin capsules.   
6.11  CLOUD POINT MEASUREMENT 
For all the formulations the cloud point was found to be below 80°C and the 
results were shown in Table 20a and Table 20b. From the above result, it can be 
concluded that a stable micro emulsion of SEDDS can be formed at physiological 
temperature in- vivo. 
6.12  DETERMINATION OF REFRACTIVE INDEX (RI) 
The RI of the prepared formulations was determined using Abbe 
refractometer. It is indicated from the results that the isotropic nature of the 
formulations was found to be in range of 1.3330±0.0002 to 1.3366 ± 0.0005 for 
Atorvastatin calcium and 1.3330±0.0002 to 1.3358±0.0004 for Glibenclamide as 
shown in Table 20a and Table 20b. It can be seen from the Table 20a and Table 20b 
the refractive index of the majority of the prepared formulations have similar values 
as that of distilled water (1.3330±0.0002 n.d.) at 28 ± 0.5°C were found to be clear as 
water141. The closure of the formulations RI value to water indicated the transparency 
property of the formulations. The results indicated that RI values increased with 
increase in concentration of oil and corresponding decrease in aqueous content. AF3 
exhibited the highest RI value of 1.3366 ± 0.0005 for Atorvastatin calcium in which 
the oil concentration was 80% as indicated in Table 20a. The Glibenclamide SEDDS 
formulations of GF3, GF8 exhibited a higher RI value of 1.3356±0.0005 and 
1.3358±0.0004 since their oil concentration was more than 20% as indicated in Table 
20b.  
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6.13  DROPLET SIZE, ZETA POTENTIAL AND POLYDISPERSITY 
INDEX (PDI) ANALYSIS 
The PDI for all the formulations were less than 0.5 (AF3-1.097) and the 
formulations with Smix showed lower PDI values thus indicating the uniform size 
distribution. The results of PDI were shown in Table 20a and Table 20b. After drug 
addition there was no significant difference in PDI values indicating no interference 
of the drug with the performance of the spontaneous emulsification.  
Among the formulations the optimized Atorvastatin calcium SEDDS (OPFA) 
was found to have a mean globule size of 169.7nm with a PDI 0.2, and zeta potential -
31.8mV as shown in Fig. 14a and Fig. 14b.The selected optimized formulation of 
Glibenclamide  SEDDS  (OPFG)  was  found  to  have  a  mean  globule  size  of  172nm  
with a PDI 0.244, and zeta potential -24.8mV as shown in Fig 15a and Fig 15b.The 
higher (above +30 or −30 mV) Zeta potential of optimized SEDDS indicates that 
microemulsion was stable. 
 
Fig. 14a Particle size of optimized formulation OPFA for Atorvastatin calcium 
SEDDS 
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Fig. 14b Zeta potential of optimized formulation OPFA for Atorvastatin calcium 
SEDDS 
 
 
Fig. 15a Particle size of optimized formulation OPFG for Glibenclamide SEDDS 
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Fig. 15b Zeta potential of optimized formulation OPFG for Glibenclamide 
SEDDS 
6.14  DRUG LOADING 
The Atorvastatin and Glibenclamide SEDDS formulations were subjected to 
drug loading studies. The drug content was carried out by UV-visible 
spectrophotometer (Shimadzu UV-1700) and the drug loading was performed as per 
procedure described in section 5.12.11. A linear calibration curve was obtained at 247 
nm for Atorvastatin calcium and 226.5 nm for Glibenclamide in the range of (2-20 
µg/m1)  with  a  correlation  coefficient  (r2) of 0.999.The drug content of Atorvastatin 
calcium was calculated from the Beers Lambert’s law equation Y = 
0.045.concentration + 0.003 (r2 = 0.999; p < 0.001)] and Y= 0.118.concentration+ 
0.002 (r2 = 0.999; p < 0.001) for Glibenclamide. The % drug loading for optimized 
formulation of Atorvastatin calcium (OPFA) and Glibenclamide (OPFG) was found to 
be 87.2% ± 2.25 and 89.3% ± 2.23 respectively. It was clearly inferred increase in 
Smix concentration enhances maximum drug load in SEDDS.  
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6.14 IN VITRO DISSOLUTION STUDIES 
The in vitro drug release studies were performed as per procedure described 
under 5.12.12 for Atorvastatin calcium SEDDS and 5.12.13 for Glibenclamide 
SEDDS. The in vitro dissolution profile of Atorvastatin calcium optimized 
formulations OPFA, AF4, AF5, AF11 and AF13 carried out by USP II dissolution 
apparatus in phosphate buffer pH 6.8 and Glibenclamide optimized formulations 
OPFG, GF1, GF2, GF7 and GF12 in phosphate buffer pH 7.4 was significantly higher 
than with API and marketed tablet (Storvas 10 mg for Atorvastatin calcium and 
Daonil 5mg for Glibenclamide) as shown in the Table 21a and Table 21b and Fig.16a 
and Fig. 16b. It could be suggested that spontaneous micro-emulsification resulted in 
the faster rate of drug release into the aqueous phase in the form of small and mono 
dispersed droplets139. The drug content was calculated from the Beers Lambert’s law 
equation of Y =0.012.concentration+0.001 (r2 = 0.999; P < 0.001) for Atorvastatin 
calcium and Y= 0.018.concentration + 0.001 (r2 = 0.999; P < 0.001) for 
Glibenclamide. 
Table 21a : Cumulative percent release of Atorvastatin calcium from various 
formulations 
Time 
in 
min 
AF1* AF5* AF11* AF13* 
OPFA 
SEDDS 
API 
Marketed 
Tablet 
0 0 0 0 0 0 0 0 
5 29.56±0.69 28.89±0.88 27.45±0.59 25.56±1.25 26.21±0.74 38.69±1.24 33.21±2.03 
10 34.58±2.08 38.56±0.63 33.46±1.28 32.45±0.19 39.3±0.23 47.56±0.75 45.23±1.12 
20 52.56±1 55.33±2.02 56.59±0.56 57.53±0.73 58.36±0.45 65.22±1.12 60.33±2.21 
30 74.23±1.59 73.52±1.94 75.56±1.50 74.87±0.22 72.66±0.32 80.45±1.23 79.54±1.64 
40 76.89±1.38 76.26±0.55 77.62±1.20 78.66±0.16 79.5±0.18 86.23±1.56 85.62±0.54 
50 84.98±1.27 82.56±1.16 83.32±1.30 84.98±0.02 86.72±0.16 89.21±2.73 86.74±2.21 
60 91.26±2.74 90.21±1.48 90.36±0.17 91.63±0.44 91.3±0.55 92.34±1.23 90.69±1.72 
75 92.27±1.78 92.24±2.55 92.48±0.56 93.56±1.22 94.5±0.49 93.86±0.62 92.66±1.54 
90 95.85±1.30 96.16±0.72 97.28±1.13 98.56±0.44 99.75±0.31 95.64±1.26 93.31±1.18 
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Fig 16a Dissolution comparison graph of API, marketed and optimized 
formulation of Atorvastatin calcium SEDDS 
 
 
Table  21b :  Cumulative  percent  release  of  Glibenclamide  SEDDS from various  
formulations 
Time 
in min 
GF1* GF2* GF7* GF12* 
OPFG 
SEDDS 
API 
Marketed 
Tablet 
0 0 0 0 0 0 0 0 
5 91.2 90.8 92.1 94.1 95±3.51 38.7±1.98 35.31±2.22 
10 92.4 93.4 94.3 95.3 96.8±1.97 55.9±2.24 52.4±3.71 
20 94.6 95.7 95.4 96.5 97.2±3.14 87.3±3.21 85.5±3.26 
30 95.2 96.1 97.8 97.3 99.7±2.74 93.8±2.67 92.3 ±3.47 
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Fig 16b Dissolution comparison graph of API, marketed formulation and   
optimized formulations of Glibenclamide SEDDS 
 
6.14.1 Kinetic modeling and Mechanism of drug release of optimized 
formulations 
The dissolution data of optimized formulations OPFA and OPFG showed first 
order release kinetics with higher correlation coefficient R2-0.9848 for Atorvastatin 
calcium and R2- 0.9978 for Glibenclamide are shown in Table 22 and illustrated in 
Fig. 17a and Fig 17b. In vitro release kinetics data were computed using DD solver 
and the resultant data were fitted to the Korsmeyer-Peppas exponential equation to 
establish the mechanism of drug release. The exponent, n has been proposed as 
indicative of the release mechanism. The ‘n’ values for OPFA and OPFG was found 
to be 0.406 and 0.024 which suggested that drug release follows Fickian diffusion 
controlled mechanism for Atorvastatin calcium and Quasi Fickian diffusion for 
Glibenclamide. 
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Table 22 : Release kinetic study of optimized formulations for Atorvastatin 
calcium and Glibenclamide 
FC 
Zero order 
kinetic R2 
First order 
kinetic R2 
Higuchi 
Kinetic R2 
Korsmeyer-Peppas 
R2 n value 
OPFA 0.9569 0.9848 0.9366 0.9701 0.406 
OPFG 0.9569 0.9978 0.9519 0.8821 0.024 
 
 
Fig.17a. Dissolution first order release kinetics of optimized formulation OPFA 
 
 
Fig.17b. Dissolution first order release kinetics of optimized formulation OPFG 
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6.15 IN VITRO DIFFUSION RELEASE STUDY 
Diffusion study was carried out to study the release behavior of formulation 
from liquid crystalline phase around the droplet using dialysis technique. In vitro 
diffusion profile of Atorvastatin calcium from optimized SEDDS in phosphate buffer 
(pH 6.8) is given in Table 23a. It was observed that at the end of 12 hour, formulation 
OPFA SEDDS showed about 99.24% diffusion due to its nano range globule size and 
presence of surfactant/co-surfactant. In contrast, the marketed tablet (Storvas 10mg) 
showed about 98.18 % diffusion of the drug in 12 hours due to low aqueous 
solubility. In  vitro diffusion profile of Glibenclamide from optimized SEDDS in 
phosphate buffer (pH 7.4) is given in Table 23b. It was observed that at the end of 
24h, formulation OPFG SEDDS showed about 99.8% and 96.23% for the marketed 
tablet (Daonil 5mg) at the end of 2 hours (Table data only for 2 hours). 
 
Table 23a : Percent cumulative drug absorbed through dialysis membrane of 
optimized Atorvastatin calcium SEDDS formulations 
Time 
in hours 
AF4* AF5* AF11* AF13* 
OPFA 
SEDDS 
Marketed 
Tablet 
0 0 0 0 0 0 0 
0.5 82.19±1.23 84.93±1.54 83.45±0.76 82.31±0.78 89.32±2.17 81.25±2.25 
1 92.19±0.78 93.42±2.78 92.64±1.23 91.89±0.98 92.22±0.91 90 ±1.14 
2 93.75±1.84 94.23±1.66 93.62±2.46 93.16±1.19 93.43±1.56 92±1.98 
4 94.94±2.21 94.45±2.56 94.89±0.78 94.23±2.56 95.36±2.45 94 ±2.54 
6 96.28±0.73 96.82±0.84 96.4±0.92 96.45±0.74 96.39±1.47 95 ±2.69 
8 97.67±0.94 97.14±2.41 97.54±1.47 97.67±1.64 98.56±0.95 96.9±1.85 
12 98.45±1.86 98.25±1.78 98.23±2.82 98.21±2.47 99.24±2.26 98.18±0.99 
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Table 23b : Percent cumulative drug absorbed through dialysis membrane of 
optimized Glibenclamide SEDDS formulations 
Time 
in hours 
GF4* GF5* GF11* GF13* 
OPFG 
SEDDS 
Marketed 
Tablet 
0 0 0 0 0 0 0 
0.5 97.3±2.73 96.4±2.57 95.3±1.96 96.5±0.64 97.2±0.95 82.92±1.97 
1 98.6±0.97 98.1±0.72 97.4±0.72 98.4±2.21 99.3±1.74 90.32±2.19 
2 99.2±1.43 99.5±0.87 98.6±1.65 99.6±1.93 99.8±2.12 96.23±1.41 
 
 
6.16 STABILITY STUDIES 
The optimized SEDDS of Atorvastatin calcium and Gibenclamide were loaded 
in soft gelatin capsules (Size 3).They were stored under cold condition (4-8°C) at 
refrigerator and room temperature (25°C)  were  subjected   to  stability  studies  to  
evaluate their  stability  and  the  integrity  of  the  dosage  form. The samples were 
also charged at elevated temperature of 50°C in stability chambers (Labtech India) 
with ambient humidity condition. It  was analyzed from the results that  there was no 
significant change in the % drug loading and particle size as given in Table 24a and 
Table 24b.  
The formulations were found to be stable at cold, room temperature and at 
elevated temperatures when the samples were analyzed for its particle size and % 
drug  loading  after  first  and  6  months.  It  was  also  seen  that  the  formulation  was  
compatible  with the   soft  gelatin  capsule  shells, as there was no sign of capsule she
ll deformation. Furthermorethe formulation was found to show no phase separation 
and drug precipitation. Thus, the  studies confirmed the stability of the developed 
formulation and  its compatibility with soft gelatin capsules.  
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Table 24a : Stability studies of optimized Atorvastatin calcium SEDDS 
formulations 
Temperature   (°C) 
Particle Size (nm) % drug load 
After 1 
Month 
After  6 
month 
After 1 
month 
After  6 
month 
Cold Temperature (2 -8°C) 173±2.23 176± 1.23 87.2±1.33 83.7±1.89 
Room Temperature (25±2°C) 169.7±1.85 171.7±0.86 88.9±2.24 86.2±2.65 
Elevated Temperature (50±2°C) 170±2.35 175.6±1.56 85.9±1.42 81.9±2.78 
Data expressed as mean ± SD, n=3  
 
 
 Table 24b : Stability studies of optimized Glibenclamide SEDDS formulations 
Temperature   (°C) 
Particle Size (nm) % drug load 
After 1 
Month 
After  6 
month 
After 1 
month 
After  6 
month 
Cold Temperature (2 -8°C) 174±2.23 178± 1.23 86.2±1.33 83.7±1.89 
Room Temperature (25±2°C) 172±1.85 174.7±0.86 89.3±2.23 85.9±2.65 
Elevated Temperature (50±2°C) 180±2.35 185.6±1.56 84.9±1.42 80.9±2.78 
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CHAPTER 7 
DISCUSSION 
7.1 SOLUBILITY STUDY 
Atorvastatin  calcium of  BCS Class  II  drug  is  a  cholesterol-lowering  agent  is  
widely used to treat hyperlipidaemias. The drug has poor water solubility in water and 
absolute bioavailability of only 14% which was proved by Lea et al 161 and Black et 
al162 due to its presystemic clearance in the gastrointestinal mucosa or hepatic first-
pass metabolism163.The partition coefficient (Log P) for the drug is 6.36. Since it’s a 
weak acid of pKa 4.46 the drug remains unionized in the pH of the stomach. 
Glibenclamide (GBD) of BCS Class II drug is a second generation sulfonylurea. It is 
orally used as a hypoglycemic agent to treat noninsulin-dependent (type II) diabetes 
mellitus164, 165. The aqueous solubility of GBD is low and highly pH-dependent in the 
physiological range because of its pKa value of 5.3. Low aqueous solubility gives rise 
to unsatisfactory dissolution profiles leading to potential problems of poor 
bioavailability and bioequivalence of the drug’s dosage form166, 167. However, the oral 
absorption of both the drugs is limited by its poor solubility and bioavailability. The 
Atorvastatin calcium and Glibenclamide SEDDS were developed by performing the 
preliminary solubility studies to examine the highest solubilizing capacity of the drug 
in an oil phase, surfactant and co surfactant. For achieving the maximum solubility of 
the drug different lipid classes of triglycerides with the long chain, medium chain and 
synthetic triglycerides of different HLB values were utilized. The solubility of a drug 
in oils, surfactants and co surfactants was identified for optimum loading of the drugs 
in SEDDS formulations.  
The Atorvastatin calcium was found to have maximum solubilizing capacity in 
sunflower oil which is a long chain triglyceride, capable of solubilizing the drug in a 
specific amount facilitate self-emulsification and increase the fraction of Atorvastatin 
calcium through the intestinal lymphatic system. In solubility studies, MCT's such as 
coconut oil are used since the modified and hydrolyzed vegetable oils168 show more 
solubility and appreciable self-emulsifying property. The solvent capacity for 
hydrophobic drugs can be improved by using sunflower oil which is a triglyceride. 
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Peceol a novel a semi synthetic medium chain derivative was chosen as oil phase for 
Glibenclamide since it was found to have maximum solubility when compared to the 
other oils and in which the solubility was found to be minimium in sunflower oil as 
indicated in results of Table 12. Peceol is an efficient solubilizer for Glibenclamide 
which was proven by Patil Prashant P et al169 in his research work. The labrasol which 
showed the highest solubilization capacity was selected as surfactant followed by 
capryol PGMC, labrafil 1944 CS and Labrafil 2125 for formulation of Atorvastatin 
calcium SEDDS as shown in Fig. 6a. A similar work has been published by Shafiq S 
et al25 using poorly water soluble drug in which the highest solubility of the drug was 
in labrasol among all surfactants. Capryol PGMC (Propylene glycol monocaprylate 
type I) of HLB 6 is a water insoluble surfactant which is included in SEDDS 
formulations along with a cosolvent170.  From  Fig.  6b  it  was  illustrated  that  labrasol  
was chosen as surfactant because it showed maximum solubility followed by labrafil 
1944 CS, capryol PGMC and labrafil 2125 for formulation of Glibenclamide SEDDS. 
The medium length alkyl chain surfactant labrasol was selected as a surfactant for 
both the drugs since it has maximum solubilizing capacity and it was represented for 
drugs having poor intestinal absorption171. Transcutol HP showed maximum solubility 
for Atorvastatin calcium and Glibenclamide and it was selected as the cosurfactant for 
the formulation of SEDDS as indicated in Table 12. 
The  cosolvents  such  as  ethanol  and  PEG  are  not  included  as  for  the  
development of SEDDS because they cause serious problems of evaporation from 
sealed gelatin capsules which results in the precipitation of drug inside the shell. The 
cosolvent transcutol HP is most preferred for the development of SEDDS since it is 
more stable and less volatile than ethanol when compared with other cosolvents172 and 
it was proved to be good solubilizer for poorly water soluble drugs. Transcutol HP is a 
strong solubilizer with low toxicity has a long history of safe use as a solvent in many 
products including pharmaceuticals, cosmetics and food applicationsb . The self-
emulsifying systems form fine oil/water emulsions with only gentle agitation, upon 
their introduction into aqueous media. The surfactant and co-surfactant get 
preferentially adsorbed at the interface, reducing the interfacial energy as well as 
providing a mechanical barrier to coalescence. The decrease in the free energy 
required for the emulsion formation consequently improves the thermodynamic 
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stability of the micro emulsion formulation23, 174.  Therefore,  the  selection  of  oil  and  
surfactant and the mixing ratio of oil to S/CoS, play an important role in the formation 
of the micro emulsion.  
7.2  CONSTRUCTION OF PHASE DIAGRAM 
In the present study, sunflower oil was tested for phase behavior studies with 
labrasol and transcutol HP for Atorvastatin calcium and peceol (oil) with labrasol and 
Transcutol HP as the S/CoS mixture. As observed from the ternary plot in Figures 7a 
and  7b,  sunflower  oil  gave  a  wider  micro  emulsion  region  at  3:1  Smix  ratio  for  
Atorvastatin calcium and Peceol at 1:1 of Smix ratio. However, it was observed that 
increasing the surfactant ratio resulted in a loss of flowability and increase in 
surfactant toxicity. When co-surfactant was incorporated along with the surfactant in 
equal proportion at Smix ratio of 1:1 (Fig. 7b) a higher nanoemulsion region was 
observed in Glibenclamide SEDDS. This may be due to the addition of co-surfactant 
leading to further decrease in the interfacial tension, which will lead to increase in the 
fluidity of the interfacial film, thus increasing the entropy175. The % of oil, surfactant 
and cosurfactant selected for both the drugs were selected from the phase diagram and 
only those formulations which use the minimum and maximum concentration of Smix 
were taken for the formulation of SEDDS. Moreover, the self-emulsification ability of 
SEDDS depends on the formulation parameter variables such as surfactant/ 
cosurfactant and oil ratio, a polarity of the emulsion, globule size and charge on the 
droplets. The stability and efficiency of the drug is increased by self-emulsification 
property.  
7.3  OPTIMIZATION OF SEDDS  
Based on the ternary phase diagram and self-emulsification studies, sunflower 
oil (X1),  Smix-  labrasol  and  transcutol  HP  (X2) were chosen as components for 
Atorvastatin calcium SEDDS and peceol (X1), Smix- labrasol and transcutol HP (X2) 
were chosen for Glibenclamide SEDDS. To perform the 32 factorial design it was 
essential to identify the concentration of self-emulsification region from ternary phase 
diagrams of the SEDDS containing oil, surfactant and cosurfactant.  The factorial 
design  was  carried  out  for  optimization  of  two  dependent  variables  such  as  globule  
size (Y1) and % drug loading (Y2) and concentrations of oil(X1), Smix(X2) were taken 
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as dependent variables. The experimental runs and the observed Y1, Y2 responses for 
13 formulations were reported in Table 14a and Table 14b as generated by using 
Design Expert software version 10.0.2.0. The values of Y1 and Y2 observed responses 
ranged from 106.8 nm to 415 nm and 70.1% to 91.5% for Atorvastatin calcium. The 
Y1 and Y2 values were between 169.7nm to 616.3nm and 82% to 92.3% respectively 
for Glibenclamide. The model selection was based on the comparisons of several 
statistical parameters including standard deviation (SD), R-squared values, % 
correlation variation (% CV) and Sum of Squares (SS). The details are mentioned in 
the Table 16a and Table 16b which suggested special quadratic model for analyzing 
Y1 and  Y2 responses, respectively. Adequate precision is a measure of the signal to 
noise ratio. A ratio greater than 4 is desirable. The ratio was found to be 7.629 and 
16.864 for Y1 and  Y2 responses, respectively for Atorvastatin calcium. For 
Glibenclamide the ratio was found to be 7.414 and 7.335 for Y1 and  Y2 responses 
which indicates adequate precision. The analysis of variance (ANOVA) was applied 
for estimation of significance of the model. The ANOVA responses were summarized 
in Table 15a and Table 15b. A model is considered to be significant if the if the p-
value (significance probability value) is less than 0.05 using 5% significance level.  
From the p-values presented in Table 15a and Table 15b it can be concluded that for 
responses Y1 and  Y2, quadratic model were significant. From Table 17a the 
interaction terms X1X2, X22 are significant terms for Atorvastatin calcium and both are 
significant model terms for globule size and % drug load. From Table 17b the main 
variable X1 is significant model term for globule size in Glibenclamide. The 
polynomial regression equations as discussed in the results and analysis section 
represent the quantitative effect of independent variables (X1 and  X2) and their 
interactions on the responses (Y1 and  Y2). A positive sign in interpretation of the 
regression equations for both the drugs represented a synergistic effect, while a 
negative sign indicated an antagonistic effect. The theoretical values of Y1 and  Y2 
were obtained by substituting the values of X1 and  X2 in the polynomial regression 
equation. The relationship between the dependent and independent variables for 
Atorvastatin calcium were further elucidated using 2D contour plots and 3D response 
curves which were represented by Figures 10a, 10b, 10c and 10d. Figures 11a, 11b, 
11c and 11d showing the 2D contour plots and 3D response curves represented the 
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effect of variables of X1, X2 on the responses of Y1 and Y2, respectively. From Figure 
10b of 3D response curve of Atorvastatin calcium it was clearly refined that when the 
concentration of Smix was increased from 30% to 70% the globule size was 
minimized. The same effect was observed in Figure 11b of Glibenclamide the particle 
size Y1 response was decreased when the Smix concentration was increased from 30% 
to 50%. From Figure 10d it was illustrated the % drug loading of Atorvastatin calcium 
was  increased  when the  level  of  oil  concentration  was  increased  from 40% to  80%.  
The % drug loading of Glibenclamide showed a significant effect when the 
concentration of oil was increased from 15% to 25% which is represented by Figure 
11d. After studying the effect of the independent variables on the responses, the levels 
of these variables that give the optimum response were determined. The optimum 
formulation gives a minimum droplet size and higher % drug loading  value along 
with  optimum  amount  of  oil  and  optimum  amount  of  surfactant  in  the  resultant  
SEDDS. Numerical optimization was achieved by Design expert software using 
desirability function which sets the minimum and maximum targets for the 
constraints. In the present study the experimental target was programmed with 
minimum globule size and maximum drug loading for the optimized SEDDS 
formulation  and  the  results  obtained  are  desirable.  The  selected  values  obtained  for  
Atorvastatin  calcium  during  the  optimization  process  of  X1,X2 were found to be 
67.586% of oil, 52.529% of Smix and the predicted response were Y1=153.651nm, 
Y2= 88.582 % respectively. The optimized formulation of Glibenclamide consisted of 
15.046 % of oil, 41.047 % of Smix with the predicted response of Y1= 169.678 nm, 
Y2=90.743 %. For confirmation a fresh formulation in triplicate was prepared at the 
optimum levels of the independent variables and the resultant SEDDS formulations 
were evaluated for the responses. The results of experimental value were in close 
agreement with predicted values for both the drugs as shown in Table 18 and the 
biasness were calculated which was found within the limits. The overlay plot of 
Atorvastatin calcium for two responses illustrated in Figure 12a showed the optimized 
concentration of oil (67.5761%) and Smix (52.5328% with the result of minimum 
particle size as 153.597 nm and 88.5782% as maximum drug loading for Atorvastatin 
calcium. The overlay plot of the predicted responses for Glibenclamide in Figure 12 b 
showed optimum concentrations 15.046% of oil, 41.047% of Smix with Y1=169.678 
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nm,  Y2=90.743 for Glibenclamide. The desirability function plots of Atorvastatin 
calcium and Glibenclamide are illustrated in Figures 13a and 13b and the desirability 
function values were found to be 0.856 for Atorvastatin calcium, 0.921 for 
Glibenclamide  which  were  found  to  be  within  the  limits  from  0  to  1.  If  any  of  the  
responses fall outside their desirability range, the overall function becomes zero. 
7.4  SELF-EMULSIFICATION, DRUG PRECIPITATION, PHASE 
SEPARATION AND ASSESSMENT OF EMULSIFICATION TIME 
STUDIES 
 The self-emulsification was visually assessed to measure the apparent 
spontaneity of nanoemulsion formation. SEDDS when diluted in water were found to 
be non turbid and bluish transparent in appearance indicating spontaneous 
emulsification. All the resulting nanoemulsions were transparent with some 
opalescence in appearance and did not show any sign of phase separation. All the 
results of the nanoemulsion formulations were transparent and their absorbances were 
below 1 which showed good optical clarity as illustrated in Table 20a and Table 20b. 
The selection of surfactants and cosurfactants are determined by emulsification ability 
which depends on the physicochemical properties such as globule size, Zeta potential, 
turbidity measurement and PDI of the resulting nanoemulsion. All the formulations of 
both the drugs showed rapid emulsification time within a minute which proves the 
performance of the formulations for enhancing the dissolution profile. Thus it can be 
concluded that the absorption of the drug can be increased in vivo if the formulations 
have low emulsification time. The  results  are  correlated  with  the  findings  of  
Warisnoicharoen et al176 which concluded that emulsification is also influenced by the 
structure and chain length of the surfactant. Labrasol a hydrophilic surfactant having 
HLB value of 12 rendered very good nanoemulsions that required a short 
emulsification period. 
7.5  TURBIDITY MEASUREMENTS 
The rapid equilibrium reached by the dispersion and reproducibility of the 
process29 is determined by turbidity measurements. The results obtained are within the 
limits for both the drugs. The emulsification efficiency is confirmed by a decrease in 
turbidity values which results in the corresponding decrease in droplet size. In the 
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formulation AF3 of Atorvastatin calcium the turbidity value was high of 210 NTU 
due to the larger droplet size of the emulsion formed of 290 nm which was shown in 
Table 14a and Table 20a. In the formulation GF5 of Glibenclamide SEDDS the 
turbidity value was high of 142 NTU due to the larger droplet size of the emulsion 
formed of 402.3nm which was shown in Table 14b and Table 20b. Labrasol is a high 
dispersible surfactant produces small droplet size and good PDI from all surfactants. 
7.6  REFRACTIVE INDEX AND VISCOSITY MEASUREMENT 
There was no significant difference in the refractive index values of the 
formulations tested. The refractive index values close to that of the water (1.333) 
prove the isotropicity of the formulations as indicated in Table 20a and Table 20b.  
7.7  DROPLET SIZE 
The globule size observed for all  the formulation was less than 620 nm. The 
drug loading did not showed significant difference in the polydispersity values. The 
droplet size distribution is one of the most important characteristics of nanoemulsion 
for stability evaluation and is a critical step in the pathway of enhancing drug 
bioavailability. The smaller nano emulsion particle size leads to larger interfacial 
surface area, thus promoting rapid absorption and improved bioavailability. 
7.8  ZETA POTENTIAL 
The emulsion stability is directly related to the magnitude of the surface 
charge and the zeta potential is stability indicative parameter in colloidal system that 
is the system will resist aggregation. The reason for this behavior could be attributed 
to the strong repulsive Coulomb force between charged particles which 
counterbalances the vander Waals attraction force. Generally, an increase in 
electrostatic repulsive forces between micro emulsion droplets prevents the 
coalescence of micro emulsion droplets. High absolute (positive and negative) zeta 
potential values (above +30 or −30 mV) should preferably be achieved in most of the 
emulsions prepared in order to ensure the creation of a high-energy barrier against 
coalescence of the dispersed droplets177. The zeta potential of the optimized 
formulations of Atorvastatin calcium and Glibenclamide were found to be -31.8 mV 
to -24.8mV which were nearer the limits with good separation as indicated in the Fig. 
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15a, Fig. 15b. The zeta potential values were found to carry negative charges due to 
the presence of free fatty acids. Significant increase in the value of zeta potential was 
observed after drug loading, higher absolute values of zeta potential generally, 
indicated an increase of electrostatic repulsive forces between emulsion droplets 
preventing the coalescence droplets and increases in the stability. Among all the 
vehicles tested Labrasol (surfactant) and Transcutol HP (co-surfactant) proved to be 
the most promising vehicles for SEDDS formulation.  
7.9  POLYDISPERSITY INDEX  
The  PDI  for  all  the  formulations  were  less  than  0.5,  formulation  with  
combination of Smix showed lower PDI values as illustrated with the results given in 
Table 20a and Table 20b, thus indicating the uniform size distribution improving the 
performance of the spontaneous emulsification. 
7.10  CLOUD POINT 
The cloud point is an essential factor in the SEDDS consisting of non-ionic 
surfactants, and it is responsible for the successful formation of a stable 
microemulsion32.When the temperature is higher than the cloud point, an irreversible 
phase separation will occur and the cloudiness of the preparation would have a bad 
effect on drug absorption because of the dehydration of the polyethylene oxide 
moiety. Hence, the cloud point for SMEDDS should be above 37°C which will avoid 
phase separation occurring in the gastrointestinal tract. The cloud point for all the 
formulation as shown in Table 20a and 20b tested was above 37°C. Therefore, it 
would suggest a stable micro emulsion can be formed at physiological temperature in-
vivo. 
7.11  DRUG LOADING  
The maximum drug loading for Atorvastatin calcium SEDDS has been 
obtained ranging from 7.1 mg to 9.15mg, and for Glibenclamide ranged from 8.2 mg 
to  9.23  mg  for  all  thirteen  formulations.  The  results  of  predicted  responses  and  
measured responses of the % drug loading for the optimized formulations was very 
well matched for both the drugs as shown Table 18 showing minimum biasness and 
maximum drug loading of 8.72 mg for Atorvastatin calcium  and 8.93 mg of 
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Glibenclamide can be incorporated safely in to the optimized formulations of OPFA 
and OPFG. 
7.12  IN VITRO DISSOLUTION STUDY AND STABILITY STUDY 
The dissolution study of API, marketed formulation and optimized 
formulations were performed in 6.8 pH phosphate buffer for Atorvastatin calcium. 
The comparison results in Fig.16a depicted that the optimized formulation above 90 
% drug release in 30 min showed the pH independent release of Atorvastatin from 
SEDDS formulations. The rapid release of Atorvastatin from SMEDDS formulations 
could be attributed to the spontaneous formation of micro emulsion with a small 
droplet size, which permitted a faster rate of drug release into the aqueous phase, 
much faster than that of plain Atorvastatin. Thus, this greater availability of dissolved 
Atorvastatin from the SEDDS formulation could lead to higher absorption and higher 
oral  bioavailability.  Drug  release  from  the  all  SEDDS  formulation  was  found  to  be  
significantly higher as compared with that of plain Glibenclamide and marketed tablet 
as showed in Fig. 16b. All Glibenclamide SEDDS formulation released drug above 
90% within 5 min as showed in Table 21b. It could be suggested that the SEDDS 
formulation  resulted  in  spontaneous  formation  of  a  micro  emulsion  with  a  small  
droplet size, which permitted a faster rate of drug release into the aqueous phase, 
much faster than that of plain Glibenclamide and marketed tablet. Thus, this greater 
availability of dissolved Glibenclamide from the SEDDS formulation could lead to 
higher absorption and higher oral bioavailability. It was also showed that increase in 
surfactant concentration and decrease in oil concentration in formulation increase in 
drug release. The selected optimized formulations OPFA and OPFG from Table 24a 
and Table 24b were physically stable and did not showed any changes in the color and 
appearance of the formulation. Also there was no significant change in the drug 
content and release through the time of the stability study after the formulations being 
subjected to different stress conditions (cold temperature of 4-8°C and elevated 
temperature of 50±2°C)  of  temperatures.  Thus  it  can  be  concluded  that  SEDDS  
formulation for Atorvastatin calcium and Glibenclamide were stable. 
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CHAPTER 8 
SUMMARY AND CONCLUSION 
The  purpose  of  this  study  was  to  develop  an  oral  administrable  SEDDS  of  
poorly water soluble drugs of Atorvastatin calcium and Glibenclamide under 
Biopharmaceutical classification system of class II classification. Solubility 
evaluation and ternary phase diagram were carried out to select excipients of SEDDS. 
The composition of Atorvastatin calcium loaded and Glibenclamide loaded SEDDS 
was optimized using 32 facorial design. The impact of the formulation parameters on 
mean globule size and percentage drug load were studied by applying the analysis of 
variance and regression models. Several formulation and process variables were 
evaluated and optimized by response surface methodology. The optimum formulation 
was prepared by response optimizer through desirability function and the 
experimental values were found to be in close agreement with the predicted values. 
Optimized formulation was further subjected to stability studies. Optimal Atorvastatin 
calcium SEDDS contains sunflower oil as oil phase, labrasol as a surfactant and 
transcutol HP as cosurfactant (Smix) in the ratio of 67.586% oil and 52.529% % w/w 
Smix formulates SEDDS with lower droplet size (169.7nm), PDI (0.2), and zeta 
potential (-31.8 mv) and percentage drug load (87.2%) values. The optimal 
glibenclamide SEDDS contains peceol as oil phase, labrasol as a surfactant and 
transcutol HP as co-surfactant (Smix) in the ratio of 15.046% oil and 41.047% %w/w 
Smix formulates SEDDS with lower droplet size (172 nm), PDI (0.244), and zeta 
potential (-24.8mV) and percentage drug load (89.3%) values. It was concluded that 
the smaller particle size and drug load more the release of drug which results in better 
bioavailability. The in vitro evaluation parameters such as emulsification time, 
viscosity determination, cloud point measurement, turbidity measurement, refractive 
index and spectroscopic optical clarity test were performed and the results were found 
within the limits for all formulations of two drugs. The stability studies revealed that 
there was no change in particle size and percentage drug load for the two drugs after 6 
months. The in vitro drug release from optimized Atorvastatin SEDDS formulation 
were found to be 99.75% after 90 min and 99.7% after 30 min and for Glibenclamide 
SEDDS. It was extremely higher in comparison to the marketed formulation and API 
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suspension. In-vitro drug release studies closely indicate that optimized formulations 
obey first order kinetics and the mechanism of drug release was by fickian diffusion. 
The results further concluded that SEDDS can be explored as a potential drug carrier 
for dissolution enhancement of Atorvastatin and Glibenclamide and other poorly 
soluble drugs. 
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CHAPTER 9 
IMPACT OF THE STUDY 
The impact of the present research work is that self-emulsifying drug delivery 
systems are the newer approach to enhance the dispersibility and minimize the 
particle size of dispersed systems, thereby potentially increasing oral absorption for 
poorly water soluble drugs. 
Atorvastatin calcium, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor belonging to BCS Class II category is a plasma lipid-regulating 
agent. Atorvastatin calcium has therapeutic application in hyperlipidemia and 
cardiovascular events. The oral bioavailability of Atorvastatin calcium is only 12% 
and poor bioavailability has been attributed to its poor solubility in water and high 
presystemic  clearance  (>  80%).  The  utility  of  SEDDS improved  the  dissolution  and  
bioavailability of Atorvastatin calcium.  The higher drug load would lead to better 
patient compliance by reducing the size of the final dosage form and thereby the side 
effects of Atorvastatin calcium like myotoxicity (myopathy, myositis, and 
rhabdomyolysis) and hepatotoxicity can be reduced.  
Glibenclamide (GBM) belongs to BCS Class II category of poor solubility and 
poor bioavailability drug used for the treatment of non-insulin dependent Diabetes 
mellitus.  The oral absorption is dissolution rate limited and requires enhancement in 
the solubility and dissolution rate for increasing its oral bioavailability. An optimal 
self-emulsifying drug delivery system (SEDDS) containing GBM was formulated for 
enhancement of solubility and dissolution rate and thereby increasing its 
bioavailability. The study revealed that higher amount of surfactants significantly 
increased dissolution of Glibenclamide while decreasing emulsion droplet size and 
emulsification time.  
Overall, the study suggested that dissolution and oral bioavailability of 
Atorvastatin calcium and Glibenclamide could be improved by SEDDS technology. 
This concept must be extrapolated in drug-food interaction studies.   
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